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Abstract 
 
 
 
THE ROLE OF TUMOR AND TUMOR MICROENVIRONMENT ON BREAST CANCER-
ASSOCIATED ADIPOCYTE PLASTICITY 
 
By Janina Vaitkus Pearce, B.S. 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy in Clinical and Translational Research, Cancer and Molecular Medicine at 
Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2019 
 
 
Director: Francesco S. Celi 
Professor, Department of Internal Medicine 
Division Chair, Division of Endocrinology, Diabetes, and Metabolism 
 
 
 
Cancer-associated cachexia is a condition defined by a sustained net-negative energy 
imbalance. Although the different types of adipose tissue – white, beige, and brown – 
have been implicated in contributing to cancer-associated cachexia, the mechanisms of 
these maladaptive changes and their impact on whole-body energy expenditure have 
not been fully elucidated. Using breast cancer as our model, we demonstrate white 
adipose tissue browning in murine and human breast cancer; furthermore, we 
demonstrate that this effect is extremely localized and takes place early in tumor 
progression. We utilized in vitro cell culture techniques and demonstrate that cancer 
secreted factors and cross-talk with white adipocytes decrease expression of classic 
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white adipose tissue-related genes. We also demonstrate in murine and human culture 
models that cancer secreted factors reduce white adipocyte lipid droplet size, and 
cross-talk between cancer cells and adipocytes results in an increase in lipolysis-related 
gene expression. Interestingly, our results strongly suggest that in mice, neither cancer 
secreted factors nor cross talk with adipocytes can induce white adipose tissue 
browning, indicate that this process likely occurs independently of direct cancer 
interactions with local white adipocytes. We demonstrate that interleukin 6, a cytokine 
with previous implications in white adipose tissue browning, induces interleukin 6-
mediated signaling; however, that signaling alone is not enough to directly induce white 
adipose tissue browning. We present preliminary data suggesting that immune cell 
population shifts within the white adipose tissue of mice with breast cancer tumors may 
be source of white adipose tissue browning.  We show that the Virginia Commonwealth 
University Health System has an identifiable population of patients with cancer with 
what we hypothesize as maladaptive thermogenic adipose tissue activity, and discuss 
ongoing experiments aimed at understanding the implications of these changes on 
whole body energy expenditure in human patients.  Lastly, in a case of autoimmune 
diabetes mellitus in the setting of an extra-adrenal paraganglioma, we demonstrate that 
the interaction between cancer and whole-body metabolism is multifaceted. Together, 
these experiments demonstrate that adipose tissue plasticity occurs in breast cancer 
(and other cancers), and that different drivers for individual changes exist within the 
tumor microenvironment. We predict that further exploration of the exact mechanisms 
and translational implications will provide useful information to lead to new therapeutic 
treatments for patients with cancer-associated cachexia. 
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Chapter 1: Background 
 
Please note that some of the material within this Chapter comes from our previously 
published article, DOI 10.1177/1535370216683282. The final, definitive version of this 
paper has been published in Exp Biol Med (Maywood), Volume 242/Issue 5, March 
2017 published by SAGE Publishing [1]. 
 
1.1 Energy balance 
The First Law of Thermodynamics, also referred to as the Law of Conservation of 
Energy, states that energy cannot be created or destroyed [2]. In the context of 
metabolism, energy balance is defined as the difference between energy intake and 
energy expenditure (EE). Taken together with the Law of Conservation of Energy, 
changes in an individual’s weight must be attributed to an imbalance in either energy 
intake or expenditure. A positive energy balance, where energy intake is greater than 
energy expended, causes weight gain; a negative energy balance, where energy intake 
is less than energy expended, results in weight loss (Figure 1).  However, this balance 
is more complex than simply dietary intake and exercise; the classic “static,” or “linear,” 
model of energy balance is being replaced by the concept of “dynamic” energy balance, 
in which factors such as genetics, early life events, mood, stress, and metabolic and 
hormonal signaling also contribute to the regulation of an individual’s energy balance 
[3].  
In present-day society, the effects of sustained positive energy balance are seen 
in the global obesity pandemic, where rates of obesity have roughly tripled in the past 
35 years [4]. While some individuals with obesity may be classified as ‘metabolically 
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healthy’ [5], obesity is often associated with other health problems and increases the 
risk for development of comorbidities such as diabetes, cardiac disease, liver disease, 
and reproductive dysfunction, and cancer [6]. Obesity and its associated health 
problems also come with a substantial economic cost: in 2008 in the United States 
alone, the costs associated with obesity and its associated health problems were 
estimated to be about $147 billion [7]. 
Deleterious effects can also be seen in cases of sustained negative energy 
balance. Severe burns, trauma, and sepsis can all result in a negative energy balance 
that causes undesirable health consequences [8-10]. While obesity increases the risk of 
cancer development [6], sustained negative energy balance in the context of cancer can 
result in cancer-associated cachexia (CAC), discussed in detail in section 1.4.  
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Figure 1. Conceptual overview of energy balance 
Energy balance is a complex, dynamic process with multiple contributing factors. Imbalances result in 
weight gain (positive balance, on left) or weight loss (negative balance, on right). 
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1.2 Measuring energy expenditure 
Collectively, total energy expenditure (TEE) represents the total amount of 
energy used in daily functioning. TEE is comprised of resting energy expenditure (REE, 
also known as basal energy expenditure or BEE), activity energy expenditure (AEE), 
and thermic effects of food, or diet-induced thermogenesis (DIT). REE is the energy 
required to maintain basic cell and organ functions such as respiration and regulation of 
body temperature [11]. AEE is the energy used to perform exercise and non-exercise 
related tasks [12], and DIT is the energy used to metabolize substrates consumed in the 
diet [11]. Similar to energy balance, TEE is influenced by a large range of factors, 
including but not limited to age, body composition, thyroid hormone, catecholamines, 
pharmacologic therapies, and diseases [12].  
Measuring energy expenditure (EE) is a useful tool in animal and human studies 
and can provide a point-estimate of energy utilization at rest, after eating, during 
exercise, and under other experimental conditions. Predictive equations, such as the 
Harris-Benedict equation, are historically based on specific patient populations. This is 
problematic, as our population’s phenotype is changing over time and therefore 
invalidates many of these older predictive equations [11, 12]. 
  There are several approaches to measuring EE. Heat, carbon dioxide, and 
oxygen are products of substrate utilization:  
𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 +  𝑂ଶ  𝑜𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛  𝐶𝑂ଶ + 𝑂ଶ  +  ℎ𝑒𝑎𝑡.  
Direct calorimetry is a technique used to calculate EE by directly measuring heat loss 
[13, 14]. Subjects enter a sealed chamber to measure body heat production, and 
software is then used to calculate EE. While this can provide accurate measurements, it 
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is burdened with several limitations, the most significant that subjects cannot bring any 
devices that will increase heat production and confound results [11, 14]. Indirect 
calorimetry can overcome these disadvantages.  
 Indirect calorimetry is a technique that utilizes the other products of substrate 
utilization – by measuring CO2 and O2 gas exchange – to indirectly measure EE [13]. 
There are several different methods by which indirect calorimetry can be performed. 
Portable methods, which include a mouthpiece and mask attached to a small backpack-
encased analyzer, allow for subjects to maintain relatively unrestricted mobility; 
however, they may be uncomfortable for the patient and limit the length of study design 
due to battery life constraints [14]. Metabolic carts using facemasks, mouthpieces, or 
‘domed hoods’ are not limited by battery life and are fast and accurate in data collection; 
however, these are often uncomfortable for patients and limit patient mobility [14].  
Whole-room indirect calorimeters – also known as “respiration chambers” or 
“metabolic chambers,” allow for maximum patient mobility and comfort. These are 
rooms that vary in size from small (fitting a twin sized bed or exercise bike, for example) 
to large (fitting a bed, toilet, sink, and exercise equipment simultaneously), providing the 
capability for a range of experimental designs (Figure 2 shows the VCUHS small and 
large open-circuit whole-room indirect calorimeters). While these large volumes can 
increase the equilibration time, our lab has demonstrated robust temporal accuracy in 
these systems [15].  Sleep studies, exercise studies, resting EE studies, combinations 
of these, and more are possible using these systems. Additional procedures such as 
blood and urine collection can be added to protocols using the whole-room indirect 
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calorimeters, and additional equipment can be used within the calorimeters to acquire 
additional data, such as accelerometers to measure movement.  
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Figure 2. Whole-room indirect calorimeters at VCUHS 
(A) Small and (B) Large whole-room indirect calorimeters located in the Clinical Research Service Unit 
(CRSU) in North Hospital at the Virginia Commonwealth University Health System (VCUHS).  
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1.3 Adipose tissue 
Adipose tissue, previously viewed as an inert fat depot in isolated areas within 
the body, is now regarded as a large, interactive, multi-compartment organ with clear 
organization and anatomy [16-18]. Additionally, the secretomes of these depots can act 
locally (paracrine organ function) and systemically (endocrine organ function) [19, 20]. 
The composition of adipose tissue includes mature adipocytes, as well as other 
cell types that are important for each adipose tissue depots’ function. These include 
vascular endothelial cells which provide the necessary vascular supply to the tissue, 
nerve endings from the sympathetic nervous system, adipocyte precursor cells, and a 
variety of immune cells [21-23].  
Mature adipocytes are terminally differentiated cells, although recent evidence 
suggests that they can be reprogrammed [24].  Turnover of adipocytes is quite low, but 
de novo differentiation does occur [25].  
 
1.3.1 White adipose tissue (WAT) 
The largest component of adipose tissue is white adipose tissue (WAT), which 
primarily consists of large, spherical adipocytes with a unilocular lipid droplet consuming 
most of the cell volume [18]. WAT is found in both subcutaneous and visceral depots, 
and increased visceral WAT mass is associated with increased metabolic risk [26, 27]. 
WAT has important endocrine and paracrine roles throughout the body [18, 28, 29], and 
in general terms, functions to store energy, mainly in the form of triglycerides [30, 31]. 
Developmentally, white adipocytes are derived from myogenic factor 5 (MYF5)-negative 
precursors (Figure 3). 
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1.3.2 Brown adipose tissue (BAT) 
In contrast to WAT, brown adipose tissue (BAT) primarily functions to expend 
energy [30]. Until recently, functionally-significant BAT was thought to be present only in 
neonates, undergoing rapid involution with age [30, 32-35], despite early reports that 
indicated the presence of BAT in adult humans [33, 34, 36]. The development and use 
of positron-emission tomography (PET) allowed for visualization of BAT in adult humans 
[37], and in combination with other functional analyses [38, 39], sparked the recent 
resurgence in interest in BAT’s function in health and disease. Details of WAT and BAT 
development and gene signature are discussed elsewhere [30, 40, 41], but it is 
important to note that, at least in mice, anatomically-defined BAT adipocytes are derived 
from a cell lineage different from WAT, which instead share a lineage with myocytes 
(muscle cells) which are MYF5-positive [42, 43]. Adult human BAT depots are located 
near the aorta and within the supraclavicular region of the neck [18]. These adipocytes 
contain multilocular lipid droplets, and their ability to expend uniquely great amounts of 
energy is largely due to the presence and activation of a proton leakage pathway [44] 
mediated by uncoupling protein 1 (UCP1) – the hallmark of BAT function [33, 45].  
UCP1 uncouples oxidative phosphorylation from ATP synthesis in the inner 
mitochondrial membrane (Figure 4) to dissipate energy in the form of heat [46, 47]. 
UCP1 is one of several members of the uncoupling protein family; of these, UCP2 and 
UCP3 are most similar to UCP1 in homology. UCP1 is found specifically in thermogenic 
adipocytes, UCP2 is expressed in many cell types [48], and UCP3 is expressed more 
selectively, most notably in skeletal muscle [49]. Both UCP2 and UCP3 are important in 
several cellular processes, for example, in regulating the cell’s response to reactive 
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oxygen species-mediated oxidative stress and in fatty acid metabolism (reviewed by 
[48, 50, 51]; however, interestingly, of the uncoupling protein family, only UCP1 is able 
to confer a thermogenic phenotype – neither UCP2 nor UCP3 are capable of eliciting 
this effect [52, 53]. The UCP1 gene in humans is located on chromosome 4 and has two 
regulatory elements in the 5’ non-coding region that regulate its transcription. These 
bind to key transcriptional regulators such as peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PPARGC1A) and PR domain zinc finger protein 16 
(PRDM16) (reviewed by [54]). UCP1 is regulated post-translationally as well. Free long 
chain fatty acids and purine nucleotides have been shown to serve opposing functions: 
purine nucleotides inhibit UCP1 activity, and free long chain fatty acids removing that 
purine-mediated inhibition to activate UCP1 function [55].  
 
1.3.3 Beige adipose tissue  
More recently, an additional type of adipocyte, defined as ‘brite’ (brown-in-white) 
[56] or ‘beige’ [57], was identified. These adipocytes are located within and share cell 
lineage with white adipocytes [30] but express UCP1 and function like brown adipocytes 
[56] (Figure 3A). While some authors suggest that beige cells develop de novo [58], the 
model of transdifferentiation – development of beige adipocytes from pre-existing white 
adipocytes [59] – predominates [18]. Interestingly, in addition to sustained exposure to 
cold, multiple different pathways promote the white-to-beige transition leading to a 
similar cellular phenotype, reviewed by Giralt [30]. Importantly, beige adipose tissue can 
expand in response to several mediators and is a target of both endocrine and 
paracrine stimuli [60]. 
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This relatively ‘new’ beige adipose tissue has generated a great deal of 
excitement, as its function is similar to classical BAT in expending energy and may have 
additional protective roles against obesity [30]. On the other hand, its capability of 
developing, expanding, and activating under local stimuli, including extracellular matrix 
components [61], make this tissue a potential driver of CAC in response to tumor 
microenvironment.  
Together, all three adipose tissue types (Figure 3A), as well as their 
differentiation and maintenance (Figure 3B), are clearly important in the energy balance 
that is disrupted in CAC. 
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Figure 3. White, beige, and brown adipose tissue  
(A) White adipose tissue (‘White’ in image) has the lowest thermogenic activity, while brown adipose 
tissue (‘Brown’ in image) has the highest. White and beige adipocytes share the same Myf5-negative 
lineage, but beige and brown adipose tissue share increased UCP1 expression which confers 
thermogenic activity. (B)  General overview of process of adipogenesis and transdifferentiation of white to 
beige adipocytes (“WAT browning”). Abbreviations defined in List of Abbreviations. 
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Figure 4. Uncoupling protein 1 (UCP1) is the hallmark of thermogenic adipose tissue 
UCP1 is located within the inner mitochondrial membrane. Normally, protons generated by the electron 
transport chain (complexes I through IV as indicated in image) move through the ATP synthase to 
generate ATP; however, when UCP1 is activated, the proton gradient is collapsed via proton transport 
through UCP1, which generates heat.  
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1.4 Cancer-associated cachexia (CAC) 
1.4.1 History, definition, and staging  
Changes in metabolism and altered energy requirements have been documented 
in patients with cancer as early as the 1950s [62], yet it was not until the 1970s that the 
multifaceted nature of cancer-associated cachexia (CAC, also referred to as cancer 
cachexia) was appreciated [63, 64]. While early studies suggested that CAC was the 
result of tumor-driven anorexia alone [65], it is now established that CAC is not solely 
the result of decreased food intake; other contributing factors such as malabsorption 
and altered metabolism play a role as well [63, 64]. In the early 2000s, increased 
emphasis was placed on consolidating clinical and basic research findings to develop 
guidelines for defining, staging, and treating CAC.  
CAC, according to a recent international consensus developed by Fearon and 
Strasser, is defined as a “multifactorial syndrome defined by an ongoing loss of skeletal 
muscle mass (with or without loss of fat mass)” [66]. Almost all cancers can be 
associated with CAC, although some more commonly than others [67]. Classically, CAC 
is described in three stages: precachexia, cachexia, and refractory cachexia. Several 
assessment criteria were proposed and described in detail by Fearon [66]; the most 
obvious is the degree of weight loss a patient experiences, but others include catabolic 
drive and loss of muscle mass and strength. The consensus guidelines were quickly 
applied to and validated in clinical practice, and additional assessment and 
management algorithms were proposed [68, 69].  
While these guidelines represent significant improvements, there is still a lack of 
simple clinical indicators and markers to allow for earlier and straightforward 
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classification of CAC [69]. Despite increased awareness of this condition, CAC is still 
very common and treatments are inadequate [70], suggesting that a comprehensive 
understanding of the molecular and physiologic pathways leading to the development 
and progression of CAC is still lacking. The large inter-individual variability in the 
prevalence and severity of CAC in patients with the same tumor type [71, 72] further 
supports the need for improving the knowledge of the pathophysiologic mechanisms 
responsible for CAC. Given the high prevalence of obesity in the general population, 
early stages of CAC may be missed when the diagnosis is based purely on weight loss 
criteria (referred to as the ‘obesity paradox’ [72]).  This factor demonstrates the need for 
improvement in the early diagnosis of this condition. 
 
1.4.2 Prognosis, effects, and treatment options 
The inverse association between weight loss and survival in patients with cancer 
is well known [73]. Recent estimates propose that CAC affects 60-80% of all patients 
with advanced cancer [69], and is directly implicated in at least 20% of cancer-related 
deaths [74], demonstrating that CAC is an independent risk factor for poor prognosis. 
The loss of body mass and altered body composition in CAC leaves patients vulnerable 
to increased toxicity from anti-tumor therapies such as chemotherapy [69, 75, 76]. This 
may directly result in increased morbidity and mortality, and may indirectly affect 
morbidity and mortality as the increased toxicity requires clinical treatment delays and 
dose reductions in therapy. Not surprisingly, patients with CAC additionally experience 
loss of physical function and decreased quality of life [69, 75].  
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Clinical advancements in defining and staging CAC have not been matched by 
similar improvements in treatment options and patient outcomes. Some studies suggest 
that CAC may be reversible if caught in the precachexia or cachexia stages [68, 76]. 
The main therapeutic strategies utilized in these stages include exercise, intense 
nutritional support, and removing any direct tumor causes (such as obstruction causing 
malabsorption) [68, 69]. Unfortunately, many cases are clinically diagnosed in the 
refractory cachexia stage, when CAC is often irreversible [66, 68] and nutritional 
support, current drug therapies, and other measures are ineffective in restoring a net-
neutral or positive energy balance [77, 78]. In the past, many studies investigating 
therapeutic drugs to combat CAC, such as eicosapentaenoic acid diester [79] and 
bortezomib [80] have failed to demonstrate favorable outcomes. While experiments and 
studies investigating new potential therapeutic targets have been ongoing, when Fearon 
published his article in 2011, there were no active clinical drug trials for CAC [66]; since 
then, several drugs in the pipeline have entered into the clinical trial phases. A review 
by Dingemans and colleagues in 2014 identified 12 phase II clinical trials with 11 
compounds [81]. Each of these drugs are expected to help combat CAC via one of the 
following mechanisms: increasing appetite, improving digestion, decreasing systemic 
inflammation, and improving the muscle synthesis-versus-degradation ratio [81]. Other 
drugs have recently entered phase III trials, but difficulties in meeting multiple clinical 
endpoints indicate the need for a more comprehensive approach. Anamorelin, a ghrelin-
receptor agonist, demonstrated an ability to improve lean body mass in a phase II 
clinical trial with patients with non-small cell lung cancer and CAC [82]. However, this 
phase II trial, and a subsequent phase III trial, reported that while lean body mass 
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improved, functional improvements in hand grip strength did not [82, 83] – highlighting 
the potential discrepancy between proxies of end-organ effect and patient-centered 
significant outcomes. Enobosarm, a selective androgen receptor modulator, showed a 
significant increase in total lean body mass in phase II studies [84], but according to 
information thus far presented in abstract format, it has not yielded consistent endpoint 
results in phase III trials [85, 86]. As described below, there are many contributing 
factors to CAC, so the development of these drugs is certainly a step in the right 
direction. However, few compounds make it past phase II and III studies, and those that 
have (and will) may not fully address the spectrum of pathophysiologic components of 
CAC to be effective in mitigating or reversing all of the clinical components of CAC. 
 
1.4.3 Contributing factors 
The factors contributing to the development and maintenance of CAC are 
grounded in the axiom of energy balance: weight loss or gain only occurs when there is 
a sustained imbalance between energy intake and energy expenditure [64, 87]. In the 
case of CAC, there is a persistent net-negative energy balance, with components linked 
to both decreased energy intake and increased energy expenditure. Decreased energy 
intake may occur via several mechanisms, including anorexia caused by chemosensory 
distortions, malabsorption, and early satiety [66, 68, 71, 75]. Increased energy 
expenditure may result from inflammation, increased tumor metabolism, and 
altered/increased metabolism [68, 71, 72, 77]. To this end, the heterogeneity of adipose 
tissue is particularly relevant in the pathophysiology of CAC. Adipose tissue 
metabolism, aside from its more obvious role in obesity and diabetes, has been 
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demonstrated to play a role in other states of metabolic dysfunction such as CAC. As 
such, we identify and discuss the specific contributions of adipose tissue to the 
development and progression of CAC. 
 
1.4.4 Adipose tissue contributions to CAC: lipolysis 
The breakdown of adipose tissue – lipolysis – is perhaps the most evident 
component of adipose tissue’s contribution to CAC [88]. Fat loss observed in patients 
with CAC is thought to occur via breakdown of adipose tissue (mainly WAT) in response 
to a negative energy balance due to cancer-associated anorexia and other pathologic 
factors recently reviewed by Ebadi and Mazurak [89, 90]. The importance of lipolysis in 
CAC was demonstrated in a study that showed that the inhibition of lipid mobilization 
can improve the CAC state [91]. A murine model of animals implanted with murine 
adenocarcinoma 16 tumors reported changes in adipose tissue that included shrunken 
adipocytes and decreased expression of adipose tissue transcription factors [92]. In 
2018, investigators demonstrated early adipose tissue wasting in a new murine model 
of CAC in pancreatic cancer [93]. 
From a clinical perspective, a critical component of the body mass loss observed 
in CAC is the depletion of muscle mass, which usually precedes the observation of 
significant changes in adipose tissue mass and is associated with decrease in muscle 
function and mobility. Fearon and Strasser’s consensus findings highlight that skeletal 
muscle loss is a necessity for a clinical diagnosis of CAC, but that adipose tissue loss 
may or not be present [66]. However, lipolysis and lipid wasting may occur to an extent 
before muscle loss [91]. Additionally, studies in a mouse model of colon cancer 
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demonstrated an increase in protein kinase-A mediated lipolysis in early stage cachexia 
[94], and this ‘early’ lipolysis was implicated in 1) the inception of a negative energy 
balance that worsens over the course of CAC progression, and 2) a direct loss of 
skeletal muscle [95]. Lipolysis results in increased free fatty acids in circulation, which 
then get taken up by skeletal muscle; the excess of intramuscular free fatty acids results 
in several biochemical changes, such as the expression of ubiquitin lipases Atrogin-1 
and MuRF [96], that lead to skeletal muscle atrophy [97]. Indeed, Stephens showed a 
positive association between the extent of body weight loss in cancer patients and the 
amount of lipid droplet accumulation within skeletal muscle cells [98]. In a study of late-
stage CAC, protein kinase-A mediated lipolysis was not observed as in early stages, but 
instead more lipases were observed and contributed to skeletal muscle dysfunction and 
atrophy [99]. These findings suggest that there are likely different stages of lipid 
metabolic responses in CAC. Physiologically, one would expect that lipolysis and 
resulting loss of WAT mass would stimulate other pathways in the body to drive 
anabolism and energy intake, such as leptin. Leptin is produced by WAT and its levels 
are positively correlated to a patient’s state of adiposity, regardless of age or body mass 
index (BMI) [89]. Low levels of leptin are expected in patients exhibiting fat loss with 
CAC, which should result in increased activation of orexigenic pathways; however, 
studies demonstrate that this feedback may be disrupted in cancer, resulting in an 
undesirable decrease in signaling pathways such as neuropeptide Y [100]. It is 
important to recognize that inflammation is known to be a key player in lipolysis and the 
general increased catabolic drive observed in CAC (reviewed by Penet [77]). Since 
adipose tissue depots have interspersed lymphocytes [18] and macrophages [101], 
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there may be a functional relationship between lipolysis and increased inflammation. 
However, CAC can present even in the absence of frank systemic inflammation [66], 
and therapies targeting inflammatory cytokines such as tumor necrosis factor-alpha and 
eicosapentaenoic acid diester have not been successful in ameliorating CAC [79, 102]. 
This finding is consistent with the multifactorial nature of CAC.  
 
1.4.5 Adipose tissue contributions to CAC: beige and brown adipose tissue expansion 
and activation  
Several studies highlight increased resting energy expenditure in animal models 
as well in humans affected by CAC, and point to adipose tissue as a culprit [103-105]. 
While lipolysis literally represents a loss of adipose tissue (especially WAT) mass, BAT 
and beige adipose tissue depots appear to contribute to CAC via increased energy 
expenditure. 
BAT was first proposed as a contributor to CAC in 1989 [106], but this hypothesis 
was not investigated further until the rediscovery of functional BAT in adult humans [38]. 
In a mechanistic study, Tsoli and colleagues found that activation of BAT (via increased 
Ucp1 expression) contributed to the development of CAC in mice with cachectic colon 
cancer cell line injections [103]. Interestingly, CAC and BAT activation were not present 
in mice with non-cachectic colon cancer cell line injections [103]. In another study, BAT 
activity was measured via 18F-fluorodeoxylucose positron emission 
tomography/computed tomography (FDG PET/CT) in human patients with cancer, and 
was found to correlate positively with cancer stage [107]. However, classical BAT is 
relatively limited in mass, localized to relatively small depots within the body, therefore 
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severely limiting its capacity to offer substantial contributions to energy expenditure and 
CAC in humans [108, 109]. More studies are needed to provide a quantitative 
assessment of classical BAT’s contributions to CAC [110].  
WAT, however, has much larger depots, so the expansion of beige adipose 
tissue within WAT depots may confer greater increases in energy expenditure, and may 
contribute significantly to CAC. Not surprisingly, WAT browning was identified in 
patients with pheochromocytomas [111], neuroendocrine tumors that secrete 
norepinephrine, a known trigger of white-to-beige trans-differentiation. However, WAT 
browning has also been observed in other tumor models beyond catecholamine-
secreting tumors. Mechanistic studies in mice include genetic models of Kras-lung, 
Kras-pancreatic, and K5-SOS carcinomas [112], chemically induced liver carcinoma 
[112], graft/injection models of B16 melanoma [112] and Lewis lung carcinoma [112, 
113], C26 colon carcinoma with and without interleukin 6 (IL6) expression [112], and 
human pancreatic carcinoma xenografts [112]. In these models, investigators reported 
the presence of WAT browning and its contribution to the observed CAC. This was 
demonstrated by increased expression of Ucp1 mRNA and UCP1 protein [112, 113], 
and also through increased expression of other genes crucial for beige adipose tissue 
development, such as Prdm16 and Ppargc1a [113]. The authors also performed 
functional analyses of the proposed beige adipose tissue to demonstrate increased 
energy expenditure using oxygen consumption rate assays as well as body weight, 
tissue weight, physical activity, oxygen uptake (VO2), carbon dioxide production (VCO2), 
respiratory exchange ratio (RER), and heat generation measurements [112, 113]. 
Additionally, two drivers of white-to-beige trans-differentiation were identified: IL6 [112] 
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and parathyroid hormone-related peptide (PTH-rp) [113]. These are the first studies to 
identify causative agents secreted by tumors that contribute to WAT browning and result 
in increased energy expenditure, which contributes to CAC. importantly, WAT browning 
was observed early in the progression of CAC, before skeletal muscle atrophy occurred 
(consistent with the observations in lipolysis studies [91, 94]), suggesting that adipose 
tissue dysfunction may occur prior to clinically-evident adipose tissue loss, contributing 
to the development of CAC. Furthermore, Petruzzelli and colleagues examined, via 
immunohistochemistry, adipose tissue samples acquired from human patients with CAC 
and a multitude of cancers: Kaposi’s sarcoma, melanoma, cholangiocarcinoma, colon 
adenocarcinoma, pancreatic neuroendocrine cancer, pleomorphic lung carcinoma, and 
lung adenocarcinoma [112]. Results showed that many of the WAT samples had 
increased UCP1 expression and adipocyte atrophy. While there is still much to 
understand, these results clearly support the role of WAT browning in the development 
and progression of CAC.  
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Figure 5. Adipose tissue in CAC 
A summary of adipose tissue contributions to cancer-associated cachexia (CAC). Cancer and its 
microenvironment (top) influence white, beige, and brown adipose tissue (colored respectively). WAT 
undergoes lipolysis, which results in a direct loss of adipose tissue mass and also contributes to skeletal 
muscle mass loss. As the process progresses, skeletal muscle loss may act as positive feedback for 
further adipose tissue lipolysis. WAT may also undergo browning to undergo trans-differentiation to beige 
adipose tissue, expressing uncoupling protein 1 (UCP1) and thereby expending greater amounts of 
energy. Similarly, existing classical brown adipose tissue may be activated, resulting in greater UCP1 
expression with a resulting increase in energy expenditure. Collectively, these changes result in a net-
negative energy balance, which contributes to the development and progression of CAC. 
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1.4.6 The other side of the coin: the role of adipose tissue in promoting cancer 
progression 
It is important to recognize that the adipose tissue-cancer interactions also go in 
the opposite direction. Cancer may directly and indirectly affect adipose tissue, and 
adipose tissue may directly and indirectly affect cancer growth and survival, as well 
[114]. Recent studies demonstrated that adipose-derived fibroblasts and cancer-
associated adipocytes can contribute to cancer progression [19, 115, 116], and another 
study demonstrated that increased beige and brown adipose tissue contributes to tumor 
progression [117]. Since higher rates of lipolysis and browning are strongly correlated 
with later-stage CAC, the hypothesized cross-talk between tumor and adipose tissue 
may generate a positive feedback loop facilitating cancer progression and the clinical 
impact of CAC.  
 
1.4.7 Potential therapeutic strategies to restore adipose tissue homeostasis in CAC 
As mentioned previously, aberrations in adipose tissue metabolism and 
homeostasis in malignancy result in a decrease in both adipose tissue and muscle 
mass. An ideal therapeutic approach would improve both adipose tissue and lean 
muscle mass; however, this has not been successful due to the differences in cell 
lineage of muscle and WAT. Their common precursor is the mesenchymal stem cell, but 
adipogenesis and myogenesis have very different differentiation signals and pathways, 
such differences in Wnt signaling [118]. Differences are also observed mechanically, as 
softer substrates promote adipogenesis while stiffer substrates promote myogenesis 
[119]. These differences, and subsequent lack of overlapping triggers, make the 
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development of a single therapeutic aimed at increasing both WAT and muscle mass 
incredibly difficult. 
This relationship between adipose tissue changes and muscle loss is observed in 
other non-malignancy states as well: in postmenopausal women with type 2 diabetes 
mellitus, for example, increased intramuscular adipose tissue was associated with 
decreased hand grip strength [120]. In the elderly population, increased thigh muscle 
lipid content, represented by lower skeletal muscle attenuation coefficients on computed 
tomography images, was demonstrated to be negatively associated with muscle 
attenuation and strength [121]. Even in patients without metabolic disease, increased 
thigh intramuscular adipose tissue is associated with predictors of increased metabolic 
syndrome risk [122]. Current clinical trials investigating potential therapeutic agents for 
patients with CAC are promising, but the drugs being tested do not directly address the 
contributions of white, beige, and brown adipose tissue to CAC (such as reducing the 
release of free fatty acids from WAT, or inhibiting the white-to-beige transition). AR-42, 
a histone deacetylase, has recently demonstrated preclinical success in reducing levels 
of MuRF1 and Atrogin-1 lipases and decreasing muscle degradation [123]. So, while 
still mostly speculative, it is possible that restoring adipose tissue homeostasis by 
targeting these areas of dysfunction will contribute to further improvements in patient-
centered outcomes. For example, inhibition of WAT lipolysis and its downstream effects 
on skeletal muscle atrophy could lead to improvement of hand-grip strength (used as a 
proxy for overall muscle strength and function) and assessments of physical activity 
(usually via patient-reported rating of physical functioning). Patients’ self-reported 
quality of life and psychosocial status will likely improve if adipose tissue mass loss (and 
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skeletal muscle, as well) was dampened – in part because patients may feel that they 
are in better control of their weight and can keep their strength, and also in part because 
conservation of adipose tissue mass would likely result in a decrease in anti-tumor 
therapy toxicities. While studies investigating a ketogenic diet demonstrate improved 
quality of life in patients with advanced cancer [124], to our current knowledge, no 
studies have investigated the capability to restore adipose tissue mass and the 
subsequent effect of restoring adipose tissue mass on CAC. A comprehensive 
understanding of the physiology and pathophysiology of adipose tissue, cancer, and 
CAC will hopefully lead to the discovery of key components and drivers within the 
development and progression of CAC that can be manipulated and targeted to benefit 
the patient. This is not a simple task, but as research progresses, the future applicability 
to patients suffering from CAC must always be considered a primary endpoint.  
 
 
1.5 Breast cancer 
1.5.1 Epidemiology and rationale for use 
Changes in normal breast tissue can be malignant or benign. While benign 
conditions, such as fibroadenomas, fibrocystic changes of the breast, and cysts, are 
estimated to account for approximately 80% of breast conditions, malignant breast 
changes – breast cancer – have a staggering prevalence and impact on human health. 
Worldwide, breast cancer is the most common cancer type diagnosed, and the most 
common cause of cancer death in women [125]. Among women in the United States, 
breast cancer is the most common cancer diagnosed and the second-leading cause of 
cancer death [126, 127]. In the United States alone, an estimated 266,120 new cases of 
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breast cancer will have been diagnosed in women in 2018. About 20% of patients with 
breast cancer die from the disease, often due to incurable metastatic disease [126]. 
A 2009 study including over 2000 patients with breast cancer showed that 
approximately 25% of patients with breast cancer are diagnosed with cachexia [128]. 
Although the percentage of patients with CAC in other cancers was found to be greater, 
such as in gastric and esophageal cancer (with 41.5 and 41.9% of patients with CAC, 
respectively [128]), the enormous prevalence of breast cancer relative to these other 
cancers reinforces the importance of studying CAC and WAT browning within this 
cancer type. A tabular visualization of these numbers is included in Table 1.   
While the high prevalence of breast cancer, both in the United States and world-
wide, serves as justification for the clinical importance of studying CAC in breast cancer, 
there are advantages to utilizing breast cancer for mechanistic studies of WAT browning 
in cancer in vitro and in vivo. Breast cancer is usually immediately adjacent to breast 
adipose tissue based on basic breast anatomy, which allows for local, mechanistic 
studies. Additionally, because localized breast cancer and breast tissue does not 
immediately interact with other systems, using breast cancer as a model to study WAT 
browning in cancer eliminates the confounding variables seen in other models (such as 
malabsorption in gastrointestinal-related cancers).  
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Table 1. Burden of cancer-associated cachexia (CAC) in breast cancer 
Cancer 
type 
Estimated number of 
new patients (men and 
women) diagnosed with 
disease in 2018 [126] 
Percentage of 
patients with any 
one of the cachexia 
definitions [128] 
General breast 
cancer CAC burden 
(estimated new 
cases x percentage 
with cachexia) 
Breast 268,670 24.8% 66,630 
Gastric 26,240 41.5% 10,890 
Esophageal 17,290 41.9% 7,245 
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1.5.2 Pathophysiology  
The breasts, or mammary glands, comprise a specialized organ with specialized 
function in women: to produce milk to provide nutrients and passive immunity to their 
nursing offspring after childbirth. The glands’ anterior border is comprised of the 
epidermis (skin) and superficial facia of the anterior thoracic wall, and the posterior 
border consists of the deep fascia of the anterior thoracic wall, retromammary bursa, 
and pectoralis muscles. Each gland contains approximately of 10-20 lobes connected 
by ducts, ultimately forming the lactiferous sinus which then exits through the nipple 
anteriorly. The lobes are supported by fibrous stroma, Cooper ligaments, and adipose 
tissue. The tissue also contains well-organized vasculature, innervation, and lymphatic 
drainage (detailed in [129]). 
Risk factors for the development and progression of breast cancer have been 
studied extensively, and include nulliparity, familial history, history of benign breast 
disease, and obesity [130, 131]. Considering that the ducts and lobules comprise the 
mammary glands, it is not surprising that the two main types of breast cancer are ductal 
and lobular. These cancers are further classified into subtypes based on several 
molecular markers: estrogen receptor (ER), progesterone receptor (PR); and human 
epidermal growth factor receptor 2 (HER2). The four main subtypes of breast cancer 
are: luminal A (ER and/or PR+, HER2-); luminal B (ER and/or PR+, HER2+); HER2-
enriched (ER-, PR-, and HER2+), and triple negative (ER-, PR-, and HER2-). It is 
important to note that the presence of other receptors and markers, such as androgen 
receptor, Ki67, B-Myb, and Twist can be useful, and studies are ongoing to understand 
the predictive values of these more recent, novel markers [132].  
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Tumor size (T), lymph node spread and extent (N), and extent of metastases (M) 
are the three criterion that make up the TNM staging algorithm, which create a staging 
‘score’ ranging from 0 (representing breast cancer in-situ) to IV (representing the most 
advanced breast cancer) [131]. Breast cancer most commonly metastasizes to the 
bone, lung, brain, and liver [133]. Treatment options for breast cancer are variable 
depending on the type and extent of disease. Surgery, radiation, and chemotherapy are 
all therapeutic options, and hormonal and targeted therapies can be used as well [131].  
 
1.6 Tumor microenvironment (TME) 
1.6.1 General concepts  
 The tumor microenvironment (TME) has several features that distinguish it from 
normal, healthy tissue. In addition to the presence of tumor (cancer) cells, the TME 
often has mesenchymal stem cells abnormally recruited as well as activation of cancer-
associated fibroblasts. The TME is often characterized by necrosis, hypoxia, and an 
acidic pH, with increased interstitial pressure, abnormal extracellular matrix deposition, 
and abnormal, disorganized, and often ‘leaky’ vasculature with increased blood flow 
[134, 135]. This leaky vasculature facilitates increased infiltration of a variety of immune 
cells, many of which are implicated in cancer-related processes [136]. As described 
already in sections 1.4.4 through 1.4.6, changes in adipocytes and adipose tissue 
depots may also contribute to cancer progression.  
 In breast cancer, key changes within the TME are known to aid in tumor 
progression and metastasis [137]. Mitochondrial function (or dysfunction) in different 
TME compartments has been shown to contribute to breast cancer growth [138]. 
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Altered signaling induced by breast cancer cells promotes tumor-beneficial processes 
such as angiogenesis, resistance to therapy, and cell proliferation [139]. The TME is 
associated with dynamic changes in inflammatory status, with many different 
chemokines and cytokines involved. Interleukin 6 (IL6) is one such cytokine. 
 
1.6.2 Interleukin 6 (IL6) 
IL6 is a glycosylated protein comprised of 184 amino acids, synthesized and 
secreted by a variety of cells, such as neutrophils, macrophages, smooth muscle cells, 
T cells, monocytes, fibroblasts, endothelial cells, and even preadipocytes [140-143].  
There are three IL6-initiated signaling cascades: the janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) pathway, the mitogen-activated protein 
kinase (MAPK) pathway, and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) 
pathway (reviewed by [21]). We focus on the JAK/STAT pathway due to its implicated 
role in other models of WAT browning [144]. JAKs are constitutively associated with the 
cytoplasmic tail of GP130 [140]; after the IL6:IL6RA complex binds GP130, JAKs are 
then activated by autophosphorylation and function to phosphorylate tyrosine residues 
in the cytosolic portion of GP130. This recruits STAT transcription factors to propagate 
target effects, and suppressors of cytokine signaling (SOCS) which act as feedback 
inhibitors [145]. 
Signaling initiated by IL6 is a multi-step process. First, IL6 must bind to a specific 
receptor, IL6 receptor alpha (IL6RA; also known as IL6R, or cluster of differentiation 
CD126). IL6RA can be either membrane-bound or soluble; if soluble, it is usually the 
result of proteolytic cleavage from the membrane (although translation of alternatively 
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spliced mRNA may also be a source) [146-148]. IL6RA is not ubiquitously expressed; 
instead, it is cell-specific, primarily found on hepatocytes, neutrophils, monocytes, and T 
cells [149]. After IL6 binds to IL6RA, this IL6:IL6RA complex then associates with the 
transmembrane protein glycoprotein 130 (GP130; also known as IL6 signal transducer 
IL6ST, IL6RB, or cluster of differentiation CD130) [150]. IL6 alone will not bind to GP130 
without first associating with IL6RA [151]. Unlike IL6RA, GP130 is expressed on all cells 
within the body [152, 153]. Dimerization of GP130 serves as the signal transducer for 
propagation of the JAK/STAT pathway [151]. 
IL6 is an inflammatory cytokine with pleiotropic actions, and has various roles in 
the breast and tumor environment, which includes cancer cells and adipocytes as well 
as adipocyte precursors, endothelial cells, and macrophages [154]. Elevated IL6 levels 
increase protein catabolism and skeletal muscle wasting which contributes to CAC 
[155].  Through its canonical signaling pathway via signal transducer and activator of 
transcription 3 (STAT3), the role of IL6 in CAC has been expanded to include other 
organ systems beyond skeletal muscle, including adipose tissue (reviewed by [156]). 
IL6 is thought to be involved in the dedifferentiation and inflammatory characteristics of 
breast cancer-associated adipocytes [157] and has been shown to stimulate WAT 
lipolysis [158]; however, its roles in BAT activation and WAT browning are only of recent 
interest. Increased BAT activity and WAT browning occurs in cancer and may contribute 
to CAC [103, 112, 113]. Specifically, IL6 has been implicated as a direct driver of WAT 
browning in models of colon cancer [112, 158].   
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1.7 Summary 
Sustained net-negative energy imbalance, as seen in CAC, represents a 
substantial clinical burden. White, beige, and brown adipose tissues are known to be 
involved in the development and progression of CAC, although exact mechanisms are 
not fully understood for all processes, especially in breast cancer. Breast cancer 
represents an ideal model to study the interactions between tumor, tumor 
microenvironment (especially IL6), and white adipose tissue.  
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Chapter 2: Materials and Methods 
 
 
All mice were bred and maintained in Virginia Commonwealth University animal 
facilities and utilized in accordance with protocols approved by the Institutional Animal 
Care and Use Committee (IACUC) at VCU: AM10309 (Dr. Xianjun (Frank) Fang 
laboratory), AD10000814 (Dr. Charles Clevenger laboratory), AD10001219 (Dr. Paula 
Bos laboratory), AM10065 (Dr. Daniel Conrad, now Dr. Rebecca Martin laboratory), 
AD10001447 (Dr. Francesco Celi laboratory). 
All human subjects research was performed in accordance with VCU IRB and 
PRMC-approved protocols (HM20009089 and MCC-17-13470, respectively). 
 
 
2.1 Tissue acquisition  
2.1.1 Mouse tissue acquisition  
In collaboration with Dr. Frank Fang, female B6.FVB-Tg(MMTV-
PyVT)634Mul/LellJ mice (also referred to as “C57BL/6J MMTV-PyVT” mice, Jackson 
Laboratory, stock #022974) at approximately 4 months of age were euthanized via 
isofluorane and cervical dislocation before being transferred to our lab for tissue 
extraction. Bilateral adipose tissue pads (interscapular, axillary, inguinal, and ovarian) 
were harvested and used for immunohistochemistry (see section 2.2) and gene 
expression analysis (see section 2.14). For axillary and inguinal adipose tissue pads, 
when tumor was present, some of the adjacent tumor was included with the adipose 
tissue that was placed in formalin for downstream immunohistochemistry. 
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In collaboration with the lab of Dr. Charles Clevenger, female PyMT FVB/N-Tg 
(MMTV-PyMT) 634 Mul/J mice (also referred to as “FVB MMTV-PyMT” mice, Jackson 
Laboratory, stock #002374) at approximately 4 and 13 weeks of age, as well as age-
matched female control FVB/NJ mice (Jackson Laboratory, stock #001800), were 
euthanized before transfer to our lab for tissue extraction. Bilateral adipose tissue pads 
(interscapular and inguinal) were harvested and used for gene expression and protein 
analyses (see sections 2.14 and 2.15, respectively).  
C57BL/6J wild-type mice (Jackson Laboratory, stock #000664) and BALB/cJ 
wild-type mice (Jackson Laboratory, stock #000651) were euthanized at approximately 
3 weeks of age via isoflurane. Inguinal white adipose tissue pads were removed under 
sterile conditions in a cell culture hood and used to isolate primary stromal vascular 
fraction cells for cell culture (see section 2.4.1). 
 
2.1.2 Human tissue acquisition  
 Benign breast tissue from women undergoing elective breast reduction surgeries 
was obtained through the VCU Tissue and Data Acquisition and Analysis Core 
(TDAAC). Deidentified samples were then moved under the cell culture hood, fibrous 
and connective tissue was removed, and adipose tissue was used for 
immunohistochemistry (see section 2.2.2) and isolation of primary stromal vascular 
fraction cells for cell culture (see section 2.4.2). 
 Slides with deidentified human samples of breast cancer with adjacent adipose 
tissue were obtained from the TDAAC for use in immunohistochemistry. 
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2.2 Immunohistochemistry (IHC) 
2.2.1 Mouse IHC 
Bilateral adipose tissue pads (interscapular, axillary, inguinal, and ovarian), with 
tumor when applicable, were harvested from female B6.FVB-Tg(MMTV-
PyVT)634Mul/LellJ mice at approximately 4 months of age and immediately placed into 
10% buffered formalin (Fisher Chemical) for 6 days. Tissues were then transferred to 
70% ethanol until embedding and sectioning was performed by the VCU Massey 
Cancer Center’s Cancer Mouse Model Shared Resource. All tissues were embedded 
with paraffin using a standard dehydration, clearing, and paraffin infiltration program via 
a Sakura Tissue Tek automated processor, and were sectioned at 5µm thickness. 
Mouse UCP1 expression in the tissues was detected via immunohistochemistry 
using the SuperPicture 3rd Gen IHC Detection Kit (Invitrogen 87-8973) reagents and 
slight protocol modifications. Slides were deparaffinized in xylene and rehydrated in a 
graded series of ethanol, ending with distilled water and finally PBST. Slides were then 
placed in citrate buffer (Sigma-Aldrich C9999) diluted to 1X in distilled water and heated 
in a microwave for antigen retrieval. Peroxidase quenching solution (included in kit) was 
placed on slides and incubated for 10 minutes. After washing with PBST, slides were 
covered with 5% BSA (Fisher Scientific BP1600-100, diluted in TBST) for one hour. The 
slides were incubated in UCP1 primary antibody (abcam 10983; diluted 1:500 in 1% 
BSA) or 1% BSA (to serve as post-antibody negative control) at 4°C in a dark cold room 
overnight. The next day, after washing with PBST, HRP Polymer Conjugate (included in 
kit) was added to cover the tissue area and left to incubate for 30 minutes. Slides were 
washed in PBST and DAB Chromogen (included in kit) was added for approximately 2 
 
 
63 
 
minutes to visualize binding. Slides were then washed with tap water and 
counterstained with diluted Hematoxylin Solution Gill No.2 (Sigma-Aldrich GHS232) for 
30 seconds. After washing with tap water, slides were dehydrated using a reverse-
graded series of ethanol, ending with xylene, and glass slides were mounted using 
HistoChoice Mounting Media (Amresco/VWR H157). 
Slides were digitally scanned using the NanoZoomer 2.0-HT Whole Slide Imager 
Digital Pathology Slide Scanner (Meyer Instruments) by the Department of Pathology.  
2.2.2 Human IHC 
Slides were stained by the VCU Massey Cancer Center’s Cancer Mouse Model 
Shared Resource Core for UCP1 using primary antibody (abcam ab155117, diluted 
1:200). Stained slides were scanned at 20X magnification by the Core facility. Slide 
images were captured using Phenochart 1.0.9 software.  
 
2.3 IHC staining intensity: qualitative and quantitative measures 
Qualitative assessment of IHC intensity was determined via blinded scoring by 
Dr. Trang Le in the Division of Endocrinology, Diabetes, and Metabolism. Images were 
assigned random number labels and sent to Dr. Le for scoring. For each sample, Dr. Le 
assigned a numerical value to grade the average staining intensity in the adipose tissue 
at 1) the tumor-adipose tissue interface and 2) the adipose tissue furthest from the 
tumor. The following numerical scale was used: 0 = no staining; 1 = weak staining; 2 = 
moderate staining; 3 = strong staining. These values were used to calculate the gradient 
of staining intensity.  
 
 
64 
 
Quantitative assessment was performed by computation analysis. The IHC 
images were processed and analyzed in MATLAB 2017a. A customized algorithm was 
developed to automatically detect the brown pixels and count the number of brown 
pixels by columns of each IHC image. The counts were plotted against the column 
index (which indicates the distance to the tumor cells) for curve fitting.  
 
2.4 Isolation of primary stromal vascular fraction (SVF) cells from adipose tissue 
Stromal vascular fraction (SVF) isolation was performed according to established 
protocol [159] with slight modifications for both mouse and human white adipose tissue. 
See Figure 6 for visual representation of this process.  
 
2.4.1 Mouse SVF 
For each C57BL/6 or BALB/c mouse, left and right inguinal fat pads were 
homogenized and combined into one tube, then digested in 1mg/mL Collagenase A 
(Roche 10103586001) in sterile PBS at 37°C for 90 minutes with gentle inversion of 
tubes every 10-15 minutes. After digestion, the cell solution was filtered through a 
100µm cell strainer to remove any large, undigested tissue. The remaining cell solution 
was centrifuged at 200g for 10 minutes at room temperature.  Supernatant was 
removed (including floating lipids) to leave a pellet of SVF. This SVF pellet was 
resuspended in 5mL of basal cell culture medium consisting of DMEM/F12+Glutamax 
(Thermo Fisher 10565-018), 10% fetal bovine serum (FBS; Thermo Fisher 10082-147), 
200U/mL penicillin, 0.2mg/mL streptomycin, and 25μg/mL amphotericin B (Sigma 
Aldrich A5955) and 100μg/mL Normacin (InvivoGen ant-nr-1, lot NOL-39-05A) and 
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plated on to a T25 tissue flask (Cellstar 690175). Cells were kept in a cell incubator 
(HERAcell 150i) at 37°C and 5% CO2 from this point forward. Cell culture medium was 
changed after 4 hours to remove cells that had not adhered (especially red blood cells). 
Cell culture medium was changed the next day and then every 2 days until cells 
reached 90% confluency, at which point they were passaged with Trypsin (Gibco 
25200-056) and expanded to T75s (Corning 430641U) or frozen in basal cell culture 
medium and 10% DMSO (Sigma D2650). 
 
2.4.2 Human SVF 
Adipose tissue was cut into small pieces and SVF pellet was obtained using 
methods described in section 2.4.1. The resulting human SVF pellet was resuspended 
in 5mL of basal cell culture medium consisting of DMEM/F12+Glutamax, 200U/mL 
penicillin, 0.2mg/mL streptomycin, and 25μg/mL amphotericin B, supplemented with 
either 1) 10% FBS or 2) components included in Fibroblast Growth Kit-Low serum 
(ATCC, PCS-201-041) and plated on to a T25 tissue flask. Cells were kept in a cell 
incubator and cared for using same methods described in section 2.4.1. 
 
 
 
 
 
66 
 
 
Figure 6. Process of SVF isolation for mouse and human adipose tissue samples 
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2.5 Immortalization of murine stromal vascular fraction cells  
SVF cells were isolated from the inguinal fat pad of a 1-month old male 
C57BL/6J mouse as described above in section 2.4.1. SVF cells were immortalized with 
SV40 Large T antigen (Addgene plasmid #1780) as published previously [160]. 
Immortalized SVF cells were cultured in basal medium consisting of DMEM/F12 
GlutaMAX supplemented with 200 U/mL penicillin/streptomycin and 10% FBS. These 
immortalized SVF cells are also referred to as mouse immortalized white preadipocytes, 
‘mIWPA,’ throughout the text. 
 
2.6 Differentiation of mature adipocytes 
2.6.1 Mouse immortalized white preadipocytes (mIWPA) differentiation  
mIWPA cells were grown in basal cell culture medium as described above in 
section 2.5. Cells were plated on cell culture plates coated with 0.1% gelatin solution 
(Sigma-Aldrich G1393) according to manufacturer protocol and grown to confluency in 
basal cell culture medium before differentiation. For white adipocyte differentiation, an 
induction cocktail comprised of basal medium, supplemented with 5μg/mL insulin 
(Sigma-Aldrich I9278), 1μM dexamethasone (Sigma-Aldrich D1756), 0.5mM 3-isobutyl-
1-methylxanthine (IBMX, Sigma-Aldrich I5879), and 125μM indomethacin (Sigma-
Aldrich I7378) was used for 2 days. After induction, differentiating white adipocytes were 
cultured in a maintenance cocktail comprised of basal medium supplemented with 
5μg/mL insulin for 12 days. For beige adipocyte differentiation, induction cocktail 
comprised of basal medium supplemented with 5μg/mL insulin, 5μM dexamethasone, 
0.5mM IBMX, 125μM indomethacin, 0.5μM rosiglitazone (Sigma-Aldrich R2408), and 
 
 
68 
 
1nM (T3, Sigma-Aldrich T6397) and used for 2 days. After induction, differentiating 
beige adipocytes were cultured in a maintenance cocktail comprised of basal medium 
supplemented with 5μg/mL insulin, 1μM rosiglitazone, and 1nM T3 for 12 days. See 
next subsections for experimental conditions after maturation. Medium for all cells was 
changed every 2-3 days. The maximum passage number used for any mIWPA 
experiments was passage 13. 
 
 
2.6.2 Murine primary SVF differentiation  
Primary mouse SVF cells were grown in a basal cell culture medium as 
described in section 2.4.1. Cells were plated on cell culture plates coated with 0.1% 
gelatin solution and grown to confluency in basal cell culture medium before 
differentiation. For white adipocyte differentiation, an induction cocktail comprised of 
basal medium without Normocin, supplemented with 5μg/mL insulin, 1μM 
dexamethasone, 0.5mM IBMX, and 125μM indomethacin was used for 4 days. After 
induction, differentiating white adipocytes were cultured in a maintenance cocktail 
comprised of basal medium without Normocin supplemented with 5μg/mL insulin for 12 
days. For beige adipocyte differentiation, induction cocktail comprised of basal medium 
without Normocin, supplemented with 5μg/mL insulin, 5μM dexamethasone, 0.5mM 
IBMX, 125μM indomethacin, 0.5μM rosiglitazone, and 1nM T3 and used for 4 days. 
After induction, differentiating beige adipocytes were cultured in a maintenance cocktail 
comprised of basal medium without Normocin supplemented with 5μg/mL insulin, 1μM 
rosiglitazone, and 1nM T3 for 12 days. See next subsections for experimental 
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conditions after maturation. Medium for all cells was changed every 2-3 days. The 
maximum passage number used for any primary SVF experiments was passage 4. 
 
2.6.3 Human primary SVF differentiation   
Primary human SVF preadipocytes were grown in a basal cell culture medium as 
described in section 2.4.2. Cells were plated on cell culture plates coated with 0.1% 
gelatin solution and grown to confluency in basal cell culture medium before 
differentiation. For white adipocyte differentiation, an induction cocktail comprised of 
basal medium (either of the two basal mediums described in section 2.4.2) 
supplemented with 5μg/mL insulin, 1μM dexamethasone, 0.5mM IBMX, and 125μM 
indomethacin was used for 4 days. After induction, differentiating white adipocytes were 
cultured in a maintenance cocktail comprised of basal medium supplemented with 
5μg/mL insulin for 12 days. For beige adipocyte differentiation, induction cocktail 
comprised of basal medium supplemented with 5μg/mL insulin, 5μM dexamethasone, 
0.5mM IBMX, 125μM indomethacin, 0.5μM rosiglitazone, and 1nM T3 and used for 4 
days. After induction, differentiating beige adipocytes were cultured in a maintenance 
cocktail comprised of basal medium supplemented with 5μg/mL insulin, 1μM 
rosiglitazone, and 1nM T3 for 12 days. See next subsections for experimental 
conditions after maturation. Medium for all cells was changed every 2-3 days. The 
maximum passage number used for any primary human SVF experiments was passage 
6. 
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2.7 Cancer cells lines and culture  
2.7.1 E0771  
Murine E0771 cells (CH3 BioSystems 940001) were grown in basal cell culture 
medium consisting of RPMI1640+GlutaMAX (Thermo Fisher 61870-036), supplemented 
with 10% FBS and 200U/mL penicillin, 0.2mg/mL streptomycin, and 25μg/mL 
amphotericin B. This murine breast cancer cell line has a C57BL/6 background and is 
ER+. The maximum passage number used for any experiments was passage 5.  
 
2.7.2 4T1  
Two populations of murine 4T1 cells were used in experiments. One population 
was obtained at passage 3 from the laboratory of Dr. Harry Bear, and the other was 
purchased from ATCC (ATCC CRL-2539). Both were grown in basal cell culture 
medium consisting of RPMI1640+GlutaMAX supplemented with 10% FBS and 200 
U/mL penicillin/streptomycin. This murine breast cancer cell line has a BALB/c 
background and has a more metastatic phenotype than E0771 cells. The maximum 
passage number used for any experiments was passage 7. 
 
2.7.3 LLC  
Murine Lewis lung carcinoma (LLC) cells were obtained at passage 8 from the 
laboratory of Dr. David Gewirtz, and grown in basal cell culture medium consisting of 
DMEM/F12+Glutamax supplemented with 10% FBS and 200 U/mL 
penicillin/streptomycin. The maximum passage number used for any experiments was 
passage 11. 
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2.7.4 MCF-7  
Human MCF-7 cells were obtained at passage 10 from the laboratory of Dr. 
Kazuaki Takabe and grown in basal cell culture medium consisting of 
RPMI1640+GlutaMAX supplemented with 10% FBS and 200 U/mL 
penicillin/streptomycin. This cell line of human breast adenocarcinoma is ‘luminal’ type 
A (ER+, PR+, HER2-). The maximum passage number used for any experiments was 
passage 13. 
 
2.7.5 MDA-MB-231  
Human MDA-MB-231 cells were obtained at passage 12 from the laboratory of 
Dr. Kazuaki Takabe, and grown in basal cell culture medium consisting of 
RPMI1640+GlutaMAX supplemented with 10% FBS and 200 U/mL 
penicillin/streptomycin. This cell line of human breast adenocarcinoma is ‘basal’ type 
and triple negative (ER-, PR-, and HER2-). The maximum passage number used for 
any experiments was passage 15. 
 
2.8 Cancer conditioned medium and coculture experiments 
For conditioned medium collection, cells were grown to ~70% confluency, and 
then cell culture medium was changed. This conditioned medium was harvested 24 
hours later and filtered through a 0.22µm pore size filter (Millipore SLGP033RS) for use 
in experiments. For coculture experiments, cells were grown to ~70% confluency on 
coculture inserts (Fisher Scientific 08-771-21) and then moved to the appropriate 
adipocyte wells for experiments. Empty coculture wells were placed in all other 
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adipocyte wells. The maximum passage number used for any experiments was 
passage 11. 
 
2.8.1 mIWPA experiments 
mIWPA cells were grown and induced to either mature white or beige adipocytes 
as described in section 2.6.1. On day 14, mature white preadipocytes were exposed to 
white maintenance medium plus one of the following for 24 hours: 1) no treatment 
(white control) or 2) cancer conditioned medium (E0771 or LLC) in a 1:1 ratio with white 
maintenance medium cocktail. Mature beige adipocytes continued on beige 
maintenance medium (beige control). Schematic of exposure periods visualized in 
Figure 7. 
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Figure 7. Murine immortalized SVF experiment schematic 
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2.8.2 Primary murine SVF experiments 
Primary murine SVF cells were isolated, grown, and induced to either mature 
white or beige adipocytes as described in section 2.6.2. On day 16, mature white 
preadipocytes were exposed to white maintenance medium plus one of the following for 
24 hours: 1) no treatment (white control), 2) 10µM CL 316,243 hydrate (Sigma-Aldrich 
S5976), 3) cancer conditioned medium (either E0771 or 4T1)  in a 1:1 ratio with white 
maintenance medium cocktail, or 4) coculture (with either E0771 or 4T1). Mature beige 
adipocytes continued on beige maintenance medium (beige control). Schematic of 
exposure periods visualized in Figure 8. 
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Figure 8. Murine primary SVF experiment schematic 
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2.8.3 Primary human SVF experiments 
Primary human SVF cells were isolated, grown, and induced to either mature 
white or beige adipocytes as described in section 2.6.3. On day 16, mature white 
preadipocytes were exposed to white maintenance medium plus one of the following for 
24 hours: 1) no treatment (white control) or 2) cancer conditioned medium (either MCF-
7 or MDA-MB-231) in a 1:1 ratio with white maintenance medium cocktail. Mature beige 
adipocytes continued on beige maintenance medium (beige control). Schematic of 
exposure periods visualized in Figure 9. 
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Figure 9. Human primary SVF experiment schematic 
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2.9 IL6 experiments 
Mature adipocytes from primary murine SVF cells were prepared as described in 
section 2.6.1. On day 16, mature white preadipocytes were exposed to white 
maintenance medium plus one of the following for 3 days: 1) no treatment (white 
control), 2) 10µM CL 316,243, 3) 40ng/mL mouse recombinant IL6 (R&D Systems 406-
ML/CF), 4) 40ng/mL mouse recombinant IL6 + 200ng/mL mouse recombinant IL6RA 
(R&D Systems, 1830-SR/CF). Mature beige adipocytes continued on beige 
maintenance medium (beige control). Schematic of experiment visualized in Figure 10. 
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Figure 10. IL6 experiment schematic 
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2.10 Tumor lysate & CD11b+ cell experiment 
In collaboration with the laboratory of Dr. Paula Bos, tumor lysate and isolated 
CD11b+ cells were obtained from the following murine models of breast cancer: MMTV-
PyMT at an early stage (10 weeks old at time of harvest), MMTV-PyMT at a late stage 
(24 weeks old at time of harvest), PyMT-derived cell line injected into bilateral inguinal 
mammary pads of a C57BL/6J mouse (6-8 weeks old age at time of injection, 150,000 
cells injected, harvested when tumors reach 2000mm3), E0771 cell line injected into 
bilateral inguinal mammary pads of a C57BL/6J mouse (6-8 weeks old age at time of 
injection, 500,000 cells injected, harvested 10 days later). All mice were female.  
For tumor lysate isolation, mice were euthanized via cervical dislocation. Tumors 
were dissected from mice and immediately frozen on dry ice for 10 minutes. Tissue was 
powdered using a mortar and pestle on dry ice. Cytokine lysis buffer consisting of (for 
every 50mL total): 2.5mL of 50mM Tris pH 7.5 (Fisher), 7.5mL of 150mM NaCl (Fisher), 
2.5mL of 1% NonidetP-40 (Fisher), 0.1mL of 1mM EDTA (Fisher), 37.4mL of H2O, and 
1x protease inhibitor cocktail (SIGMA cat#4693132001) was made. Frozen tissue 
powder was incubated in cytokine lysis buffer at a ratio of 1-2µL buffer for every 1mg of 
tissue for one hour in a cold room on a rotator. Solution was then sonicated three times 
at an amplitude of 40µm, 10 seconds each time with 30 seconds rest on ice in between. 
The tissue homogenate was then centrifuged three times at 14000rpm at 4°C for 10 
minutes each. In between each centrifugation, supernatant was collected and moved to 
a new tube for the next centrifugation, and pellet (cell debris, etc) was discarded. After 
final centrifugation and transfer of supernatant (tumor lysate) to final tube, lysate protein 
concentration was quantified using the Thermo Pierce BSA Protein Assay Kit (Thermo 
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23225) using the microplate protocol. Various dilutions of lysate were used to ensure 
that sample would be within the standard’s working range for quantification (examples 
include 1:1, 1:10, 1:50 in cytokine lysis buffer). Absorbance was measured at 560nm 
using a POLARstar OPTIMA plate reader. Program software was used to calculate 
protein concentrations. Tumor lysate was frozen at -80°C until needed.  
Isolation of CD11b+ cells was performed using Dynabeads magnetic separation 
technology. Mice were euthanized via cervical dislocation. Tumors near inguinal fat 
pads were removed from mice, careful to exclude lymph nodes, rinsed in ice-cold PBS, 
and then minced in 1x LiberaseTL (Roche). Homogenate was incubated for 30 minutes 
on a rotator in a 37°C incubator. 10mL of cell medium consisting of DMEM (Gibco), 
10%FBS (WZ), and penicillin/streptomycin (Gibco) was added to homogenate, and then 
filtered using 100µm pore size filters into 50mL tubes, then flushed with an extra 10mL 
of cell culture medium. Everything from this point was performed under sterile 
conditions in the lab’s cell culture room. Cells were centrifuged at 350g for 5 minutes at 
4°C. Supernatant was removed and cells were resuspended in 8mL of 43% Percoll 
(GE) + 2% FBS (VWR). Cells were centrifuged at 500g for 8 minutes at 4°C. 
Supernatant was removed again and cells were washed with 2mL of MACS sorting 
buffer (0.5% BSA, 2mM EDTA) before another centrifugation at 350g for 5 minutes at 
4°C. Supernatant was removed and cells were resuspended in 300µL of MACs sorting 
buffer and incubated in 200µL of Fc block (2.4g2) and 4µL of biotinylated CD11b 
monoclonal antibody (eBioscience 13-0112-86) for 30 minutes in cold room on a rotator. 
Magnetic bead master mix was created by diluting 100µL of Dynabeads (Biotin Binder, 
Invitrogen 11047) in 2mL of MACs in a 15mL conical tube (multiples were created when 
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needed). Tubes were placed in a magnet (DynaMagTM-15 Invitrogen 12301D) and 
remaining liquid was removed, leaving only washed magnetic beads. These beads were 
then resuspended in 100µL of MACs. 100µL of Magnetic bead master mix and 200µL of 
MACs was added to each tube of cells after incubation in Fc blocker and antibody. 
Tubes were placed in magnet for about 2 minutes, and liquid supernatant was 
discarded (CD11b+ cells should be attached to beads which went to magnet). 
Remaining cells conjugated to beads were resuspended in 500µL of MACs and 500µL 
of release buffer (Dynabead component-same catalog number) and incubated for 10-20 
minutes on a rotator in the cold room. After this, 1mL of MACs was added to each tube 
and tubes were placed on magnet. Liquid supernatant was collected into a new tube 
and beads were discarded. Suspended cells were centrifuged at 350g for 5 minutes at 
4°C, supernatant removed, and then cells were resuspended in 1mL of cell culture 
medium. Cells were counted using an automated cell counter (Life Technology 
Countess II) with Trypan blue (1:1 with cells) for live-dead differentiation. Live cell count 
was recorded, and cells were kept on ice until plated.  
Primary C57BL/6J SVF cell lines were isolated as described in section 2.6.2. 
Cells were plated on to gelatin-coated 12 well plates at passage 4 at a density of 3000 
cells/cm2. Basal cell culture medium was changed every other day until cells reached 
full confluency, at which point induction and maintenance mediums were used 
(compositions described in section 2.6.2). After 4 days of induction followed by 15 days 
of maintenance medium, some W and B wells were harvested for baseline mRNA, 
protein, and lipid droplet visualization analyses (see sections 2.14, 2.15, and 2.16, 
respectively). For the remaining wells, medium was changed to either continued white 
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or beige maintenance medium for controls, or to continue white maintenance medium 
plus one of the following experimental conditions (concentrations/amounts are for each 
well exposed): 40ng/mL of mouse recombinant IL6; 40ng/mL recombinant mouse TNFa 
(R&D Systems 410-MT-010/CF); 10uM CL 316,243 hydrate; 4µg of either MMTV early 
tumor lysate, MMTV late tumor lysate, Pymt tumor lysate, E0771 tumor lysate; 0.6µL of 
cytokine lysis buffer without protease inhibitor cocktail as a control for lysates; 28,000 
Pymt CD11b+ cells; 15,000 E0771 CD11b+ cells (pan myeloid); 1mL of E0771 cancer 
conditioned medium (see cancer conditioned medium experiments); 1mL RPMI-based 
culture medium as a control for cancer conditioned medium. Cells were harvested after 
3 days of exposure (Figure 11). 
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Figure 11. Tumor lysate & CD11b+ cell experiment schematic 
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2.11 4T1 allograft experiment 
In collaboration with the laboratory of Dr. Daniel Conrad, nine BALB/c wild-type 
(WT) (4 female, 5 male) and nine BALB/c Rag1-/- mice (4 female, 5 male) were used for 
this 4T1 allograft experiment.  
4T1 cells were prepared for injection via the following protocol: cells were 
cultured in their basal culture medium in 150mm flasks until confluent. Once cells 
reached confluency, flasks were washed with 1X PBS. Cells were scraped and 
centrifuged at 1500rpm for 5 minutes at 21°C. Supernatant was removed and cells were 
resuspended in 5mL 1X PBS and kept on ice to prevent clumping. 10µL of cell 
suspension was mixed with 10µL of 2% trypan blue to count live cells. 1X PBS was 
added to achieve concentration of 1x106 cells/mL. 
Mice were inoculated with either 200,000 4T1 cells in 200µL PBS (‘4T1 group’) or 
200µL PBS (vehicle control, ‘control group’) unilaterally in the right inguinal area using a 
26 gauge needle at the following ages for the mice ( 
Figure 12): WT females 62 days (about 9 weeks); WT males 49 days (7 weeks); 
Rag1-/- females 76 days (about 11 weeks); Rag1-/- males 57 days (about 8 weeks). Mice 
were kept in cages (separated based on sex and genotype) at 23°C. Mice were 
weighed at baseline and every other day. Injection site palpated every other day. Once 
tumor became palpable, tumor size was measured with calipers every day.  
4T1 group mice were euthanized 10 days after inoculation. Control group mice 
were euthanized 14 days after inoculation. Rectal temperature was obtained using a 
rectal temperature probe for all mice prior to euthanization. Mice were euthanized in 
isoflurane. Tumor (if present) and adipose tissues (interscapular, axillary, inguinal, and 
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gonadal) were harvested for gene expression and flow cytometry analyses (see 
sections 2.14 and 2.12, respectively).  
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Figure 12. 4T1 allograft experiment schematic 
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2.12 Flow cytometry 
Data for both cell-surface and intracellular flow cytometry were acquired on the 
LSR Fortessa flow cytometer (BD Biosciences) in the VCU Flow Cytometry Core. Data 
were analyzed using FCS Express 5 (De Novo Software). 
 
2.12.1 Cell surface flow cytometry 
Cell surface flow cytometry staining was performed as described previously [161] 
for either whole tissue or cells grown in cell culture:  
For cells grown in vitro, primary murine SVF were isolated, grown, and induced 
to either mature white or beige adipocytes as described in section 2.6.1 until day 16. 
Cells were gently washed twice with 1X PBS. Staining solution was added to each well 
(for each well on 12-well plate: 250µL total volume consisting of respective targets 
(Table 2) with Fc blocker diluted in 1X PBS) and left to incubate at 4ºC in the dark for 20 
minutes. 100µL of live-dead stain (Biolegend Zombie Aqua Dye 77143 in DMSO) diluted 
1:100 in 1X PBS was added to each well (still had staining solution it) and incubated for 
15 minutes at room temperature in the dark. 350µL of 1X FACS with Azide was added 
to each well for 5 minutes at room temperature. Cells were then gently scraped off of 
the well and moved to a FACS tube. Suspension was pipetted up and down several 
times to encourage single-cell suspension. 700µL of Fixation buffer (Biolegend 420801) 
was added to each sample and left to incubate for 20 minutes at room temperature. 
Tubes were then centrifuged at 250g for 10 minutes at room temperature. Sheets and 
clumps of cells remained floating at the top, some cellular material floated in the middle, 
and a small amount of cellular material precipitated to the bottom. The top and middle 
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portions were discarded, and the bottom portion was resuspended in 300µL of FACS 
with Azide, pipetting up and down several times to encourage single-cell suspension. 
Samples were passed through a 100µm mesh filter before running on flow cytometry 
instrument. 
For whole tissue, tissue samples were placed in 12 well dishes with 1mL of 
1mg/mL collagenase A and homogenized. For each sample, homogenized tissue and 
collagenase was moved to a 2mL Eppendorf tube and placed on a rotator in a 37°C 
incubator for about 45 minutes. Homogenized solution was filtered into 50mL tube with 
a 70µM filter (Fisherbrand 22363548). Filtered cell solution was centrifuged at 1500rpm 
for 5 minutes at room temperature. Supernatant was decanted and 100µL of 1X 
mojosort was added. This mixture was then moved to a well on a 96 well plate and kept 
on ice. Once all samples were loaded, the plate was centrifuged at 2000rpm for 4 
minutes at room temperature, decanted, and washed with 200µL of 1X PBS per well. 
This was repeated twice. 100µL of live-dead stain (Biolegend Zombie Aqua Dye 77143 
lot B194251 in DMSO) diluted 1:100 in 1X PBS was added to each well and incubated 
for 10 minutes at room temperature in the dark. Plate underwent two cycles of 100uL 1X 
mojosort buffer wash per well, centrifuged, and decanted. 50µL of 2.4g2 [162] to block 
Fc receptors (diluted in 1X mojosort) was added to each well and incubated for 10 
minutes at room temperature. 50µL of antibody mix per well (25µL brilliant blue stain 
buffer, 0.5µL of each antibody used (Table 2), and the remaining with 1X mojosort) was 
added to each well and moved to refrigerator to incubate for 30 minutes. Plate was 
centrifuged, decanted, and then samples washed with 200µL 1X mojosort per well 
before another cycle of centrifugation and decanting. Cells were then fixed with 150µL 
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of 1X fixing solution for 10 minutes at room temperature. Plate was centrifuged and 
decanted. 200µL of 1X mojosort was added to each well and the solution in each well 
was transferred to individual tubes for running flow cytometry.  
 
2.12.2 Intracellular flow cytometry 
For intracellular cytokine staining, cells (mIWPA, E0771, LLC, 4T1, mouse 
peritoneal cavity cells) were cultured in 6 or 12 well plates for each cell type until ~70% 
confluent. Murine peritoneal cavity cells were isolated by lavage the day preceding each 
experiment by the Conrad laboratory. Cells were treated with one of the following 
conditions in basal medium before harvest: 1) 1X Brefeldin A (BioLegend 420601) and 
1X Monensin (BioLegend 420701) for 6 hours; 2) 1X Brefeldin A, 1X Monensin, 1X 
phorbol 12-myristate-13-acetate (PMA; Sigma-Aldrich P1585) and 1X Ionomycin 
(ThermoFisher I24222) for 3 hours; 3) no treatment.  
Wells of same treatment group were pooled together and harvested with trypsin, 
pelleted, and resuspended in 200µL of 1X mojosort to encourage single cell 
suspensions. 100µL of cell suspension moved into two wells of a 96-well plate on ice.  
The 96-well plate was contributed at 2000rpm for 3 minutes at room temperature, 
decanted, washed with 200µL of 1X PBS per well, spun again, and decanted. 100µL of 
live-dead stain was added per well (Biolegend Zombie Aqua in DMSO, diluted 1:200 in 
1X PBS) and left to incubate in the dark at room temperature for 10 minutes. Wells were 
washed with 100µL 1X FACS with Azide, spun at 2000rpm for 4 minutes at room 
temperature, decanted, and washed again with 180µL 1X mojosort, spun, decanted. 
100µL of 2.4g2 was added in 1X FACS (40µL 2.4g2 in 4mL FACS)) for 5 minutes at 
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room temperature, then spun and decanted. 150µL of fixation buffer was added per well 
and left to incubate in the dark at room temperature for 15 minutes. Plate was spun, 
decanted. Wells were washed, spun, decanted with 170µL of 1X permeabilization buffer 
(Biolegend 421002 diluted to 1X in H2O) twice. Intracellular stain mixture was made to 
get 100µL per well: 98µL of 1X perm buffer, 1µL antibody (Table 2), and 1µL of Fc 
blocker. 100µL of intracellular stain mixture was added and incubated for 40 minutes in 
the dark at room temperature. Plate was then spun, decanted. Wells were washed twice 
with permeabilization buffer, 170µL per well each time, spun, and decanted. Wells were 
then washed with 170µL 1X FACS to seal the membrane, spun, decanted. 150µL of 
fixation buffer was added to each well and incubated at room temperature in the dark for 
15 minutes. Plate was spun and decanted. Wells were resuspended in 200µL FACS 
and transferred to flow tubes. An additional 100µL FACS was added to each tube to get 
300µL per tube. Tubes were covered in foil and placed in the refrigerator for storage 
before flow cytometry was performed. 
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Table 2. Flow cytometry antibodies  
Target Isotype Stain/ Dye Clone 
Catalog 
Number 
Lot 
Number Company 
[ ] 
Used Use 
CD45 Rat IgG2b, κ 
APC/Fire 
750 30-F11 103154 - Biolegend 2µg/mL Cell surface 
Ly6G Rat IgG2a, κ 
Brilliant 
Violet D7 108131 - Biolegend 2µg/mL Cell surface 
FcεR Rat IgG2a, κ FITC 1A8 127606 - Biolegend 2µg/mL Cell surface 
CD3ε Hamster IgG PE/Cy7 145-2C11 100320 - Biolegend 2µg/mL Cell surface 
CD45R/B
220 
Rat 
IgG2a, κ PE/Cy7 RA3-6B2 103222 - Biolegend 2µg/mL Cell surface 
I-A/I-E Rat IgG2b, κ 
Brilliant 
Violet M5/114 107632 - Biolegend 2µg/mL Cell surface 
CD11c Hamster IgG 
Brilliant 
Violet 605 N418 117334 - Biolegend 2µg/mL Cell surface 
Ly6C Rat IgG2c, κ APC HK1.4 17-5932-80 - eBiosciences 2µg/mL Cell surface 
F4/80 Rat IgG2a, κ PE BM8 123110 - Biolegend 2µg/mL Cell surface 
CD11b Rat IgG2b, κ BUV395 M1/70 563553 - BD Horizon 2µg/mL Cell surface 
FcεR1α Hamster IgG 
PE/Dazzl
e MAR-1 134332 - Biolegend 2µg/mL Cell surface 
Mouse IL-
6 
Rat 
IgG1, κ  PE MP5-20F3 554401 7159590 
BD 
Biosciences 2µg/mL Intracellular  
- Rat IgG1, κ PE R3-34 554685 7026874 
BD 
Biosciences 2µg/mL 
Intracellular 
isotype 
control 
Mouse 
GP130 
(CD130) 
Rat 
IgG2b, κ PE 4H1B35 149404 B248938 Biolegend 2µg/mL Cell surface  
- Rat IgG2b, κ PE RTK4530 400607 B255376 Biolegend 2µg/mL 
Cell surface 
isotype 
control 
Mouse 
IL6RA 
(CD126) 
Rat 
IgG2b, κ APC D7715A7 115812 B249718 Biolegend 2µg/mL Cell surface 
- Rat IgG2b, κ APC RTK4530 400611 B261320 Biolegend 2µg/mL 
Cell surface 
isotype 
control 
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2.13 RNA isolation and cDNA generation 
Total RNA was isolated with TRIzol (Thermo Fisher 15596018) according to 
manufacturer protocol for whole tissue or culture cells. Isolation was performed with 
UltraPure Glycogen (Thermo Fisher 10814-010). RNA was quantified using the 
NanoDrop 1000 Spectrophotometer (Thermo Fisher). cDNA was generated using the 
BioRad iScript cDNA Synthesis Kit (BioRad 170-8891) with an input of 1µg of RNA on a 
C1000 Thermal Cycler (BioRad). The cDNA was then diluted 1:3 in molecular grade 
water.  
 
2.14 Quantitative PCR (qPCR) 
qPCR was performed on the QuantStudio 3 Real-Time PCR System (Thermo 
Fisher) with 10µL per reaction on 96 well plates in technical duplicates or triplicates: 1X 
PowerUp SYBR Green Master Mix (Applied Biosystems A25778), forward and reverse 
primers (0.5µM for mouse, 1µM for human; refer to Table 3 and Table 4 respectively for 
sequences and information), and 3µL of diluted cDNA. The Thermo Fisher Cloud 
platform was used for analysis of efficiency-corrected Cq values using endogenous 
control (Tbp for mouse, TBP for human), and fold-changes (2^ΔΔCq) were calculated 
using Microsoft Excel.  
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Table 3. Mouse primers used for qPCR 
Gene Efficiency Full Name 
NCBI 
Gene 
ID 
NCBI 
Reference 
Sequence 
Product 
Length 
(bp) 
Variants 
Targeted 
Forward 
Primer (5’-3’) 
Reverse 
Primer (5’-3’) 
Cfd 97.247 
complemen
t factor D 
(adipsin) 
11537 
NM_01345
9.3 
 
100 V1, V2, V3 
AACCGGACA
ACCTGCAAT
CT 
 
AGTCTCCCCT
GCAAGTGTCC 
 
Cidea 99.083 
cell death-
inducing 
DNA 
fragmentati
on factor, 
alpha 
subunit-like 
effector A 
12683 
NM_00770
2.2 
 
197 Cidea mRNA 
TCCTCGGCT
GTCTCAATG 
TGGCTGCTCT
TCTGTATCG 
Dlk1 97.176 
Delta like 
non-
canonical 
Notch 
ligand 1  
13386 
 
(aka 
Pref-1) 
NM_01005
2.5 
 
109 
 
V1-V5; 
X1-X2 
 
AAGTGTGTA
ACTGCCCCT
GG 
 
TGCAAGCCCG
AACGTCTATT 
 
Fasn 99.309 fatty acid synthase 14104 
NM_00798
8.3 104 
Fasn 
mRNA 
TGCACCTCA
CAGGCATCA
AT 
GTCCCACTTG
ATGTGAGGGG 
Il6 93.237 Interleukin-6 16193 
NM_03116
8.2 
79 
 V1, V2 
CCACTTCAC
AAGTCGGAG
GC 
TTGCCATTGC
ACAACTCTTTT
CT 
Il6ra 97.549 
interleukin 
6 receptor, 
alpha 
16194 NM_010559.3 104 V1, V2 
TGAATGATG
ACCCCAGGC
AC 
ACACCCATCC
GCTCTCTACT 
Il6st 99.644 
interleukin 
6 signal 
transducer 
 
aka Gp130 
16195 NM_010560.3 60 
Il6st 
mRNA 
TTACAACAC
CAAAGTTCG
CTCA 
CTAAGCACAC
AGGCACGACT
A 
Lep 91.876 leptin 16846 NM_008493.3 
131 (128 
variant 
X1) 
Lep 
mRNA, 
X1 
GCAGTGCCT
ATCCAGAAA
GTCC 
GGAATGAAGT
CCAAGCCAGT
GAC 
Lipe 100.441 
lipase, 
hormone 
sensitive 
16890 NM_010719.5 150 
V1,V2 
X1,X2,X3 
 
CGCTACACA
AAGGCTGCT
TC 
 
AACTGGCGGT
CACACTGAG 
 
Lpl 90.259 lipoprotein lipase 16956 
NM_00850
9.2 113 Lpl mRNA 
GCGTAGCAG
GAAGTCTGA
CCAA 
AGCGTCATCA
GGAGAAAGG
CGA 
Mgll 108.576 monoglyceride lipase 23945 
NM_00116
6251.1 
 
72 V1, V4 
CGCGAGGTT
TCCTTCCCTA
A 
AAAGTCACCC
CGATTCTCCG 
Oplah 98.557 
5-
oxoprolinas
e 
75475 NM_153122.2 108 
Predicted 
isoforms 
CTGCTGGTG
GGTTCTCCC 
CCACGGTCGA
TGGCAAAATG 
Pparg 98.04 
peroxisome 
proliferative 
activated 
receptor, 
gamma 
19016 NM_011146.3 73 V2, X8 
GCATGGTGC
CTTCGCTGA 
TGGCATCTCT
GTGTCAACCA
TG 
Pparg
c1a 99.095 
peroxisome 
proliferative 
activated 
receptor, 
19017 NM_008904.2 52 
V1 
mRNA, 
V2 ncRNA 
ATGTGCAGC
CAAGACTCT
GT 
CAACCAGAGC
AGCACACTCT 
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gamma, 
coactivator 
1 alpha 
Prdm
16 97.145 
PR domain 
containing 
16 
70673 NM_027504.3 87 
V1-4, X1-
7 
CAGCACGGT
GAAGCCATT
C 
GCGTGCATCC
GCTTGTG 
Ptk2b 87.917 
Protein-
tyrosine 
kinase 2-
beta 
19229 NM_001162366.1 81 
V1-V3, 
X1-X7 
TGCAGACAG
AGATCCAGG
AGA 
TATTCGCCCA
CTCAGGAGGA 
Slc27
a1 99.235 
long-chain 
fatty acid 
transport 
protein 1 
26457 NM_011977.3 106 
Plus other 
predicted 
GGGATCTCT
CTCTCCACC
CC 
GAGCTTGCCT
GATCCAGCTT 
Slc29
a1 96.822 
equilibrativ
e 
nucleoside 
transporter 
1 
63959 NM_001199113.1 120 
V1-V5; 
other 
predicted 
CACCAGCCT
CAGGACAGG
TAT 
GTCCAGGCG
GTTTGTGAAA 
Socs
3 110.721 
Suppressor 
of cytokine 
signaling 3 
12702 NM_007707.3 122 
mRNA, 
predicted 
variant X1 
TAGACTTCA
CGGCTGCCA
AC 
CGGGGAGCT
AGTCCCGAA 
Tbp 94.570 
TATA box 
binding 
protein 
21374 NM_013684.3 98 
Tbp 
mRNA 
AGAACAACA
GCCTTCCAC
CT 
GCCGTAAGGC
ATCATTGGAC 
Tnfrsf
9 97.105 
tumor 
necrosis 
factor 
receptor 
superfamily
, member 9 
(aka 
Cd137) 
21942 NM_011612.2 104 
V1,V2,V3, 
X1 
CGTGCAGAA
CTCCTGTGA
TAAC 
GTCCACCTAT
GCTGGAGAAG
G 
Ucp1 95.837 
uncoupling 
protein 1 
(mitochond
rial, proton 
carrier) 
22227 NM_009463.3 91 
Ucp1 
mRNA 
CACCTTCCC
GCTGGACAC
T 
CCCTAGGACA
CCTTTATACC
TAATGG 
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Table 4. Human primers used for qPCR 
Gene 
 
Efficiency Full Name 
NCBI 
Gene 
ID 
NCBI 
Reference 
Sequence 
Product 
Length 
(bp) 
Variants 
Targeted 
Forward 
Primer (5’-3’) 
Reverse 
Primer (5’-3’) 
EAR2 105.984 
Nuclear 
receptor 
subfamily 2 
group F 
member 6 
2063 NM_005234.3 81 
EAR2 
mRNA 
TACACCTGC
CGGTCCAA 
ACCCGGAAGC
ACTTCTTGAG 
OPLA
H 103.185 
5-
oxoprolinas
e 
26873 NM_017570.4 106 
OPLAH 
mRNA 
GAGCCGAGC
GCCAGTTTTT
C 
GTCGATGGCA
AAGTGGAAGC 
PDK4 103.216 
[Pyruvate 
dehydroge
nase 
(acetyl-
transferring
)] kinase 
isozyme 4, 
mitochondri
al 
5166 NM_002612.3 65 
PDK4 
mRNA 
CCAAGCCAC
ATTGGAAGC
AT 
TCAAAGGCAT
CTTGGACCAC 
PPA
RGC
1A 
93.971 
Peroxisom
e 
proliferator-
activated 
receptor 
gamma 
coactivator 
1-alpha 
10891 NM_013261.3 91 
PPARGC
1A mRNA 
TGACTGGCG
TCATTCAGG
AG 
TGACTGGCGT
CATTCAGGAG 
PPA
RG 94.305 
Peroxisom
e 
proliferator-
activated 
receptor 
gamma 
coactivator 
1-alpha 
5468 NM_015869.4 70 
PPARG 
mRNA, 
and 
predicted 
variants 
ACCCAGAAA
GCGATTCCT
TCA 
GTGTCAACCA
TGGTCATTTC
TTGT 
SLC2
7A1 99.693 
Long-chain 
fatty acid 
transport 
protein 1 
376497 NM_198580.2 66 
SLC27A1 
mRNA, 
and 
predicted 
variants 
TGTACCACT
CGGCAGGAA
AC 
GGACGACTGT
CAGCCCATAG 
SLC2
9A1 99.144 
Equilibrativ
e 
nucleoside 
transporter 
1 
2030 NM_001078177.1 100 
SLC29A1 
mRNA, 
and 
predicted 
variants 
ATCGATCTG
GAGCCCGTG
GA 
ATCGATCTGG
AGCCCGTGGA 
TBP 102.419 
TATA-box-
binding 
protein 
6908 NM_003194.4 68 
TBP 
mRNA 
CGGCTGTTT
AACTTCGCTT
CC 
CAAGAAACAG
TGATGCTGGG
TC 
TME
M26 104.328 
Transmem
brane 
protein 26 
219623 NM_178505.6 111 
TMEM26 
mRNA 
TGACCTGGC
AGTACAGAA
CG 
ACGCTGATTC
CGATGTTCCA 
UCP1 101.358 Uncoupling protein 1 7350 
NM_02183
3.4 51 
UCP1 
mRNA 
GGCTTTCTT
CAAGGGGTT
GGTA 
TTCCAGGATC
CAAGTCGCAA 
 
 
 
 
97 
 
2.15 Protein quantification & western blotting 
If protein samples were stored in -80ºC freezer, they were thawed on ice prior to 
isolation and quantification. Protein isolation was performed using RIPA lysis and 
extraction buffer (Thermo Scientific 89901). RIPA buffer was supplemented with 
protease inhibitor (Roche 4693116001) and phosphatase inhibitors (Roche 
4906837001) (1 tablet each per 10mL of RIPA buffer). 1µL of 1X nuclease solution 
(Pierce 88701, diluted in supplemented RIPA buffer) was added to each sample and 
placed on rotator at room temperature for 10 minutes. Samples were then centrifuged at 
4ºC at 13,000rcf for 10 minutes.  
Protein quantification was performed using Pierce BCA Protein Assay Kit 
(Thermo Scientific 23227) according to manufacturer’s ‘microplate’ protocol. 
Absorbance was measured at 562nm using a VersaMax microplate reader (Molecular 
Devices). And standard curve was generated using a four-parameter curve with 
SoftMax Pro 5.3 software. This standard curve was then used to determine the protein 
concentration of unknown samples. 
Protein lysates were prepared for separation using 20µg of sample per well, with 
1X NuPAGE LDS loading buffer (Invitrogen NP0007) and 1X NuPAGE reducing agent 
(Invitrogen NP0009). These samples were then ‘boiled’ on a 70ºC heat block for 10 
minutes. Samples were separated on NuPAGE 4-12% Bis-Tris Midi Gels (ThermoFisher 
WG1401BOX) using an XCell4 Surelock Midi-Cell (Invitrogen) and 1X NuPAGE MOPS 
SDS running buffer (Invitrogen NP0001, diluted in H2O). 8µL of pre-stained protein 
ladder (Fisher 26616) was loaded in first and/or last well. Gel transfer was performed 
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using the iBlot Transfer Stack, PVDF, regular size (Invitrogen IB401001) ‘dry blot 
transfer’ method.  
Membranes were washed with distilled H2O and then 100% methanol. 
Membranes were left to air-dry and were re-wetted in 100% methanol before being 
transferred to box with 5% non-fat milk solution (BioRad 170-6404, diluted in 1X TBST). 
Membranes were left for blocking on a rocker at room temperature for 1 hour. 
Membranes were then washed once in TBST, cut as necessary for appropriate targets, 
and moved into separate tubes for primary antibody incubation (primary antibodies in 
Table 5 diluted in 1% BSA in 1X TBST) on a rotator in cold room overnight.  
The next day, membranes were washed three times in 1X TBST on a shaker at 
room temperature for 10 minutes each. Membranes were moved to black boxes for 
secondary antibody incubation (secondary antibodies in Table 5 diluted in non-fat milk 
solution saved from prior day) on a rocker at room temperature for one hour. 
Membranes were then washed with 1X TBST three times on a shaker for 10 minutes 
each.  
Membranes were incubated in chemiluminescence substrates for 1-2 minutes 
(Cell Signaling 7003, both diluted to 1X in distilled H2O) to detect western blot signal. 
Images were captured either using film or the ChemiDoc MP Imaging System (BioRad).  
Stat1/2/3/5 Control Cell Extracts (Cell Signaling 9133) were used for 
phosphorylated STAT3 negative and positive controls.  
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Table 5. Western blot antibodies 
Target Isotype Stain/ Dye Clone 
Catalog 
Number 
Lot 
Number Company 
Concentration  
Used Use 
Phospho-
STAT3 
(Tyr705) 
Rabbit 
IgG - D3A7 9145 S 34 Cell Signaling 1:2000 
Primary 
antibody 
Phospho-
STAT3 
(Ser727) 
Rabbit 
IgG - - 9134 S 21 Cell Signaling 1:1000 
Primary 
antibody 
STAT3 Mouse IgG2a - 124H6 9139 S 10 Cell Signaling  1:1000 
Primary 
antibody 
TBP Rabbit IgG - D5C9H 44059 S 1 Cell Signaling  1:2000 
Primary 
antibody 
UCP1 Rabbit IgG - - ab10983 
GR31884
78-5 Abcam 1:1000 
Primary 
antibody  
α-
TUBULIN 
Mouse 
IgM -  -  sc-8035 - Santa Cruz 1:1000 
Primary 
antibody 
- Rabbit IgG - - A6154 
SLBG72
01V Sigma-Aldrich 1:5000 
Secondary 
antibody 
- Mouse IgG - - A4416 
SLBS101
0V Sigma-Aldrich 1:5000 
Secondary 
antibody 
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2.16 Oil Red O staining & imaging 
Oil Red O (Sigma-Aldrich O0625) was used to stain adipocytes after 
differentiation according to established Lonza protocol (#WEB-PR-PT-2501 OIL-3). 
Wells were kept covered with water until visualized by bright-field microscopy using a 
Zeiss AxioObserver A1 Microscope at the VCU Department of Anatomy and 
Neurobiology Microscopy Facility. 
 
2.17 Lipid droplet quantification  
 Lipid droplet size was quantified using MIPAR Image Analysis Software. A 
customized recipe was developed to invert the color of the images obtained from Oil 
Red O staining and then calculate the area of each lipid droplet via color detection.  
 
2.18 Human subjects research 
All human subjects research was performed in accordance with VCU IRB and 
PRMC-approved protocols (HM20009089 and MCC-17-13470, respectively). Please 
refer to Appendices for detailed documentation. Below is a summary for of the two aims 
of this project: 
 
2.18.1 Chart review  
Aim: To identify patients with cancer and positive and negative brown adipose 
tissue on PET imaging and obtain pertinent preliminary information including MRN, zip 
code, age, gender, ethnicity, BMI, weight, primary cancer, diabetes status, fasting 
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glucose data, thyroid function testing results, medication list, PET scan image and year, 
and brown adipose tissue status. 
Methods: Investigators will query medical records using Cerner and Montage 
programs for patients who are at least 40 years of age and who have cancer and have 
had a PET scan. The PET report will be studied to assess brown adipose tissue 
presence. Information to be recorded includes: medical record number (MRN), zip code, 
age, gender, ethnicity, BMI, weight, primary cancer, diabetes status, fasting glucose 
data, thyroid function testing results, medication list, brown adipose tissue status (either 
positive or negative depending on PET image report), and PET scan image and year. 
For preliminary findings included in Chapter 6, Montage program was queried 
using the following parameters: 
1. All these words: "Brown fat" | "Brown adipose tissue" 
2. Date range: 1/1/2007 to 1/31/2017 
3. Modalities: PET (PT) and PT/CT 
 
2.18.2 Measuring energy expenditure using whole room indirect calorimeters  
Aim: To characterize and measure the difference in energy metabolism profiles, 
quality of life, and biochemical profiles of patients with cancer with and without evidence 
of brown adipose tissue activation both at room temperature and following exposure to 
warm temperature. 
Methods: We will recruit patients with cancer and brown adipose tissue activation 
to compare their energy expenditure with the energy expenditure of age-, sex-, BMI-, 
and cancer type-matched patients with no brown adipose tissue activation at room 
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temperature. We will then assess if exposure to warm temperature, a known 
intervention to quench brown fat activation, is sufficient to decrease the energy 
expenditure in cancer patients with evidence of BAT activation. The primary endpoint in 
this Aim will be Energy Expenditure, measured using whole-room indirect calorimeters. 
The indirect calorimeter technique allows for non-invasive real-time recording of energy 
expenditure and respiratory quotient (a proxy for substrate utilization) by measuring 
oxygen consumption and carbon dioxide production. Other data that will be collected for 
secondary endpoints include: a quality of life questionnaire, thermal comfort 
questionnaires, infrared photography, blood collection, and urine collection. 
There will be three visits in total for participants that complete this study. Visit 1 
will be a Screening visit, where informed consent will be obtained, inclusion/exclusion 
criteria will be confirmed, medical history will be obtained, physical examination will be 
performed, weight and vital signs will be recorded, bio-impedance analysis will be 
conducted, and a quality of life questionnaire will be filled out by the participant. At both 
visits 2 and 3, participants will have their resting energy expenditure measured by 
resting in the indirect calorimeters for 4 hours per visit. Urine and blood will be collected 
before and after each session in the calorimeter. Thermal comfort questionnaires will be 
completed before and after each session in the calorimeter. A general overview of these 
three visits is visualized in Figure 13. 
Detailed methodology regarding calculation of energy expenditure recording is 
detailed in our laboratory’s recently published article, DOI 
10.1371/journal.pone.0193467.  
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Figure 13. Human subjects research intervention study design  
For additional details, refer to Appendices. 
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2.19 Paraganglioma clinical and laboratory research 
2.19.1 Clinical results 
Imaging and lab results and clinical notes were obtained without any personal 
identifiers from the VCUHS Cerner medical system.  
All anti-GAD65 antibody assays were performed by Lab Corp using an FDA-
cleared enzyme-linked immunosorbent assay (ELISA) purchased from Kronus 
(KR7710). 
 
2.19.2 Specimen collection 
Slides were retrospectively identified archival tissues processed for routine 
surgical pathology specimen processing in the VCUHS CLIA-compliant clinical lab. 
Tissues were formalin-fixed and paraffin-embedded. Tissue blocks were cut at 4 
micrometers for slide preparation and were deidentified. 
 
2.19.3 Immunohistochemistry and imaging 
Hematoxylin and eosin (H&E) staining was performed by the Department of 
Pathology using routine processing procedures.  Human GAD65 protein expression 
(Santa Cruz, sc-377145) was detected using the SuperPicTure Polymer Detection Kit 
(Invitrogen 87-8963) and slight protocol modifications. Expression of FH and SDHB was 
assessed (FH: Santa Cruz sc-100743, SDHB: Abcam ab14714) under routine CLIA-
certified clinical protocols as reported previously [163]. Slides were digitally scanned 
using the NanoZoomer 2.0-HT Whole Slide Imager Digital Pathology Slide Scanner 
(Meyer Instruments) by the Department of Pathology. 
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2.20 Statistical analyses 
GraphPad Prism was used for visualization of data and statistical analyses. 
Appropriate tests were used to correct for multiple analyses with nonparametric 
assumptions; specific tests used are described in each figure legend. For all analyses 
unless otherwise noted, error bars = standard deviation, and p-values are represented 
as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; #p < 0.05. 
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Chapter 3: Local Browning of White Adipose Tissue Occurs in Breast Cancer 
 
3.1 Rationale 
Browning of WAT has been demonstrated in several murine cancer models and 
human cancer samples [103, 112, 113]; however, WAT browning in breast cancer has 
not been established. Breast cancer represents a unique and advantageous model for 
investigating WAT browning as it is directly contiguous with surrounding breast WAT 
and is removed from confounding variables such as nausea and malabsorption in 
gastrointestinal malignancies. In this chapter, we sought out to determine whether WAT 
browning occurs in breast cancer in both murine breast cancer models and in human 
breast cancer samples. 
 
3.2 Results 
3.2.1 WAT browning occurs locally in the C57BL/6J MMTV-PyVT murine model of 
spontaneous mammary tumor 
We first addressed whether WAT browning could be observed in the C57BL/6J 
MMTV-PyVT murine model of spontaneous breast cancer. Compared to their respective 
ovarian WAT (Figure 14A), adipocytes surrounding mammary tumors in both axillary 
and inguinal mammary fat pads demonstrate an increased staining intensity for UCP1 
protein (Figure 14B), but not as much as their respective interscapular BAT (Figure 
14A). The lipid droplets in the adipocytes closest to the tumor also appear smaller than 
lipid droplets further away.  
Results from blinded qualitative scoring demonstrate that UCP1 staining intensity 
of adipose tissue at the tumor-adipose interface is significantly increased (Figure 15A). 
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Staining intensity of adipose tissue further from the tumor was less than at the tumor-
adipose interface in both axillary and inguinal fat pads (Figure 15B). Interestingly, 
axillary adipose tissues had significantly higher staining intensity further from the tumor 
compared to inguinal adipose tissues (Figure 15B). The staining intensity gradient, 
identified as the intensity at the interface minus the intensity further from the tumor, was 
higher in the inguinal adipose tissues compared to axillary, but not significantly (Figure 
15C).  
MATLAB analyses on the images with tumor-adipose tissue interface were 
performed to quantify the number of brown pixels, as a measure of UCP1 staining 
intensity, across each image. Similar to the results in Figure 15, UCP1 protein 
expression is most robust at the tumor-adipose tissue interface, and UCP1 protein 
expression sharply declines moving further from the tumor (representative analysis in 
Figure 16, with all analyses in Figure 17). 
We then looked at gene expression levels of several key adipocyte markers in 
these adipose tissue depots. Compared to ovarian WAT controls, BAT expressed over 
256-fold more Ucp1 mRNA, while axillary WAT expressed roughly 2-fold more Ucp1 
mRNA and inguinal WAT expressed roughly 8-fold more Ucp1 mRNA (Figure 18A). For 
other markers related to thermogenic adipose tissue, interscapular BAT, compared to 
ovarian WAT control, expressed significantly more Cidea (cell death-inducing DNA 
fragmentation factor, alpha subunit-like effector A), increased (though not significantly) 
Oplah (5-oxoprolinase), Ppargc1a (peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha), and Slc29a1 (equilibrative nucleoside transporter 1), and no 
change or less Pparg (peroxisome proliferative activated receptor, gamma) and Slc27a1 
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(long-chain fatty acid transport protein 1) (Figure 18B). Expression of these genes was 
more variable for the axillary and inguinal WAT with tumor; although there were no 
statistically significant increases in gene expression, many of the WAT depots had 
increased expression of thermogenic adipose tissue genes compared to ovarian WAT 
control. For example, the right inguinal WAT depots expressed an average 3-fold more 
Cidea and Slc29a1, and axillary WAT depots demonstrate an average 20-fold increase 
in expression of Oplah, and 3-fold increase in expression of Slc29a1 (Figure 18B). 
Lastly, both Lipe (hormone sensitive lipase) and Lpl (lipoprotein lipase) expression 
levels were significantly decreased in WAT with tumor compared to ovarian WAT 
control (Figure 18C).  
We plotted individual values along with the average expression value for each 
adipose tissue and gene tested, which demonstrate a large range of variability in 
expression values for each adipose tissue depot. (Figure 19 panels B, D, and E).    
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Figure 14. Immunohistochemistry shows increased UCP1 protein expression in adipocytes 
adjacent to spontaneous mammary tumors 
Four-month old female C57BL/6J MMTV-PyVT mouse tissue was harvested and stained for UCP1 protein 
in (A) ovarian WAT (negative controls), interscapular BAT (positive controls), and (B) axillary and inguinal 
mammary fat pads with tumor. Each row corresponds to one of three individual mice. Scale bars = 
200µm. UCP1 = uncoupling protein 1, WAT = white adipose tissue, BAT = brown adipose tissue. 
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Figure 15. Qualitative scoring of UCP1 staining intensity in adipocytes adjacent to spontaneous 
mammary tumors 
Scoring was performed in adipocytes at (A) the tumor-adipocyte interface and (B) further from tumor, as 
well as staining intensity gradient (C). Statistical tests: (A), (B), and (C) one sample t-tests for each WAT 
depot compared to null hypothesis of no staining; unpaired t-tests to compare staining intensity between 
axillary and inguinal WAT depot.  UCP1 = uncoupling protein 1. 
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Figure 16. Representative MATLAB analysis of immunohistochemistry for UCP1 in adipocytes 
adjacent to spontaneous mammary tumors  
Results indicate a sharp decline in UCP1 staining intensity with increasing distance from the tumor. Scale 
bars = 200µm. UCP1 = uncoupling protein 1, WAT = white adipose tissue, BAT = brown adipose tissue. 
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Figure 17. MATLAB analyses of UCP1 immunohistochemistry in adipocytes adjacent to 
spontaneous mammary tumors 
Indicating a sharp decline in UCP1 staining intensity with increasing distance from the tumor. Scale bars 
= 200µm. UCP1 = uncoupling protein 1. 
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Figure 18. Adipose tissue depots contiguous to spontaneous mammary tumors have altered 
expression of several adipocyte-related genes  
Four-month old female C57BL/6J MMTV-PyVT mouse tissue was harvested for qPCR in ovarian WAT 
(‘Ovarian’ in image legend; negative controls), interscapular BAT (‘BAT’ in image legend; positive 
controls), left axillary WAT (‘Axil L’ in image legend), and left and right inguinal WAT (‘Ing L’ and ‘Ing R’ in 
image legend, respectively). Quantitative PCR for (A) Ucp1, (B) markers of thermogenic adipose tissue, 
and (C) other markers of white adipocytes and WAT lipolysis. Please note y-axis scale is log2. n = 2-4 
mice. Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B) and (C) Two-way 
ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 19. Variability of gene expression changes in white adipose tissue depots contiguous to 
spontaneous mammary tumors 
WAT (‘Ovarian’ in image legend; negative controls), interscapular BAT (‘BAT’ in image legend; positive 
controls), left axillary WAT (‘Axil L’ in image legend), and left and right inguinal WAT (‘Ing L’ and ‘Ing R’ in 
image legend, respectively). (A), (C), and (E) are the same from Figure 15, (B), (D), and (F) show same 
averages but with individual data points plotted. Please note y-axis scale is log2. n = 2-4 mice. Statistical 
tests: (A) and (B) Kruskal-Wallis and Dunn’s multiple comparisons tests, (C), (D), (E), and (F) Two-way 
ANOVA and Dunnett’s multiple comparisons tests. 
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3.2.2. WAT browning occurs with time specificity in the FVB MMTV-PyMT murine model 
of spontaneous mammary tumor 
We next asked whether WAT browning could be observed in another murine 
mouse model of spontaneous breast cancer, FVB MMTV-PyMT, at the protein level.  
Western blot for UCP1 was performed at two timepoints, 4 weeks and 13 weeks, for 
both wild type mice and mice with spontaneous mammary tumor development (referred 
to as ‘PyMT mice’). Image of western blot is included in Figure 20A. We quantified the 
blot intensity for each group using Image J software (Figure 20B,C). Compared to wild-
type (WT) age-matched controls, PyMT mice demonstrate increased UCP1 protein 
expression in inguinal adipose tissue at 4 weeks of age; interestingly, this trend is 
reversed at 13 weeks (Figure 20B). In interscapular BAT, UCP1 expression is increased 
in PyMT mice at 13 weeks, but not at 4 weeks (Figure 20C).  
 Gene expression analysis on the adipose tissue pads in PyMT mice 
demonstrates an approximate 2-fold decrease in Ucp1 mRNA expression at 13 weeks 
compared to 4 weeks in both inguinal WAT (Figure 21A) and interscapular BAT (Figure 
21B). Figure 21C demonstrates that at both timepoints, interscapular BAT expresses at 
least 50-fold more Ucp1.  
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Figure 20. Adipose tissue depots in mice with spontaneous mammary tumors have time-
dependent changes in UCP1 protein expression 
Four and thirteen week-old female FVB MMTV-PyMT with age-matched wild-type (WT) tissue was 
harvested for protein analysis in interscapular BAT (‘Interscapular BAT’ or ‘BAT’ in image legend; positive 
controls), and inguinal WAT (‘Inguinal WAT’ or ‘Ing’ in image legend, respectively). (A) Western blot of 
UCP1 and alpha tubulin. Quantification of western blot for (B) inguinal WAT and (C) interscapular BAT. 
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Figure 21. Adipose tissue depots in mice with spontaneous mammary tumors have time-
dependent changes in Ucp1 mRNA expression  
Four and thirteen week-old female FVB MMTV-PyMT was harvested for gene expression analysis in 
interscapular BAT (‘Interscapular BAT’ or ‘BAT’ in image legend; positive controls), and inguinal WAT 
(‘Inguinal WAT’ or ‘Ing’ in image legend, respectively). Quantitative qPCR for (A) Ucp1 in inguinal WAT 
and (B) Ucp1 in interscapular BAT with results normalized to respective 4-week expression levels. (C) 
Ucp1 mRNA expression for both adipose tissue depots, normalized to 4-week inguinal WAT.  
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3.2.3. Adipose tissue adjacent to human breast cancer exhibits variable WAT browning 
Lastly, we explored whether white adipose tissue adjacent to human samples of 
breast cancer exhibits browning. We first obtained samples of benign breast WAT from 
elective breast reduction surgeries to serve as our negative controls, and stained them 
for UCP1. Breast WAT exhibits no to minimal UCP1 protein expression, and lipid droplet 
sizes are larger – both features we expect from benign WAT (Figure 22). 
We then stained human breast cancer samples with adjacent adipose tissue for 
UCP1. These breast cancer samples were previously identified by the TDAAC and/or 
Department of Pathology as either triple negative, estrogen receptor positive, or HER2 
expressing. For all breast cancer types, adipose tissue at the tumor-adipocyte interface 
express more UCP1 than benign breast WAT, and in many samples, have lipid droplets 
that are smaller in diameter compared to benign breast WAT (representative images, 
one from each cancer type in Figure 23). While expression of UCP1 appears to be 
greater than benign breast WAT in all samples, the intensity of stain appears to vary 
significantly (Figure 24, Figure 25, Figure 26).  
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Figure 22. Benign breast white adipose tissue from human female subjects do not express UCP1 
protein  
Breast WAT from four different female subjects undergoing elective breast reduction surgery was stained 
for UCP1 protein. Each row corresponds to one of four individual human subjects. Scale bars for 4X 
magnification = 200µm; 10X magnification = 100µm. 
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Figure 23. Immunohistochemistry shows increased UCP1 protein expression and decreased lipid 
droplet size in adipocytes adjacent to human breast carcinomas 
Representative IHC images for UCP from the following: Benign breast tissue (1st row), triple negative 
breast cancer (2nd row),  HER2+ breast cancer (3rd row), estrogen receptor breast cancer (ER+ BC, 4th 
row).  Scale bars for 1.25X magnification = 800µm; 4X magnification = 200µm; 10X magnification = 
100µm. 
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Figure 24. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to 
triple negative human breast carcinomas.  
Each image represents a unique patient sample. All images at 10X magnification, with scale bars = 
100µm. 
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Figure 25. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to 
HER2+ human breast carcinomas.  
Each image represents a unique patient sample. All images at 10X magnification, with scale bars = 
100µm. 
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Figure 26. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to 
estrogen receptor-positive (ER+) human breast carcinomas.  
Each image represents a unique patient sample. All images at 10X magnification, with scale bars = 
100µm. 
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3.3 Discussion 
We first asked whether WAT browning could be observed in murine models of 
breast cancer. In the C57BL/6J MMTV-PyVT model, we show that adipocytes closest to 
the tumor-adipocyte interface in vivo have increased UCP1 protein expression, the 
hallmark of thermogenic adipose tissue function, via immunohistochemistry (Figure 14). 
The increase in UCP1 protein expression is most robust at the tumor-adipose tissue 
interface, and UCP1 protein expression sharply declines moving further from the tumor, 
demonstrated qualitatively by higher intensity scoring at the tumor-adipocyte interface 
(Figure 15) and quantitatively by a trend that fits the inverse power law upon curve 
fitting (Figure 16, Figure 17). This suggests that the strength of browning is inversely 
related to the center of its driver, the tumor cells, which has recently been noted in a 
xenograft model of breast cancer as well [117]. We also observe smaller lipid droplets in 
these adipocytes, which has been observed and described as a characteristic of 
‘cancer-associated adipocytes (CAA)’ at the tumor forefront [116]. Together, the 
decreased lipid size and increased UCP1 expression in adipocytes closest to the tumor 
in our IHC images confirm the phenotypic changes consistent with a maladaptive 
transdifferentiation from white to beige adipose tissue in response to the tumor 
microenvironment.  Furthermore, the localized nature of this browning suggests a 
paracrine signaling interaction between the tumor and adjacent adipocytes. 
mRNA expression levels of key adipocyte gene markers further support 
adipocyte plasticity in these WAT depots with tumor (Figure 18). Ucp1 mRNA 
expression was increased in two of the three WAT fat pads with spontaneous mammary 
tumor, with up to an 8-fold increase in expression. Other markers related to thermogenic 
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adipose tissue, such as Cidea, Oplah, and Slc29a1, were increased in the axillary 
and/or inguinal WAT with tumor development. Interestingly, WAT in the fat pads with 
tumor expressed significantly less Lipe and Lpl, two markers of WAT lipolysis. This 
supports the hypothesis that the smaller lipid droplets observed at the tumor-adipocyte 
interface in our IHC images are the results of WAT browning as opposed to WAT 
lipolysis.   
It is important to highlight the variability in the mRNA expression data, most 
notably in the thermogenic adipose tissue-related genes (Figure 19). This variability is 
not surprising considering that the tissue analyzed was comprised of white adipose 
tissue both proximal and distal to the spontaneous mammary tumors. It is likely that 
WAT at the tumor-adipocyte interface was variably excised, as it was dissected via 
manual inspection. We do not have the capability to perform laser capture 
microdissection on our samples, which would be the best way to assess this, especially 
considering the very localized (~200um) browning effect noted on IHC. 
In another murine model of spontaneous breast cancer, the FVB MMTV-PyMT 
model, we demonstrate additional evidence to support WAT browning in breast cancer. 
Interestingly, both WAT and BAT depots in these mice with early (4 week) and later (13 
week) stage tumors appear to exhibit time-dependent changes in UCP1 protein 
expression (Figure 20).  Pooled samples of human breast cancer xenografts grown in 
mice have been shown to express varying amounts of UCP1 protein dependent on the 
length of xenograft growth, with UCP1 present at 1 week post-implantation, peaking at 
5-7 weeks, and decreasing to less than the 1-week level at 15 weeks [117]. While these 
changes may have contributions from cells within the entire tumor microenvironment, 
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our results suggest temporal regulation of adipocyte plasticity in breast cancer. Ucp1 
mRNA expression levels in these tumors suggest a decrease in transcript expression at 
later timepoints in both inguinal WAT and interscapular BAT (Figure 21); however, these 
results were obtained by comparing mice with tumor, without the use of age-matched 
controls as in our western data. We also recognize the same limitations to these results 
as explained for the C57BL/6J MMTV-PyVT mRNA results earlier in this section. 
Additional studies with a larger samples sample size (as ours only had 2 mice per 
group) would be useful to confirm this time-dependence, and eventually probe into the 
mechanisms behind it.  
Lastly, as we have seen WAT browning in two different murine models of 
spontaneous mammary tumor, we asked whether WAT browning occurs in human 
samples of breast cancer. We first demonstrate that benign breast WAT has no UCP1 
expression at baseline using samples from 4 women of different ages (Figure 22), and 
then show via IHC that UCP1 protein expression is increased in white adipocytes 
surrounding human breast carcinoma samples (Figure 23). This supports the global 
concept of WAT browning in cancer, as IHC studies performed by Petruzzelli and 
colleagues demonstrated that several other human cancers (melanoma, colon, 
pancreatic, and lung cancers) were associated with increased UCP1 in WAT [112].  
In human breast cancer samples, similar to what we observed in our mouse IHC, 
there appears to be a gradient of UCP1 expression, highest at the tumor-adipocyte 
interface and decreasing moving distally from the tumor (Figure 23). Interestingly, it 
appears that some of the tumor cells stain positively for UCP1 in several of the samples. 
In the literature, there are several reports of UCP1 expression in cancer, including 
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breast cancer xenografts and human samples of non-small cell lung cancer [117, 164], 
so this observation is not surprising.  
We further demonstrate that this increase in UCP1 expression in WAT in cancer 
is seen in a variety of subtypes of breast carcinoma, including triple negative (Figure 
24), HER2 expressing (Figure 25), and ER+ (Figure 26) breast cancers. Future 
analyses using additional samples with a larger volume/area of WAT adjacent to tumors 
will be helpful to determine whether differences exist between receptor statuses. 
Correlating stage of tumor at time of resection with UCP1 staining intensity would 
provide additional insight into the time-dependency we noted in our murine studies on 
the human level.  
While increased UCP1 staining intensity is observed in all breast cancer 
subtypes we analyzed, there is certainly variability in staining intensity between 
individual samples (Figure 24, Figure 25, Figure 26). It is well established that inter- and 
intra-organism tumor heterogeneity exists in breast cancer [165, 166]. Since we 
hypothesize that the tumor and tumor microenvironment are responsible for these 
adipocyte changes, it is therefore not surprising that the variability between tumor and 
host responses would result in variable adipocyte changes.  
 
3.4 Conclusion 
 Taken together, our results demonstrate the presence of WAT browning 
(increased UCP1 expression and decreased lipid droplet size) in adipose tissue 
surrounding tumors in both murine and human breast cancers. This illustrates the 
importance and translational potential of our work. Furthermore, our results suggest a 
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local, paracrine (cell-cell) interaction between adipocytes and tumor and tumor 
microenvironment as the driver of the adipocyte changes. These are the interactions 
that we explore in the next two chapters. 
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Chapter 4: Cancer-Adipocyte Interactions Induce Changes to White Adipocytes In Vitro  
 
4.1 Rationale 
Based on the WAT browning observed in vivo (Chapter 3), we established a cell 
culture system which would allow us to methodically and systematically study the 
effects of individual components of the tumor microenvironment on adipocytes in vitro. 
Furthermore, as the WAT browning demonstrated in Chapter 3 is extremely localized in 
nature, and other studies have implicated tumor-secreted factors in WAT browning and 
remodeling [113], we asked whether local factors secreted by breast cancer cells (and 
other cancer cells) are the driver of these local WAT changes. 
 
4.2 Results 
4.2.1 Immortalized murine SVF cells are capable of undergoing differentiation to mature 
white and beige adipocytes  
We first tested the differentiation capacity of our lab’s immortalized male mouse 
inguinal stromal vascular fraction cells (referred to as mouse immortalized white 
preadipocytes, or mIWPAs). Immature stromal vascular fraction cells are able to 
successfully undergo differentiation to both mature white and beige adipocytes with high 
percentage of differentiation (Figure 27A).  Expression of Dlk1 (Delta like non-canonical 
Notch ligand 1), a marker of immature/undifferentiated adipocytes, is increased by 
about 5-fold in undifferentiated preadipocytes compared to differentiated white and 
beige adipocytes (Figure 27B). Expression of other gene markers associated with 
mature adipocytes was decreased in the preadipocytes, most notable being Cidea. 
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Lastly, Ucp1 was significantly increased in the mature beige adipocytes, demonstrating 
that our in vitro immortalized cell culture model expresses appropriate differences in 
thermogenic gene expression. 
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Figure 27. Immortalized murine SVF are capable of differentiation to mature white and beige 
adipocytes 
Inguinal SVF isolated from inguinal WAT from a young male C57BL/6J mouse were immortalized, then 
cultured and differentiated to either white or beige adipocytes as described in methods. (A) 
Representative Oil Red O staining after completed induction and maintenance protocol.  Scale bars = 
100µm. (B) Quantitative PCR for various adipocyte-related markers. Please note y-axis scale is log2. n = 
4 for all groups. Error bars = standard deviation. Statistical tests: (B) 2-way ANOVA and Dunn’s multiple 
comparisons tests. 
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4.2.2 Cancer conditioned medium from E0771 and LLC cells do not induce WAT 
browning in our immortalized cell culture model 
We next asked if white preadipocyte exposure to cancer-conditioned medium 
would induce maturation of beige adipocytes. As described in methods section 2.8.1 
(Figure 7), immortalized preadipocytes were exposed to cancer conditioned medium at 
various stages of differentiation: either the induction phase, the maintenance phase, 
both, or pretreatment and both. When preadipocytes are exposed to E0771 cancer 
conditioned medium during the induction phase and the cancer conditioned medium is 
removed for the duration of maintenance, there are no changes in gene expression 
profiles (Figure 28A). When preadipocytes undergo normal induction and then are 
exposed to cancer conditioned medium throughout the maintenance period, there is a 
significant decrease in mRNA expression of Ucp1, and decreases (though not 
statistically significant after correcting for multiple comparisons) in Cidea and Ppargc1a 
(peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) (Figure 28B). 
When preadipocytes are exposed to cancer conditioned medium throughout both 
induction and maintenance phases of differentiation, statistically significant decreases in 
Cidea, Ppargc1a, and Ucp1 are observed (Figure 28C). No changes are observed with 
pre-treatment before and during differentiation (Figure 28D). For all treatment groups, 
no changes in lipolysis-related genes Lipe or Lpl occurred. 
We also asked if the time during maintenance was important. We demonstrate 
again that exposure to cancer conditioned medium before induction, or throughout 
induction, do not increase Ucp1 expression (Figure 29A,B). Significant decreases in 
Ucp1 mRNA expression were detected in mature adipocytes after exposure to cancer 
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conditioned medium at various timepoints throughout the maintenance period of 
differentiation (Figure 29C-F). Lastly, we demonstrate that exposure to cancer 
conditioned medium during both induction and maintenance results in the most dramatic 
and significant decrease in Ucp1 and Cidea expression (Figure 29G). 
While these results highlight the changes from cancer conditioned medium that 
can be observed in differentiating adipocytes, we next asked whether transdifferentation 
could occur – whether mature white adipocytes could transdifferentiate into beige 
adipocytes – when exposed to cancer conditioned medium. This question is more 
physiologically relevant as there is only a small percentage of adipocyte turnover 
(preadipocyte differentiation into mature white adipocytes) in vivo [25]. We exposed fully 
mature white adipocytes to E0771 cancer conditioned medium exposure for 7 or 14 
consecutive days. Interestingly, our results suggest that similar to differentiating 
adipocytes, mature white adipocyte exposure to cancer conditioned medium results in a 
significant decrease in Ucp1 mRNA expression (Figure 30).  
We next asked whether we would observe a similar decrease in Ucp1 expression 
using cancer conditioned medium from another mouse cancer cell line. Using cancer 
conditioned medium from Lewis Lung Carcinoma (LLC) cells, we demonstrate that the 
effect of decreased Ucp1 is consistent across exposure to cancer conditioned medium 
from these two distinct cell lines (Figure 31B). Lastly, we asked whether 24 hours of 
exposure could induce these changes. Our results suggest that 24 hours of exposure is 
sufficient to cause a decrease in Ucp1 mRNA expression in our in vitro model with both 
cell lines (Figure 31C). 
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Figure 28. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned 
medium during phases of differentiation; part 1 
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium 
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene 
markers in mature adipocytes after (A) cancer conditioned medium during only the induction phase (‘I 
only’) of differentiation, (B) cancer conditioned medium during only the maintenance phase (‘M only’) of 
differentiation, (C) cancer conditioned medium during both induction and maintenance phases (‘I+M’) of 
differentiation, and (D) cancer conditioned medium before differentiation and during both induction and 
maintenance phases (‘Pretreat+I+M’) of differentiation. Please note y-axis scale is log2. n = 3. Statistical 
tests: (A), (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 29. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned 
medium during phases of differentiation; part 2 
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium 
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene 
markers in mature adipocytes after exposure to (A) cancer conditioned medium before differentiation 
(‘pretreated preadipocytes’), (B) cancer conditioned medium during only the induction phase of 
differentiation (‘I only (D2)’), (C) cancer conditioned medium during only the first three days of the 
maintenance phase (‘M only (D5)’), (D) cancer conditioned medium during only the first six days of the 
maintenance phase (‘M only (D8)’), (E) cancer conditioned medium during only the first nine days of the 
maintenance phase (‘M only (D11)’), (F) cancer conditioned medium during only the entirety of the 
maintenance phase (‘D14’), and (G) cancer conditioned medium during both induction and maintenance 
phases of differentiation (‘I+M’). Please note y-axis scale is log2. n = 3. Statistical tests: (A), (B), (C), and 
(D) Two-way ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 30. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned 
medium after maturation 
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium 
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene 
markers in mature adipocytes after mature, fully differentiated white adipocytes were exposed to cancer 
conditioned medium for (A) 7 days or (B) 14 days. Please note y-axis scale is log2. n = 3. Statistical tests: 
(A), (B) Two-way ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 31.  Mature adipocyte mRNA expression is altered after exposure to cancer conditioned 
medium both during and after maturation 
(A) Quantitative PCR for Ucp1 in immortalized SVF (‘preadipocytes’ in image) before differentiation and in 
mature white (‘White’ in image) and beige (‘Beige’ in image) adipocytes after differentiation. (B) and (C) 
Quantitative PCR for Ucp1 in immortalized SVF exposed to cancer conditioned medium either (B) during 
differentiation or (C) after differentiation was completed as described in methods. For (B) and (C), white 
control is indicated as ‘W,’ ‘E0771’ represents E0771 conditioned medium, and ‘LLC’ represents LLC 
conditioned medium. Please note y-axis scale is log2. n = 3-5. Statistical tests: (A), (B), (C) Kruskal-Wallis 
and Dunn’s multiple comparisons tests. 
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4.2.3 Primary murine stromal vascular fraction cells allow for in vitro differentiation to 
white and beige adipocytes. 
Next, we established a primary cell culture system that would confer additional 
advantages to our methodical experiments to study the effects of breast cancer (and 
other cancers) on adipocytes in vitro. Primary SVF cells (also referred to as 
preadipocytes) are capable of undergoing differentiation to both mature white and beige 
adipocytes (Figure 32). Oil Red O staining demonstrates successful differentiation in 
both white and beige groups, with larger lipid droplets in the white differentiation group 
(Figure 32 and Figure 33A). Expression of white adipocyte-associated genes Cfd 
(complement factor D, also known as adipsin) and Lep (leptin) were significantly 
decreased in both preadipocytes (not expressed for leptin) and beige adipocytes 
relative to white adipocytes, and expression of Fasn (fatty-acid synthase) was 
significantly decreased in preadipocytes (Figure 33C). Lastly, expression of 
thermogenic adipocyte genes Cidea, Ppargc1a, Tnfrsf9 (tumor necrosis factor receptor 
superfamily, member 9), and Ucp1 were significantly increased in differentiated beige 
adipocytes (Figure 33D). 
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Figure 32. Primary murine inguinal SVF can differentiate into mature white and beige adipocytes 
Oil Red O brightfield images from primary culture female inguinal white (left column) or beige (right 
column) adipocytes after full induction and maintenance periods (day 16). A,B,C,D represent 4 different 
female primary culture lines. Scale bars = 100µm. 
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Figure 33. Primary murine SVF are capable of differentiation to mature white and beige adipocytes 
Inguinal SVF isolated from young female C57BL/6J mice were differentiated to either white or beige 
adipocytes as described in methods. (A) Representative Oil Red O staining confirming that our protocol is 
highly selective for culture of preadipocytes capable of undergoing successful differentiation.  Scale bars 
= 100µm. Quantitative PCR for (B) Dlk1, (C) markers of white adipocytes, (D) markers of beige 
adipocytes. Please note y-axis scale is log2. n = 5 primary SVF cell lines. Error bars = standard deviation. 
Statistical tests: (B) Kruskal-Wallis and Dunn’s multiple comparisons tests, (C) and (D) Two-way ANOVA 
and Dunnett’s multiple comparisons tests. SVF = stromal vascular fraction, n.d. = not detected. 
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4.2.4 Cancer conditioned medium and coculture alter white adipocyte gene expression, 
but do not increase thermogenic gene expression in murine primary differentiated white 
adipocytes  
To further investigate the localized WAT browning observed in vivo in Chapter 3, 
we exposed differentiated, mature white adipocytes from primary mouse SVF to the 
conditioned medium from E0771 murine breast cancer cells (Figure 34), or cocultured 
them with E0771 cells (Figure 36). Ucp1 mRNA expression in white adipocytes exposed 
to E0771 cancer-conditioned medium was decreased, although not significantly, relative 
to control white adipocytes, and was significantly decreased when compared to both 
control beige adipocytes and white adipocytes exposed to the β3 adrenergic agonist CL 
316,243 (Figure 34A). Western blot of UCP1 confirms these mRNA expression results 
on the protein level (Figure 35).  
Cancer-conditioned medium exposure did not result in increased expression of 
any of the thermogenic genes tested, except a trend towards higher Tnfrsf9 (Figure 
34B). Interestingly, a significant decrease in the white adipocyte-associated genes Fasn 
and Lep was observed in the cancer-conditioned medium treated adipocytes (Figure 
34C). We also tested for genes associated with lipolysis, and found that white 
adipocytes exposed to E0771 cancer-conditioned medium had no changes in 
expression of Lpl or Mgll (monoglyceride lipase), but expressed less Lipe compared to 
control white adipocytes (Figure 34D).  
When differentiated white adipocytes were cocultured with E0771 cells, the same 
pattern of Ucp1 expression was observed: a decrease (although not statistically 
significant) in Ucp1 expression compared to control white adipocytes, but significantly 
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lower Ucp1 expression compared to white adipocytes treated with CL 316,243 (Figure 
36A). While there were no changes in gene expression of the thermogenic genes Cidea 
or Ppargc1a, white adipocytes cocultured with E0771 cells expressed significantly more 
Tnfrsf9 (Figure 36B).  Similar to the cancer-conditioned medium results (Figure 34), 
white adipocytes cocultured with E0771 cells expressed significantly less Fasn and Lep 
mRNA compared to white control adipocytes, with no change in Cfd expression (Figure 
36C). Lastly, expression of Mgll was significantly increased in white adipocytes 
cocultured with E0771 cells, while expression of Lipe and Lpl was decreased but not 
significantly (Figure 36D).  
Lastly, we asked if these results could be replicated using a different murine 
mouse model for SVF and breast cancer (BALB/c mice and the 4T1 breast cancer cell 
line). We show, similar to Figure 34 and Figure 35, that exposure of mature white 
adipocytes from BALB/c mice to 4T1 cancer conditioned medium decreases Ucp1 
mRNA expression (Figure 37A) and UCP1 protein expression (Figure 38). 4T1 cancer 
conditioned medium exposure resulted in only a 2-fold increase in Tnfrsf9, which was 
not statistically significant (Figure 37B). Of the white adipocyte-associated genes tested, 
only Lep expression was significantly decreased with 4T1 exposure (Figure 37C). 
Lastly, although none of the lipolysis-related genes were significantly different after 4T1 
cancer conditioned medium exposure, there were slight trends of decreasing Lpl 
expression and increasing Mgll expression (Figure 37D).  
Coculture of BALB/c -derived mature white adipocytes with 4T1 cells resulted in 
relatively similar gene expression patterns (Figure 39): no change in Ucp1 expression 
(Figure 39A), non-statistically-significant 4-fold increases in Tnfrsf9 expression (Figure 
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39B) and 2-fold decreases in Lep expression (Figure 39C), and no changes in lipolysis-
related gene expression (Figure 39D). 
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Figure 34. E0771 cancer-conditioned medium alters white adipocyte mRNA expression, but does 
not induce white adipocyte browning in vitro  
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or E0771 cancer-
conditioned medium (noted as ‘CC’ in images) and compared to controls as described in methods. 
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes, 
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 7 primary C57BL/6J SVF cell lines. 
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way 
ANOVA and Dunnett’s multiple comparisons tests.   
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Figure 35. Representative western blot of UCP1 and TBP demonstrating that E0771 cancer-
conditioned medium does not induce white adipocyte browning in vitro 
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or E0771 cancer-
conditioned medium (noted as ‘CC’ in images) and compared to white ‘W’ and beige ‘B’ controls. Western 
blot performed in two of the seven primary C57BL/6J SVF cell lines used. 
 
 
146 
 
 
Figure 36. E0771 coculture alters white adipocyte mRNA expression, but does not induce white 
adipocyte browning in vitro. 
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or cocultured with 
E0771 cells (noted as ‘Coculture’ in images) and compared to controls as described in methods. 
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes, 
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 7 primary C57BL/6J SVF cell lines. 
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way 
ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 37. 4T1 cancer conditioned medium alters white adipocyte mRNA expression, but does not 
induce white adipocyte browning in vitro 
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or 4T1 cancer-
conditioned medium (noted as ‘CC’ in images) and compared to controls as described in methods. 
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes, 
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary BALB/cJ SVF cell lines. 
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way 
ANOVA and Dunnett’s multiple comparisons tests.   
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Figure 38. Western blot of UCP1 and TBP demonstrating that 4T1 cancer-conditioned medium 
does not induce white adipocyte browning in vitro 
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or 4T1 cancer-
conditioned medium (noted as ‘CC’ in images) and compared to white ‘W’ and beige ‘B’ controls. Western 
blot performed in all three of the BALB/cJ SVF cell lines used. 
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Figure 39. 4T1 coculture alters white adipocyte mRNA expression, but does not induce white 
adipocyte browning in vitro. 
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or cocultured with 
4T1 cells (noted as ‘Coculture’ in images) and compared to controls as described in methods. 
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes, 
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary BALB/cJ SVF cell lines. 
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way 
ANOVA and Dunnett’s multiple comparisons tests. 
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4.2.5 Human breast-derived stromal vascular fraction cells allow for in vitro 
differentiation to white and beige adipocytes 
We wanted to determine whether changes that occurred in murine cell culture 
experiments could be replicated with human cell culture. Based on the results in mouse 
cell lines, we decided to use human SVF. We tested differentiation requirements in 
female human breast SVF and found that they require additional supplementation in 
their cell culture medium in order to successfully differentiate, as demonstrated by 
differences in Oil Red O staining (Figure 40).  
We demonstrate that our human SVF cell culture system, similar to in mice, is 
capable of differentiating into mature white and beige adipocytes with adequate 
differentiation and larger lipid droplet accumulation in mature white adipocytes (Figure 
41A). Additionally, UCP1 mRNA expression is significantly increased in our beige 
adipocytes compared to white, and was not detected at all in the undifferentiated 
SVF/preadipocytes (Figure 41B).  These results demonstrate a viable human in vitro 
model for studying the effects of tumor and tumor microenvironment on adipocyte 
plasticity. 
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Figure 40. Human breast SVF requires additional medium supplementation to allow for robust 
differentiation to mature white and beige adipocytes.  
Isolated white preadipocytes from female normal breast tissue obtained during breast reduction surgery 
were differentiated to mature white and beige adipocytes with or without supplementation with the ATCC 
Low Serum Fibroblast Growth Kit as described in methods. Representative Oil Red O images 
demonstrate (A) poor differentiation percentage in cells without supplementation, (B) robust differentiation 
in cells with supplementation. Scale bars = 100µm. hbbWPA = human benign breast white preadipocytes.  
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Figure 41. Primary human SVF are capable of differentiation to mature white and beige 
adipocytes.  
SVF cells isolated from human female normal WAT were differentiated to either white or beige adipocytes 
as described in methods. (A) Representative Oil Red O staining confirming that our protocol is highly 
selective for culture of preadipocytes capable of undergoing successful differentiation. Scale bars = 
50µm. (B) Quantitative PCR for thermogenic adipose tissue-related genes. N = 2. Statistical tests for (B) 
Two-way ANOVA and Dunnett’s multiple comparisons tests. SVF = stromal vascular fraction, n.d. = not 
detected. 
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4.2.6 Cancer conditioned medium induces changes to white adipocyte gene expression 
in human primary differentiated white adipocytes 
The first question using our human SVF cell culture system, similar to that in our 
murine SVF cell culture system, was whether exposure to breast cancer conditioned 
medium at various points in the differentiation process would result in WAT browning. 
As described in methods section 2.8.3 (Figure 9), human SVF cells were exposed to 
MCF-7 and MDA-MB-231 cancer conditioned medium at various stages of 
differentiation: either the entire induction phase, partial or entire maintenance phase, or 
both induction & maintenance periods. Compared to mature white adipocytes, exposure 
to MCF-7 or MDA-MB-231 cancer conditioned medium during only the induction phase 
of differentiation resulted in no changes in Ucp1, but significantly decreased TMEM26 
(transmembrane protein 26) expression (Figure 42A). Expression of several other 
thermogenic adipose tissue-related genes such as EAR2 (nuclear receptor subfamily 2 
group F member 6), OPLAH, and PPARGC1A were decreased, while PDK4 
(mitochondrial pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 4) 
expression was approximately 2-fold higher in both cancer conditioned medium treated 
groups, but no changes were significant (Figure 42A). Exposure to MCF-7 or MDA-MB-
231 cancer conditioned medium during only the first half of the maintenance phase of 
differentiation resulted in significant decreases in many of the genes tested, although 
there was no change in UCP1 expression (Figure 42B). When differentiating white 
adipocytes were exposed to MCF-7 or MDA-MB-231 cancer conditioned medium 
throughout the entirety of the maintenance phase of differentiation, there were still 
trends towards decreased expression of many of the thermogenic adipose tissue-
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related genes; however, for UCP1 expression, there was a 2.2-fold increase (not 
statistically significant) in the group treated with MCF-7 conditioned medium, and a 
statistically significant 3.8-fold increase in the group treated with MDA-MB-231 
conditioned medium (Figure 42C). When exposure to cancer conditioned medium 
spanned the entirely of the induction and maintenance phases, the MDA-MB-231 
conditioned medium treatment group expressed significantly more UCP1, roughly 6.4-
fold more than mature white adipocyte controls (Figure 42D). 
 We also analyzed the Oil Red O images and quantified lipid droplet sizes. 
Control beige adipocytes have significantly smaller lipid droplets than mature white 
adipocytes (Figure 43A). Regardless of the timing or duration of cancer conditioned 
medium exposure, maturing white adipocytes exposed to either MCF-7 or MDA-MB-231 
cancer conditioned medium had significantly smaller lipid droplets when compared to 
white adipocyte controls (Figure 43B-E). 
Lastly, we tested the effects of these cancer conditioned mediums on mature 
white adipocytes in an SVF cell line derived from a different human patient during 
differentiation and after maturation for 24 hours. Interestingly, although this SVF cell line 
had appropriate UCP1 expression levels in undifferentiated, mature white, and mature 
beige adipocytes (Figure 44A), exposure to MCF-7 and MDA-MB-231 cancer 
conditioned medium throughout differentiation resulted in a significant decrease in 
UCP1 expression (Figure 44B). Exposure to mature white adipocytes to cancer 
conditioned medium for 24 hours resulted in slightly different results, with a roughly 2-
fold increase in UCP1 expression in the MCF-7 conditioned medium group, and 8-fold 
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decrease in UCP1 expression in the MDA-MB-231 conditioned medium group (Figure 
44C).  
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Figure 42. Mature human adipocyte mRNA expression is differentially altered after exposure to 
MCF-7 and MDA-MB-231 cancer conditioned mediums during phases of differentiation 
Primary SVF derived from normal WAT from a 27 year old woman were exposed to either MCF-7 
conditioned medium (dark gray bars), MDA-MB-231 conditioned medium (light gray bars), or control white 
medium (white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and 
adipocyte gene markers in mature adipocytes after exposure to (A) cancer conditioned medium during 
only the induction phase of differentiation (‘I only (D5)’), (B) cancer conditioned medium during only the 
first half of the maintenance phase (‘M only (D10)’), (C) cancer conditioned medium during only the 
entirety of the maintenance phase (‘M only (D15)’), and (D) cancer conditioned medium during both 
induction and maintenance phases of differentiation (‘I&M’). Please note y-axis scale is log2. n = 2-3. 
Statistical tests: (A), (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 43. Lipid droplet size significantly decreases in mature human adipcoytes after exposure to 
MCF-7 and MDA-MB-231 cancer conditioned mediums during differentiation 
Primary SVF derived from benign breast WAT from a 27 year old woman were differentiated to mature 
white or beige adipocytes. Lipid droplet sizes in (A) white (gray dots) versus beige (black dots) control 
adipocytes, (B) cancer conditioned medium during only the induction phase of differentiation, (C) cancer 
conditioned medium during only the first half of the maintenance phase, (D) cancer conditioned medium 
during only the entirety of the maintenance phase, and (E) cancer conditioned medium during both 
induction and maintenance phases of differentiation. For (B), (C), (D), and (E), MCF-7 conditioned 
medium (blue dots), MDA-MB-231 conditioned medium (magenta dots), or control white medium (gray 
dots) N=2 wells per group, with over 300 lipid droplets analyzed per condition. Statistical tests: (A) 
Unpaired t-test without assuming same standard deviation between groups; (B), (C), (D), (E) One-way 
ANOVA and Dunnett’s multiple comparisons tests. 
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Figure 44. Mature adipocyte mRNA expression is differentially altered after exposure to MCF-7 and 
MDA-MB-231 cancer conditioned mediums both during and after maturation 
(A) Quantitative PCR for Ucp1 in primary human SVF derived from normal WAT from a 51 year old 
woman (‘preadipocytes’ in image) before differentiation and in mature white (‘White’ in image) and beige 
(‘Beige’ in image) adipocytes after differentiation. (B) and (C) Quantitative PCR for UCP1 in primary 
human SVF exposed to cancer conditioned medium either (B) during differentiation or (C) after 
differentiation was completed as described in methods. For (B) and (C), white control is indicated as ‘W,’ 
‘MCF7’ represents MCF-7 conditioned medium, and ‘MDAMB231’ represents MDA-MB-231 conditioned 
medium. Please note y-axis scale is log2. n = 2-3. Statistical tests: (A), (B), (C) Kruskal-Wallis and Dunn’s 
multiple comparisons tests. 
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4.3 Discussion 
We utilized our lab’s immortalized white SVF, derived from the inguinal WAT of a 
male C57BL/6J mouse, to produce an in vitro model of adipocyte differentiation that 
could be used to investigate the role of the cancer cell secretome in adipocyte plasticity 
both during and after adipocyte differentiation. E0771, an estrogen-receptor positive 
murine breast cancer cell line, is commonly used in many in vitro and in vivo C57BL/6 
breast cancer studies [167-170]. Use of an established breast cancer cell line, as 
opposed to the use of whole tumor lysate, provides a strategic advantage in the 
mechanistic study of WAT browning in vitro because it is cultured without other cells 
within the tumor microenvironment, which could confound results, and eliminates the 
problems of inter- and intra-organism tumor heterogeneity [165, 166]. However, these 
are not perfect replacements for cancer cells isolated from tumors grown in vivo, and 
this should be kept in mind when interpreting our experimental results. 
Our results using cancer conditioned medium from E0771 cells suggest that 
exposure to cancer conditioned medium during the initial induction phase of 
differentiation does not impact mature adipocyte gene expression; instead, exposure 
during the induction and maintenance phase or during the maintenance phase alone 
appears to have the most significant effects (Figure 28, Figure 29). This time-specificity 
is not surprising, as other studies have influenced adipogenesis at time-specific periods 
of differentiation. In 3T3-L1 ‘white preadipocytes,’ mature adipocytes can initiate 
induction of differentiation of nearby preadipocytes, suggesting a role of endogenous 
paracrine signaling in the induction phase [171]. Also in 3T3-L1 preadipocytes, 
adipogenesis can be thwarted by retinoic acid-mediated decreases in PPARgamma and 
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C/EBPalpha, but only when exposed during the induction phase [172, 173]. Even in 
differentiation of brown adipocytes, STAT3 is required during the induction phase, but 
not the maintenance phase [174].  Other factors, such as Lipin 1 (an enzyme involved in 
lipid biosynthesis) and Microprocessor complex subunit DGCR8 (a protein critical for 
miRNA biogenesis), have been shown to be necessary for both differentiation and 
maintenance of white and/or brown adipocytes [175, 176].  Our results suggest that 
exposure during the initiation period must be maintained throughout maintenance, or 
even introduced just during the maintenance phase alone, in order to alter adipocyte 
mRNA expression in the context of cancer 
We were surprised to observe that cancer conditioned medium exposure results 
in a decrease in mRNA expression of several thermogenic gene markers – Ucp1, 
Cidea, and Ppargc1a – opposite our initial hypothesis. This suggests, contrary to other 
studies, that the cancer cell secretome is not a direct driver of WAT browning in vitro. 
Additionally, no changes in lipolysis-related gene expression via Lipe or Lpl were 
identified in any of the treatment groups, further negating our hypothesized direct role of 
cancer conditioned medium on adipocyte changes in this model.  
While these results give valuable insight into the effects of cancer conditioned 
medium on differentiating white preadipocytes, adipocyte turnover in vivo is quite low, 
with an annual turnover rate measured at approximately 10% in adults [25]. This means 
that the majority of cells impacted by any perturbations to surrounding environment are 
mature, rather than differentiating, adipocytes. We therefore tested whether E0771 
cancer conditioned medium would induce transdifferentiation of white to beige 
adipocytes. We demonstrate that exposure of mature, fully differentiated, white 
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adipocytes to the conditioned medium of E0771 cells does not induce WAT browning, 
but instead results in a decrease in Ucp1 expression. Again, these results were 
opposite our initial hypothesis. Furthermore, this decrease in Ucp1 expression occurred 
regardless of whether the exposure lasted for one week, two weeks, or even just 24 
hours (Figures 27, 28).  
This prompted the use of 24 hour exposure periods for subsequent experiments 
discussed later in this discussion, as this shorter timeframe provides several 
advantages: it allows us to study more acute signaling changes which may initiate the 
long term changes; it decreases the need for multiple medium changes which 
introduces inherent variability (although we do our best to ensure consistency between 
each harvest of cancer conditioned medium); it decreases risk of adipocyte detachment 
before harvesting (based on our lab’s observations, the risk for detachment increases 
the longer the mature adipocytes remain in culture, even with the use of gelatin-coated 
cell culture plates). 
 Lastly, we demonstrate that decreased Ucp1 expression is not a response limited 
to the E0771 cell line. A similar, and to an extent more robust, decrease in Ucp1 mRNA 
expression occurred after exposure to LLC conditioned medium (Figure 31). LLC cancer 
conditioned medium has been shown to induce muscle catabolism contributing to CAC 
[177], but more importantly has been implicated in PTHrP-mediated WAT browning in 
LLC tumor-driven cachexia in mice [178]. While we did not test our conditioned medium 
for the presence of PTHrP, we used a filter with pore sizes that would allow passage of 
PTHrP into the filtered medium used for adipocyte treatment, so our results suggest that 
any PTHrP-mediated changes are not direct in nature. Obtaining the same results – a 
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decrease in Ucp1 mRNA expression – with two completely different cancer cell lines 
adds significant confidence to our conclusion that the cancer cell secretome is not the 
driver of WAT browning in this cell culture model.  
However, several key limitations to this model exist. These SVF cells, similar to 
the commercially-available 3T3-L1 preadipocyte cell line [179], are derived from males, 
not female mice. It is well-established that metabolic differences exist between sexes in 
both mice and humans [180-182]. Use of a female SVF cell line would be advantageous 
for breast cancer studies. These male SVF cells were immortalized with SV40 Large T 
antigen, which inherently alters the genetic composition of these cells [160]. Although 
we demonstrate that these cells are capable of differentiating into white and beige 
adipocytes based on mRNA expression data (Figure 27) and have used these cells for 
other adipogenesis-related studies [183], we cannot be certain that the decrease in 
Ucp1 expression is confounded by the immortalized nature of these cells. While cell 
lines offer several advantages, they are not always true replacements of primary cells 
[184]; studies comparing other primary versus immortalized cells have identified 
differential protein expression patterns that may lead to different experimental results 
[185]. Lastly, these studies were performed with experimental replicates using the same 
male immortalized SVF cell line, as opposed to SVF cells derived from different 
individual mice. With these three limitations in mind, we sought to establish a more 
robust and reliable cell culture system to test whether cancer conditioned medium could 
cause WAT browning.  
We have established a viable cell culture system using primary inguinal SVF 
from female mice (Figure 32, Figure 33). The mRNA expression profiles of the 
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preadipocytes, differentiated white adipocytes, and differentiated beige adipocytes are 
appropriate for each respective cell type when compared to those of other models and 
whole tissue lysates [186]. Qualitatively, there appears to be a more noticeable 
difference between the lipid droplet sizes in mature white versus beige adipocytes in 
these primary cell lines (Figure 33A) when compared to the immortalized cell line 
(Figure 27A), suggesting that the immortalized preadipocyte cell line may in fact 
produce a difference in baseline differentiation. Quantitatively, there were more 
significant differences in mRNA expression values between preadipocytes, white 
adipocytes, and beige adipose when using these primary SVF (Figure 33 versus the 
immortalized SVF Figure 27). These significant differences are even more robust since 
they come from the consolidation of data from adipocytes differentiated from SVF 
derived from five different, individual female mice.   
The exposure of white differentiated adipocytes from primary SVF to CL 316,243, 
a β3 adrenergic agonist used as a positive control, results in an appropriate increase in 
Ucp1 mRNA expression (for example, Figure 34A). This unique feature of the primary 
preadipocytes provides a model of white to beige adipocyte transdifferentiation. 
Together, these data demonstrate that the differentiation of primary inguinal SVF cells 
from female mice provides a robust cell culture system, which is uniquely suited for 
studying the local effects of breast cancer and other components within the tumor 
microenvironment on white adipocyte browning. 
We utilized this primary SVF in vitro cell culture system to explore whether the 
E0771 cell secretome or E0771 coculture with white adipocytes would induce WAT 
browning. To our surprise, Ucp1 mRNA expression in white adipocytes exposed to 
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E0771 cancer conditioned medium or E0771 coculture was decreased relative to control 
white adipocytes (Figure 34 and Figure 36, respectively).  Although not statistically 
significant, the trend of lower Ucp1 expression in white adipocytes exposed to either the 
E0771 secretome or E0771 coculture was consistent with expression trends 
demonstrated in the immortalized preadipocyte cell culture system.  
Ucp1 mRNA was used as the primary target in our studies, as UCP1 is the 
hallmark of thermogenic activity, and total Ucp1 mRNA correlates well with total UCP1 
protein in mouse models of cold-induced adipocyte browning [187]. Furthermore, 
western blotting of UCP1 in our experiments confirmed our Ucp1 mRNA expression 
results on the protein level (Figure 35). This provided additional justification for the use 
of Ucp1 mRNA expression. However, in the future, it would be helpful to gather 
additional data related to the activity of the increased UCP1 protein, for example, by 
measuring oxygen consumption rate and extracellular acidification rate using the 
Seahorse Analyzers (Agilent). This will require technical troubleshooting, as our initial 
attempts at using this technology were unsuccessful due to adipocyte detachment from 
cell culture plates even with the use of gelatin-coating. 
While there were no changes in gene expression of the thermogenesis 
associated genes Cidea or Ppargc1a, white adipocytes cocultured with E0771 cells 
expressed significantly more Tnfrsf9 (Figure 36B). White adipocytes exposed to 
conditioned medium had increased, although not statistically significant, Tnfrsf9 (Figure 
34B). Tnfrsf9 has been found to be elevated in breast cancer xenografts [117], but 
within adipocytes, its expression changes often parallel Ucp1 and Ppargc1a [188], 
which we did not observe in our results. TNFRSF9 (also known as CD137) promotes 
 
 
165 
 
the activation of a variety of immune cells [189], and can enhance natural killer cell-
mediated destruction of breast cancer cells [190]. It is therefore possible that cross-talk 
between white adipocytes and the E0771 cell line induces an immune-
eliciting/enhancing response by the adipocytes.  
Lep and Fasn mRNA levels were significantly decreased in both treatment 
conditions compared to control differentiated white adipocytes, with no change in Cfd 
expression (Figure 34C and Figure 36C). In WAT, leptin expression is associated with 
lipid droplet size, so it was initially surprising that its expression is decreased in our 
experimental system with plentiful nutrients in the cell culture medium, but also seemed 
logical as this suggests lipolysis within the cells. Additionally, leptin is overexpressed in 
breast tumors [191] and contributes to tumorigenesis by playing a role in mesenchymal-
epithelial transition and in regulating angiogenesis [192]. Additionally, leptin has been 
shown to induce Notch signaling leading to increased breast cancer aggressiveness 
[169]. Therefore, we speculate that the observed decrease in Lep expression by mature 
white adipocytes represents a protective response after exposure to E0771 conditioned 
medium or coculture. Multiple studies have shown that overexpression of fatty acid 
synthase, a key enzyme for de novo fatty acid synthesis, in breast cancer cells confers 
a more aggressive phenotype and allows for tumor growth and migration [193], so its 
decreased expression in adipocytes after treatment is consistent with a protective 
response. Additionally, transcription of Fasn is regulated, at least in part, by leptin [194], 
whose mRNA expression we show here as also being downregulated.  
We also tested for genes associated with lipolysis, and found that white 
adipocytes exposed to E0771 cancer conditioned medium had no changes in 
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expression of Lpl (lipoprotein lipase) or Mgll (monoglyceride lipase), but expressed less 
Lipe (hormone sensitive lipase) compared to control white adipocytes (Figure 34D). 
However, expression of Mgll was significantly increased in white adipocytes cocultured 
with E0771 cells, while expression of Lipe and Lpl was decreased but not significantly 
(Figure 36D). Increased monoglyceride lipase, an enzyme involved in lipolysis to 
generate fatty acids, is implicated in progression of several cancer cell types, including 
aggressive breast cancer [195]. Our results suggest that E0771-adipcyte cross talk, not 
simply E0771 cell secretome components, may induce Mgll expression to provide 
substrates for E0771 cancer cell utilization. Further experiments are needed to target 
the cancer-adipocyte cross talk-related drivers of this process, and to determine if this 
process results in paracrine or endocrine signaling contributing globally to CAC. 
In our last set of murine cell culture experiments in this chapter, we established 
primary SVF cell lines derived from BALB/c mice and used the 4T1 breast cancer cell 
line to test the reproducibility of our C57BL/6J-E0771 results in a different mouse strain. 
The 4T1 breast cancer cell line is an animal model for stage IV breast cancer, has a 
more metastatic phenotype than classic E0771 cells [196], and is commonly used for in 
vitro and in vivo BALB/c breast cancer studies [197] and allograft studies [198, 199]. 
4T1 conditioned medium exposure or coculture with BALB/c-derived mature 
adipocytes demonstrated very similar results to our E0771 experiments. Ucp1 mRNA 
expression in white adipocytes exposed to 4T1 cancer conditioned medium or 4T1 
coculture was decreased relative to control white adipocytes, although not statistically 
significant (Figure 37A and Figure 39A, respectively).  Western blotting of UCP1 in 
these experiments confirmed, again, our Ucp1 mRNA expression results on the protein 
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level (Figure 38). There were no statistically significant changes in thermogenic 
adipocyte-related gene expression, although there was a trend towards increased 
Tnfrsf9. As described above, it is still possible that an immune-eliciting/enhancing 
response by the adipocytes occurs in the presence of breast cancer. The only white 
adipocyte gene marker that was changed in these 4T1 experiments was a decrease in 
Lep expression after exposure to 4T1 cancer conditioned medium (Figure 37C). This is 
slightly different from the E0771 results, which demonstrated a decrease in Lep and 
Fasn in both treatment groups, but still suggests that an increase Lep expression by 
mature white adipocytes represents a protective response in the presence of breast 
cancer. No changes in any of the lipolysis-related genes occurs in the 4T1 experiments, 
which suggests that differences between the E0771 and 4T1 cancer cell lines and/or 
C57BL/6- and BALB/c-derived adipocytes may influence this aspect of adipocyte 
plasticity. 
We then utilized human cell culture methods to test whether breast cancer 
directly induces WAT browning in vitro. First, we established the necessary cell culture 
conditions to induce white and beige differentiation from female human benign breast 
SVF cells, and found that human SVF cells need a low serum supplementation in order 
to maximize health and differentiation capacity (Figure 40). The medium 
supplementation has 2% FBS as opposed to 10% in the medium for murine cell culture, 
and includes additional supplementation of L-glutamine, ascorbic acid, recombinant 
human insulin, recombinant human FGF basic (fibroblast growth factor basic, also 
known as FGF2), and hydrocortisone hemisuccinate. Many cells are cultured in low or 
serum-free medium either at baseline or for particular experimental designs [200], and 
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decreased serum here may be helpful here by increasing sensitivity of differentiating 
cells to induction and/or maintenance medium. While L-glutamine and ascorbic acid are 
both included in the DMEM medium used in our lab for most cell culture, they are 
supplemented at much higher concentrations here, with approximately 3 times more L-
glutamine and 8 times more ascorbic acid. Ascorbic acid is a water soluble molecule, 
and additional amounts may be helpful as it acts as an antioxidant, electron donor for 
several enzymes, and helps to protect against peroxidation of unsaturated fatty acids 
[201]. Insulin is included in all induction and maintenance mediums, but is not in pre-
differentiation medium for mice; we suspect human SVF may require the additional 
signaling that insulin provides to stimulate healthy cell proliferation before differentiation. 
Hydrocortisone hemisuccinate is a water-soluble immunosuppressant, and we suspect 
that it aids in human cell culture by dampening any autocrine or paracrine signaling that 
may strain the cell before or during differentiation. Lastly, FGF2 activates tyrosine 
kinase activity in vivo [202], and in murine adipogenesis studies using 3T3-L1 cells, the 
nonreceptor tyrosine kinase c-Abl (Abelson murine leukemia viral oncogene) is critical 
for initiation of differentiation [203]; we therefore expect that the addition of FGF2 aids in 
priming our SVF for differentiation and in promoting differentiation once it begins. Once 
optimized, our conditions yielded differentiation to mature white and beige adipocytes 
with appropriate differences in lipid accumulation and UCP1 expression (Figure 41). We 
then used this model to test the effects of two human breast cancer cell lines with 
different receptor expression and aggressiveness on white adipocyte plasticity: MCF-7 
(estrogen receptor positive) and MDA-MB-231 (triple negative, more aggressive 
phenotype) [196]. 
 
 
169 
 
Using SVF derived from benign white breast adipose tissue from a 27 year old 
woman with a history of diabetes mellitus, we show, similar to that in mice (Figure 28), 
that most significant changes occur when differentiating cells are exposed to cancer 
conditioned medium during periods of maintenance or throughout induction and 
maintenance phases (Figure 42).  UCP1 mRNA was significantly increased in maturing 
adipocytes exposed to conditioned medium from MDA-MB-231 cells. In these 
adipocytes treated with MDA-MB-231 conditioned medium, SLC27A1 was significantly 
increased, while PPARG and PPARGC1A were significantly decreased. While not 
significant, maturing adipocytes exposed to MDA-MB-231 conditioned medium 
expressed about 4-fold less EAR2, and 2-fold less OPLAH and PDK4 (Figure 42). 
Interestingly, these changes were not observed in maturing adipocytes exposed to 
conditioned medium from MCF-7 cells; instead, these adipocytes expressed similar or 
less mRNA (though not significant) for all of these genes compared to controls.  
SLC27A1 encodes SLC27A1, more commonly known as fatty acid transport 
protein 1 (FATP1), helps to control fatty acid uptake into cells [204]. Its expression has 
been shown to be inversely related to BMI and adipocyte size, and increases as human 
subjects lose weight [205]. Although its closely related family member SLC27A4 
(FATP4) has just recently been shown to be increased in human breast cancer tissues 
and increases free fatty acid uptake in the MDA-MB-231 cell line, in the same study, 
higher SLC27A1 expression was correlated with increased survival [206]. Therefore, its 
increased expression by mature adipocytes that were exposed to MDA-MB-231 cells 
likely manifests as a protective response by the adipocytes, perhaps to change 
substrate utilization to the demise of the tumor cells.  
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PPARG in mice has been shown to be necessary for brown adipose tissue 
function and intact beta-3 adrenergic signaling [207], as it is a transcriptional regulator 
on the UCP1 promoter region. In breast cancer cells, PPARG is overexpressed and can 
induce cell differentiation, although it is contested whether this exerts a positive or 
negative effect on cancer progression [208]. A 2005 study found a correlation between 
PPARG expression and estrogen receptor beta expression and that it is a favorable 
prognostic factor for disease free survival [209]. Our results demonstrate significantly 
decreased PPARG expression in the adipocytes treated with MDA-MB-231, while we 
observed a mild decrease – though not significant – in expression after treatment with 
MCF-7 conditioned medium. Since the MCF-7 cell line is estrogen receptor positive, and 
MDA-MB-231 is not, this could perhaps explain the difference in the degree of 
decreased PPARG expression. Breast cancer secreted microRNAs, such as miR-155, 
downregulate PPARG expression and lead to metabolism reprogramming in mature 
adipocytes contributing to cancer associated cachexia [210]. While we did not test for 
the presence of specific factors such as miR-155, it is possible that they are 
differentially expressed in different breast cancer cell lines and may contribute to the 
observed decrease in PPARG expression.  
Although UCP1 was significantly increased in the MDA-MB-231 conditioned 
medium treatment group, PPARGC1A was significantly decreased.  This was initially 
surprising, as PPARGC1A substantially increases PPARG activity on the UCP1 
promoter and is known to be involved in WAT browning in non-cancer-related studies 
[211, 212]; however, it is not essential. The decreased PPARGC1A may therefore be a 
response to the increased UCP1 expression, providing negative feedback to quench the 
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maladaptive increase in UCP1.  Other genes that are associated with classical brown 
adipose tissue such as OPLAH [117] and WAT browning such as PDK4 and EAR2 
[213, 214] were decreased, though not significantly, after exposure to MDA-MB-231 
cells during differentiation. This further suggests that although UCP1 is increased in 
these cells, other cell signaling processes are acting to downregulate that effect to 
return to ‘homeostasis.’ 
When comparing lipid droplet sizes in these adipocytes, our results demonstrate 
that cancer conditioned medium from either human breast cancer cell line results in 
significantly decreased lipid droplet size in mature adipocytes, regardless of when the 
exposure occurred during differentiation. Interestingly, when exposure occurred during 
maintenance or during induction and maintenance, cells exposed to cancer conditioned 
medium from MDA-MB-231 cells had a more significant decrease in lipid droplet size 
than the MCF-7 conditioned medium-treated group. These results further support our 
mRNA expression data, which suggest a differential response in adipocyte 
differentiation to MDA-MB-231 versus MCF-7 secretomes. This further supports the 
mRNA expression data for genes such as SLC27A1, which was significantly increased 
and is known to increase with decreasing adipocyte size [205]. While we had different 
thermogenic adipose tissue-related gene expression changes, the decreased lipid 
droplet sizes in both exposure groups correlate with the ‘cancer associated adipocyte’ 
phenotype that has been recently described in breast cancer [116]. An increased 
amount of lipid droplets has been shown to be associated with increased 
aggressiveness of cancer using MCF-7 and MDA-MB-231 cells [215], but it is unclear 
whether the lipid accumulation is a result of cancer-specific process or of local WAT 
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changes and process. It would be interesting to test for genes related to lipid 
metabolism and lipolysis to better understand the functional meaning of the changes 
that we and other have noted in both adipocyte and breast cancer cells. Additionally, 
cancer-associated adipose tissue has been shown to produce a protein secretome with 
inflammatory characteristics [216], which we did not explore in our studies. It would be 
interesting to test for these changes as well to better understand the complicated role of 
inflammation and how it relates to breast cancer tumorigenesis and adipocyte-specific 
changes in breast cancer. 
Lastly, we tested the effects of these two human breast cancer cell lines’ 
conditioned mediums on mature white adipocytes in an SVF cell line derived from a 
different human patient (this time, a 51 year old woman with no history of diabetes 
mellitus) during differentiation and after maturation for 24 hours. Interestingly, our 
results suggest that 24 hours of MCF-7 conditioned medium exposure is able to 
increase UCP1 mRNA expression by about 4-fold, while MDA-MB-231 conditioned 
medium decreased UCP1 mRNA expression by more than 8-fold (Figure 44C). When 
replicating the conditions using the first SVF cell line, exposure of this different SVF cell 
line to conditioned medium during induction and maintenance phases of differentiation 
resulted in significant decreases in UCP1 mRNA expression compared to control 
(Figure 44B). These results are in contrast to the results using the first SVF cell line, 
which suggested that MDA-MB-231 conditioned medium caused an increase in UCP1 
expression (Figure 42).  
These conflicting results make it challenging to establish conclusive conclusions 
regarding the direct effects of MCF-7 and MDA-MB-231 secreted factors on white 
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adipocyte plasticity. It is entirely possible that the difference between UCP1 expression 
in the first SVF cell line (Figure 42) and the second (Figure 44) are due to differences in 
the women in which these cells were isolated from. It is well established that phenotypic 
properties of tissue donors are at least partially retained when their cells are cultured in 
vitro [217]. Therefore, the age difference (27 versus 51 years of age, respectively), 
difference in diabetes status (positive versus negative, respectively), or difference in 
other factors unknown to us such as body weight, between the two women whose 
normal breast WAT was used for SVF isolation may be responsible for the differences 
we have observed in our experiments.  This suggests that individual characteristics may 
render their differentiating and mature white adipocytes more or less resilient to cancer-
mediated adipocyte changes. Additional experiments using a larger sample of human-
derived SVF cells lines would be needed for further exploration.  
Furthermore, there is clearly a differential response within an individual SVF cell 
strain to different breast cancer cell lines. There are a host of differences including and 
beyond those in the estrogen, progesterone, and HER2 receptor statuses between the 
MCF-7 and MDA-MB-231 cell lines. Differences in angiogenic factors in the secretomes 
of MCF-7 and MDA-MB-231 cells were found in a 2016 xenograft study [218]. Estrogen 
increases oxidative stress in ER-positive cell lines such as MCF-7 cells to a significantly 
greater extent than ER-negative lines such as MDA-MB-231 [219], and increased 
oxidative stress and inflammation may be involved in adipocyte changes in breast 
cancer. For example, insulin-like growth factor I receptor is increased in estrogen-
receptor-positive breast cancers such as MCF-7, resulting in PI-3K/Akt pathway 
activation that is not found in non-estrogen-receptor-positive breast cancers such as 
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MDA-MB-231 [220]. PPARalpha activation is higher in MDA-MB-231 cells than in MCF-
7 cells with implications related to increased proliferation and tumorigenesis [221]. Other 
cell lines, including these, with different characteristics should be used to provide 
additional understanding and mechanisms for these differences. 
 In both these murine and human in vitro experiments, we must consider 
additional limitations to the experimental design and the impact of these on our results. 
The in vivo environment contains additional cell types not included in these more 
simplistic in vitro models. Additionally, the two-dimensional nature of our cell culture 
models is inherently different than the three-dimensional in vivo environment, which 
limits our ability to fully replicate the interactions and processes occurring in vivo. For 
example, our in vitro model does not include hypoxic conditions that are known to be 
present in tumors in vivo [134], angiogenesis which can regulate thermogenesis in vivo 
[222], nor elevated glycolysis which has been shown to occur in cancer and contribute 
to cancer-associated cachexia [223, 224]. Future experiments should consider three-
dimensional cell culture systems (reviewed by [225]) with multiple cell types to allow for 
more robust conclusions.  
 
4.4 Conclusion 
Together, our results show that cancer conditioned medium and coculture modify 
the overall adipocyte gene expression pattern, but do not alter thermogenic gene 
expression in murine in vitro studies. This supports prior literature regarding non-
thermogenic changes in cancer, and challenges those related to cancer-induced WAT 
browning; however, since the in vivo environment is multifaceted, the complexities of 
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the cells and signaling within the tumor microenvironment should be explored further 
before completely ruling out WAT browning effects from the E0771 or 4T1 breast cancer 
cell lines. In our human in vitro studies, our results using MCF-7 and MDA-MB-231 
breast cancer cell lines are more ambiguous, highlighting the importance of individual 
variability and susceptibility to breast cancer-mediated changes. Our results, especially 
in our murine experiments, suggest that the local WAT browning observed in the 
previous chapter are not mediated by factors directly secreted by, or released as a 
result of cross talk with, the E0771, 4T1, or LLC cancer cell lines. This suggests that 
local WAT browning is the result of interactions with other cells and factors within the 
tumor microenvironment.  We explore this in the subsequent chapter. 
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Chapter 5: The Role of Tumor Microenvironment in Cancer-Mediated White Adipose 
Tissue Browning and Plasticity 
  
5.1 Rationale 
In the previous chapters, we demonstrate that WAT browning occurs locally in 
vivo (Chapter 3), but that cancer conditioned medium and coculture do not alter 
thermogenic gene expression in murine in vitro studies (although they do modify the 
overall adipocyte gene expression pattern, Chapter 4). These results suggest that the 
tumor microenvironment is involved in this process, and we ask here whether several 
components – interleukin 6, tumor lysate, and a host of immune cell populations – are 
involved in WAT browning and adipocyte plasticity. 
 
5.2 Results 
5.2.1 IL6 is minimally secreted by selected murine cancer cell lines, and exposure of 
differentiated white adipocytes to exogenous IL6 does not increase Ucp1 gene 
expression 
Considering that tumor-derived IL6 has been implicated in other models of 
cancer-related WAT browning, we asked whether our ER+ murine breast cancer E0771 
cell line secreted IL6 into the conditioned medium. Our results demonstrate that the 
E0771 cells produce IL6, but at much lower levels than peritoneal cavity inflammatory 
cells as measured by intracellular flow cytometry (Figure 45A,B) and qPCR (Figure 
45C).  We also demonstrate similar expression patterns in other cancer cell lines: 4T1 
breast cancer cells and LLC cells, with LLC cells expressing significantly less Il6 mRNA 
than stimulated murine peritoneal cavity cells (Figure 46). 
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As IL6 may come from a variety of cell types within the tumor microenvironment 
in vivo, we next sought to determine whether our mature adipocytes in vitro have the 
necessary receptor machinery – interleukin 6 signal transducer (IL6ST, also referred to 
as glycoprotein 130, or GP130) and membrane-bound interleukin 6 receptor alpha 
(IL6RA) – for IL6 signaling to occur. Flow cytometry demonstrates that differentiated 
white and beige adipocytes express abundant IL6ST (aka GP130, or CD130), as 
evidenced by increased staining relative to isotype control (Figure 47A). Gene 
expression analysis for Il6st supports the flow cytometry data: white and beige 
adipocytes express at least the same amount of Il6st (encodes GP130) mRNA 
compared to stimulated peritoneal cavity cells (Figure 47B). Interestingly, white and 
beige adipocytes do not express IL6RA (CD126) on their cell membranes, evidenced by 
less flow cytometry staining than isotype control (Figure 47C). Il6ra mRNA expression is 
also decreased in white and beige adipocytes relative to stimulated peritoneal cavity 
cells (Figure 47D).  
With the above information, we investigated if exogenous IL6 exposure, with or 
without supplementation with soluble IL6RA, would induce gene expression changes 
indicative of WAT browning in vitro. Increased Socs3 (suppressor of cytokine signaling 
3) gene expression (Figure 48A) and increased phosphorylated STAT3 protein at the 
tyrosine 705 residue (Figure 48B) following 30 minutes of exposure to IL6 and 
IL6+IL6RA demonstrate the bioactivity of IL6 and IL6RA in our experimental model. To 
our surprise, exposure of white adipocytes to IL6 or IL6+IL6RA for three days did not 
increase Ucp1 mRNA expression but instead resulted in a downward trend in 
expression (Figure 49A). A similar trend in Cidea expression was observed (Figure 
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49B). The IL6+IL6RA treated group expressed significantly more Tnfrsf9 mRNA 
compared to control white adipocytes but had no changes in Ppargc1a expression 
(Figure 49B).  Lep mRNA expression was significantly decreased with IL6+IL6RA 
treatment, but no changes were observed for Cfd or Fasn (Figure 49C). No change in 
any of the measured lipolysis markers was observed in the white adipocytes treated 
with IL6+IL6RA (Figure 49D). 
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Figure 45. E0771 cells do not produce excessive IL6 
Peritoneal cavity cells and E0771 cells were stimulated to induce endogenous IL6 production as 
described in methods. (A) Intracellular flow cytometry curves showing staining data for IL6 stain and 
isotype control. (B) Quantification of intracellular IL6 from flow cytometry MFIs. (C) Quantitative PCR for 
Il6 mRNA expression. Please note y-axis scale in (B) and (C) is log2. n = 2 for peritoneal cavity cells; n = 
3 for E0771 cells. Statistical tests: (B) Unpaired t-test, (C) Mann-Whitney test. MFI = Mean Fluorescent 
Intensity. 
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Figure 46. E0771, 4T1, and LLC cells do not produce excessive IL6 
Peritoneal cavity cells, immortalized SVF preadipocytes (‘mIWPA’ in image), and different cancer cells 
(E0771, 4T1, and LLC) were stimulated to induce endogenous IL6 production as described in methods. 
(A) Quantification of intracellular IL6 from flow cytometry MFIs. (B) Quantitative PCR for Il6 mRNA 
expression. Please note y-axis scale in (B) is log2. n = 2 for peritoneal cavity cells; n = 3 for all other cells. 
Statistical tests: Kruskal-Wallis (nonparametric ANOVA) test with Dunn’s test for multiple comparisons. 
MFI = Mean Fluorescent Intensity. 
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Figure 47. Differentiated white and beige adipocytes express abundant IL6ST, but not IL6RA 
Flow cytometry for (A) cell-surface IL6ST (GP130, CD130) or (C) IL6RA (CD126) in white and beige 
adipocytes. Dashed line represents average MFI staining for each respective isotype control. Quantitative 
PCR for (B) Il6st (Gp130) or (D) Il6ra (Cd126) for peritoneal cavity cells and white and beige adipocytes. n 
= 2 for peritoneal cavity cells; n = 5 SVF cell lines for white and beige adipocytes. Please note y-axis 
scale in (B) and (D) is log2. Statistical tests: (A) and (C) Mann-Whitney test, (B) and (D) Kruskal-Wallis 
and Dunn’s multiple comparisons tests. MFI = Mean Fluorescent Intensity. 
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Figure 48. Both IL6 and IL6+IL6RA treatment induces STAT3 signaling in mature white adipocytes, 
with IL6+IL6RA treatment inducing most robust signaling.  
Differentiated white adipocytes were treated for 30 minutes with CL316,243 (noted as ‘CL’ in images), IL6 
40 ng/mL + IL6RA 200 ng/mL (noted ‘IL6+IL6RA’ in images), and controls as described in methods. (A) 
Quantitative PCR for Socs3. Please note y-axis scale is log2. n = 3 primary SVF cell lines. Error bars = 
standard deviation. Statistical tests: Friedman and Dunn’s multiple comparisons tests. (B) Western blot of 
phosphorylated STAT3 (‘p-STAT3’ with different residues indicated in image), total STAT3, UCP1, and 
TBP protein.   
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Figure 49.  Neither exogenous IL6 or IL6+IL6RA administration causes WAT browning in vitro, but 
alters white adipocyte mRNA expression  
Differentiated white adipocytes were treated for 3 days with CL316,243 (noted as ‘CL’ in images), IL6 40 
ng/mL (noted as ‘IL6’ in images), IL6 40 ng/mL + IL6RA 200 ng/mL (noted ‘IL6+IL6RA’ in images), and 
controls as described in methods. Quantitative PCR for (A) Ucp1, (B) markers of beige adipocytes, (C) 
markers of white adipocytes, (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary SVF 
cell lines. Error bars = standard deviation. Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple 
comparisons tests, (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests.  
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5.2.2 Preliminary data: potential role of tumor lysate and/or tumor-isolated CD11b+ cells 
on WAT browning 
After demonstrating that IL6 alters some adipocyte-related gene expression, but 
does not directly mediate WAT browning, we asked if the immune system component of 
the tumor microenvironment is involved in these processes. Using our primary inguinal 
SVF adipogenesis cell culture system, we exposed mature white adipocytes from two 
different SVF cell strains to a variety of conditions (refer to methods section 2.10) 
including tumor lysate and CD11b+ cells from several allograft and spontaneous murine 
breast tumors for 3 days. Mature beige adipocytes express appropriately more Ucp1 
than white adipocytes (Figure 50A, C); however, results exposure to experimental 
conditions are quite variable: some of the tumor lysate conditions altered Ucp1 mRNA 
expression in white adipocytes positively or negatively, and to varying degrees, 
depending on the SVF strain (Figure 50B, D). 
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Figure 50. Tumor lysate and tumor-derived CD11b+ cells alter Ucp1 expression in white 
adipocytes in vitro 
Quantitative PCR for Ucp1 mRNA expression. (A) and (C) Primary SVF were differentiated to mature 
white and beige adipocytes. (B) and (D) Mature white adipocytes were exposed to CL 316,243 (‘CL’ in 
image), IL6, TNF, and various tumor lysates (‘MMTV early,’ ‘MMTV late,’ ‘PyMT Lys,’ and ‘E0771 Lys’ in 
image) and CD11b cells (‘PyMT CD11b’ and ‘E0771 CD11b’ in image) for 3 days as described in 
methods. Please note y-axis scales are log2. (A) and (C) n=6 wells; (B) and (D) n = 2-3 wells per group. 
Statistical tests: (A) and (C) Mann-Whitney test; (B) and (D) Kruskal-Wallis (nonparametric ANOVA) test 
with Dunn’s test for multiple comparisons.  
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5.2.3 Preliminary data: immune cell populations shift in adipose tissue in mice with 
breast cancer 
We next wanted to explore which immune cell populations within the breast 
tumor microenvironment may be most important. After injecting wild-type and Rag1 
deficient (Rag1-/-) BALB/c mice with 4T1 breast cancer cells (refer to methods section 
2.11), we found that there were no significant changes in body weight in the mice 
between inoculation with cancer cells or saline control and euthanization (Figure 51A), 
nor were there any significant changes in rectal temperature at time of euthanization 
(Figure 51B). We harvested inguinal WAT (where the tumor cells were injected) from 
these mice to look at differences in gene expression of several key adipocyte markers 
between naïve mice and mice with tumor. 
Compared to wild-type naïve mice, inguinal WAT from wild-type mice with 4T1 
tumors expressed increased, though not significantly, Ucp1, Cidea, Prdm16, and 
Ppargc1a mRNA (Figure 51C, gray bars).  In the Rag1-deficient mouse strain, 
compared to the Rag1-/-  naïve mice, inguinal WAT from Rag1-/-  mice with 4T1 tumors 
did not have changes in Ucp1 expression, but had increased Cidea and Ptk2b 
expression and decreased Ppargc1a expression – although again, none of these 
changes were statistically significant (Figure 51C, black bars).  
We analyzed adipose tissue (inguinal WAT, axillary WAT, gonadal WAT, and 
interscapular BAT) and the tumors themselves via flow cytometry to quantify immune 
cell populations. There were no trends or changes in percentage of CD45+ cells 
between naïve or mice with tumor in either mouse strain (Figure 52A). Neutrophils 
comprised a larger percentage of all live cells in all adipose tissue pads in both mouse 
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strains with tumor (Figure 52B), and there was a less impressive increase in dendritic 
cell population in the right inguinal, axillary, and gonadal fat pads in mice with tumor 
(Figure 52C). Conversely, in most adipose tissue pads, T cell and B cell populations 
were larger in naïve (non tumor-burdened) mice (Figure 52D, E). There was a trend 
toward an increased pan-macrophage population in many of the WAT pads of mice with 
tumor, especially in the right inguinal WAT where 4T1 cells were injected (Figure 53A). 
Looking at the subpopulations of macrophages, there appears to be an increase in 
major histocompatibility complex class II (MHCII)-/lymphocyte antigen 6 complex 
(Ly6C)- and MHCII-/Ly6C+ macrophages, a decrease in MHCII+/Lys6C- macrophages, 
and no clear change in MHCII+/Ly6C+ macrophages (Figure 53B-E). 
When we analyzed the percentages of immune cell population of all living and 
CD45+ cells, the trends just described above are even more apparent: mice with 4T1 
cancer cells, regardless of wild-type or Rag1-/- strain, have a larger percentage of 
neutrophils and dendritic cells (Figure 54A-B), a smaller percentage of T cells and B 
cells (Figure 54C-D), and similar or increased percentage of pan-macrophages (Figure 
54E) in all or many adipose tissue pads. The increase in pan-macrophages is, again, 
most striking in the right inguinal WAT (Figure 54E, Figure 55A show same information). 
Of the live, CD45+, pan-macrophage cell population, we continue to see an increase in 
MHCII-/Ly6C- and MHCII-/Ly6C+ macrophages, a decrease in MHCII+/Lys6C- 
macrophages, and no clear change in MHCII+/Ly6C+ macrophages in both wild-type 
and Rag1-/- mice with 4T1 breast cancer cells (Figure 55B-E). 
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Figure 51. Weight, temperature, and Ucp1 mRNA expression data from 4T1 allograft studies in 
wild-type and Rag1-/- mice 
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or 
injected with control PBS and euthanized after tumor growth as described in methods. (A) Change in 
weight between inoculation and euthanization, (B) rectal temperature of mice at time of euthanization, (C) 
Quantitative PCR for several genes in right inguinal WAT (where injections occurred). For (C), fold 
changes were calculated with respect to each genotype’s naïve expression levels, and please note y-axis 
scale is log2. For all groups, n=2-5. Statistical tests: (A) and (B) Kruskal-Wallis (nonparametric ANOVA) 
test with Dunn’s test for multiple comparisons; (C) two-way ANOVA with Tukey's multiple comparisons 
test 
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Figure 52. Various immune cell population percentages of live cells from 4T1 allograft studies in 
wild-type and Rag1-/- mice 
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or 
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry 
results for (A) CD45+ cells, (B) Neutrophils, (C) Dendritic cells, (D) T cells, (E) B cells. For all groups, 
n=4-5 mice.  
 
 
190 
 
 
Figure 53. Macrophage population percentages of live cells from 4T1 allograft studies in wild-type 
and Rag1-/- mice 
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or 
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry 
results for (A) Pan-macrophages, (B) MHCII-/Ly6C-, (C) MHCII-/Ly6C+, (D) MHCII+/Ly6C-, (E) 
MHCII+/Ly6C+. For all groups, n=4-5 mice.  
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Figure 54. Various immune cell population percentages of CD45+ live cells from 4T1 allograft 
studies in wild-type and Rag1-/- mice 
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or 
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry 
results for (A) Neutrophils, (B) Dendritic cells, (C) T cells, (D) B cells, (E) Pan-macrophages. For all 
groups, n=4-5 mice. 
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Figure 55. Macrophage population percentages of CD45+ live cells from 4T1 allograft studies in 
wild-type and Rag1-/- mice 
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or 
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry 
results for (A) Pan-macrophages, (B) MHCII-/Ly6C-, (C) MHCII-/Ly6C+, (D) MHCII+/Ly6C-, (E) 
MHCII+/Ly6C+. For all groups, n=4-5 mice. 
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5.3 Discussion 
Since our results from Chapter 4 demonstrate that cancer cells induce changes 
to white adipocytes but do not cause WAT browning, we wanted to explore other 
possible mediators of these WAT browning changes demonstrated in Chapter 3. 
In their studies of a murine model of cachectic colon cancer, Petruzzelli and colleagues 
concluded that tumor-secreted IL6 is a direct driver of WAT browning [112]. We first 
investigated whether E0771, 4T1, and LLC cells secrete IL6 into the conditioned 
medium. All cells were treated with PMA and ionomycin, which overstimulate cytokine 
production, as well as brefeldin A and monensin, which act to inhibit intracellular protein 
and trap proteins in the endoplasmic reticulum. This method allowed us to make 
comparisons in maximum IL6 production of each cell type. 
Compared with stimulated murine peritoneal cavity cells which contain 
inflammatory cells, E0771 cells produce significantly less IL6 when measured by 
intracellular flow cytometry (Figure 45A-B) and express over 100-fold less Il6 mRNA 
(Figure 45C). When we tested IL6 expression in other cancer cell lines, we found that 
4T1 and LLC cells both secrete more IL6 than E0771 cells, although still less than  
stimulated murine peritoneal cavity cells (Figure 46A), while mRNA expression of Il6 
was significantly decreased in LLC cells (Figure 46B). The expression and secretion of 
IL6 directly by breast cancer cells is variable, depending heavily on breast cancer cell 
type [226, 227]. Moreover, it is well established that IL6 is physiologically produced by 
non-adipocyte cells within adipose tissues [228], and can be modulated by breast 
adipose tissue in models of breast cancer [229]. Based on this information, and since 
tumor-derived IL6 has been directly implicated in other models of cancer-related WAT 
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browning [112], we asked whether it possesses the ability of generating white to brown 
transdifferentiation in our primary adipocyte cell culture system, regardless of its cell 
origin.   
Since IL6 may come from a variety of cell types within the tumor 
microenvironment in vivo, we investigated whether our mature adipocytes in vitro have 
the necessary receptor machinery to ensure IL6-mediated signal transduction could 
occur. IL6 binds to either membrane-bound or soluble interleukin 6 receptor alpha 
(IL6RA, also referred to as CD126), and this IL6:IL6RA complex then associates with 
membrane-bound interleukin 6 signal transducer IL6ST (IL6ST, also referred to as 
GP130 or CD130) to induce signal transduction via the JAK/STAT3 pathway [230].  
IL6ST expression is virtually ubiquitous, while expression of membrane-bound IL6RA is 
more cell-specific [231].  We confirmed that IL6ST is expressed in our mature, 
differentiated adipocytes, both on the membrane surface as measured by flow 
cytometry and by transcript levels with qPCR (Figure 47A-B). Interestingly, flow 
cytometry data for IL6RA was less than the isotype control, suggesting lack of, or 
minimal, receptor expression (Figure 47C). Our expression levels of IL6ra mRNA are 
consistent with this finding; while mRNA was detectable, it was 64- to 128-fold lower 
than stimulated peritoneal cavity cells (Figure 47D). Since soluble IL6RA is produced by 
breast cancer cells [232] and by monocytes and macrophages [231], these results 
prompted the inclusion of soluble IL6RA in our IL6 exposure experiments to mimic the 
tumor microenvironment and to ensure that signal transduction could occur. 
With this information, we investigated whether exogenous IL6 exposure, with or 
without supplemented soluble IL6RA, would induce gene expression changes indicative 
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of WAT browning in vitro. We observed an increase in Socs3 (suppressor of cytokine 
signaling 3) gene expression (Figure 48A) and STAT3 protein phosphorylation at the 
tyrosine 705 residue (Figure 48B) following just 30 minutes of exposure to both IL6 and 
IL6+IL6RA, not surprisingly more robust in the IL6+IL6RA group.  
The suppressors of cytokine signaling (SOCS) family are molecules that inhibit 
JAK and STAT activation, regulated by its own signaling pathway: when STAT3 
signaling is increased, transcription of SOCS3 is induced to act as negative feedback on 
the signaling pathway [145]. We demonstrate substantially increased Socs3 expression 
in both IL6 and IL6+IL6RA treatment groups, which indicates that the JAK-STAT 
pathways is activated by these two treatment groups. The addition of IL6RA to the IL6 
treatment results in an even more robust increase in Socs3 expression – over 1024-fold 
that of the white adipocyte control – which tells us that IL6RA supplementation is useful 
to maximize this this signaling pathway in vitro. The phosphorylation of tyrosine 705 is 
canonical, while phosphorylation of serine 727 is a noncanonical pathway implicated in 
several physiologic states [233]. Tyr705 is associated with JAK signaling, while Ser727 
is associated with MAPK signaling [234]. We are not surprised that the tyrosine 705 
residue is phosphorylated, as JAK/STAT3 signaling is an established pathway in 
adipocyte plasticity. The lack of significant increases in serine 727 residue 
phosphorylation in the CL 316,243, IL6, or IL6+IL6RA treatment groups suggests 
MAPK/STAT3 signaling is not putative for WAT browning. Taking our Socs3 mRNA 
expression data and STAT3 phosphorylation data together, these results confirm the 
bioactivity of IL6 and IL6RA via the JAK/STAT3 signaling pathway in our experimental 
model.   
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To our surprise, exposure of white adipocytes to IL6 or IL6+IL6RA for three days 
did not increase Ucp1 or Cidea mRNA expression but instead resulted in a downward 
trend in expression (Figure 49A-B), similar to our observations in cancer conditioned 
medium (Figure 34A-B, Figure 37A-B) and coculture experiments (Figure 36A-B, Figure 
39A-B). The IL6+IL6RA treated group expressed significantly more Tnfrsf9 mRNA 
compared to control white adipocytes but had no significant changes in Cidea or 
Ppargc1a expression (Figure 49B), similar to our coculture results.  Together, these 
results suggest that IL6-induced changes to adipocytes in vivo may be dependent on 
soluble receptors from other cells and additional signaling within the tumor 
microenvironment. Lep mRNA expression was significantly decreased with IL6+IL6RA 
treatment, similar to our observations in cancer conditioned medium and coculture 
experiments, but no changes were observed for Cfd or Fasn (Figure 49C). No change in 
any of the measured lipolysis markers was observed in white adipocytes treated with 
IL6+IL6RA (Figure 49D).  
These results, especially the lack of increased Ucp1 expression, contrast the 
findings of previous studies that implicate IL6 as a direct causative agent of WAT 
browning [112]. We found this, especially the expression of IL6 by LLC cells, to be 
interesting, as LLC cell-derived parathyroid hormone related peptide (PTHrp), but not 
IL6, has been implicated as a direct mediator of WAT browning in cancer [113], yet we 
demonstrate in Chapter 4 that our LLC-conditioned medium, which presumably contains 
both PTHrP and, based on our results here, at least detectable amounts of IL6, does 
not induce white to beige transdifferentiation. However, it is important to recognize the 
differences in our current study and design limitations that may account for these 
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discrepancies. IL6’s role in WAT browning was implicated in a model of colon cancer, 
which is inherently different than breast cancer and the specific cancer cell line used in 
our studies. Other molecules, such as PTHrp, have been implicated in different models 
of CAC [113], so it is possible that other pathways may be driving the process of WAT 
browning in breast cancer. Whether IL6 exerts its effects directly or indirectly is still 
contested within the literature [235], so it is entirely possible that IL6’s role in WAT 
browning in breast cancer may be indirect. It would be interesting to test whether 
constitutively-active STAT3 would yield different results, as that could provide useful 
information regarding the time-dependent nature of this signaling pathway. Additionally, 
other cytokines related to IL6 signaling should be explored, such as oncostatin M which 
interacts with gp130 [236], to better understand these signaling pathways in vivo.  
To begin testing what processes may be involved in vivo, we exposed mature 
white adipocytes from two SVF cell strains to different tumor lysates and tumor-isolated 
CD11b+ cells. Tumor lysates inherently contain a variety of cells, including the tumor 
cells themselves as well as stromal cells and immune cells. In breast cancer, tumor 
lysate is being investigated as a vaccine because it contains multiple tumor-associated 
antigens which can induce a variety of immune cell responses [237]. A host of immune 
cell populations have been implicated in adipose tissue plasticity (reviewed by [238]). 
CD11b is part of the complement receptor type 3 (CR3, or macrophage-1 antigen 
MAC1) molecule expressed by monocytes/macrophages, granulocytes, and natural 
killer cells [239], and is implicated in cancer [240-242]. It appears that tumor lysate may 
increase Ucp1 mRNA expression regardless of whether it came from early or late stage 
MMTV tumors, PyMT allograft tumors, or E0771 allograft tumors, although these results 
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were extremely variable. Cd11b exposure may also induce Ucp1 expression, but the 
range was not as large as that in the tumor lysate groups (Figure 50). Ucp1 mRNA 
increased in beige vs white cultured adipocytes, although this varied from 32- to 64-fold 
more between the two SVF (and was only significantly different in one of the two strains, 
Figure 50A). Furthermore, the effect of CL 316,243 was extremely variable between 
these two SVF strains – in the second strain, CL 316,243 exposure for 3 days resulted 
in higher Ucp1 expression than beige control (Figure 50D). It is highly likely that this 
variability accounted for, at least part, some of the differences we saw in our exposure 
groups’ results. 
To work towards identifying cell populations that are crucial for WAT browning in 
breast cancer, we used two different BALB/c mouse strains, wild type and Rag1-/-, and 
injected 4T1 breast cancer cells in the right inguinal WAT pad to induce allograft tumor 
formation. When we isolated the WAT from the right inguinal fat pad where tumor cell 
were injected and probed for Ucp1 mRNA expression, wild-type mice with 4T1 tumors 
expressed roughly 2-fold more Ucp1 mRNA, 4-fold more Cidea mRNA, 3-fold more 
Prdm16, and 2-fold more Ppargc1a (Figure 51C, gray bars) – all markers for 
thermogenic adipose tissue activity – which suggests that WAT browning occurs in this 
model. In Rag1-/-  mice with 4T1 tumors, inguinal WAT did not have changes in Ucp1 
expression compared to naïve controls, but had increased Cidea and Ptk2b (protein-
tyrosine kinase 2-beta) expression and decreased Ppargc1a expression (Figure 51C, 
black bars).  
V(D)J recombination-activating protein 1 (RAG1) is essential for variable (V), 
diversity (D), and joining (J) recombination for immunoglobulins and T cell receptors 
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(TCRs) in developing T and B cells [243], and deficiency of RAG1 in mice results in lack 
of mature T and B cell populations [244].  Other immune cell populations such as 
macrophages, dendritic cells, and natural killer cells remain intact and functional, 
making this mouse model ideal for providing information on which cell types may or may 
not be involved in WAT browning in breast cancer. While wild type mice with tumor have 
increased expression of several thermogenic genes (Ucp1, Cidea, Ppargc1a, and 
Prdm16), the Rag1-/- mice only had increased expression of Cidea. This suggests that B 
and T cell involvement, either directly or indirectly, may be necessary for fully functional 
transdifferentiation towards the thermogenic adipose tissue phenotype. Ptk2b was 
increased in the inguinal WAT of Rag1-/- mice with tumor. PTK2B is a nonreceptor 
protein kinase involved in responses to stimuli in several organ systems and a host of 
metabolic processes, including cultured beige adipocyte differentiation in our lab’s 
murine immortalized SVF cell culture model [183].  In whole-body mouse studies, 
PTK2B (also known as PYK2) was shown to be important for glucose and weight 
homeostasis, as whole-body knock-out resulted in exacerbated weight gain and glucose 
intolerance on high fat diet [245]. In breast cancer (and others), most literature refers to 
PYK2 as an oncogene expressed by breast cancer cells with a variety of essential 
processes related to the development and progression of tumors (reviewed extensively 
by [246]). While we did not measure protein levels of PTK2B or its phosphorylation, we 
hypothesize that the increased Ptk2b expression by adipocytes is a maladaptive 
response to the presence of tumor, which aids in the growth and progression of breast 
cancer. For all of these results, it is important to note that the small scale of this 
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preliminary experiment warrants experimental replication, with a larger sample size, to 
determine whether any of these changes are significantly meaningful.   
We next used flow cytometry to isolate and quantify the different immune cell 
populations within the right inguinal WAT (where 4T1 tumors grew) as well as distal 
WAT and BAT depots. Cells which are positive for CD45, also known as leukocyte 
common antigen 45, are white blood cells, excluding red blood cells. Of live cells, there 
did not appear to be any significant changes in the percentage of leukocytes (CD45+ 
cells) between naïve mice and mice with tumor. In the Rag1-/- mice, there appears to be 
a slight increase in the percentage of CD45+ cells in mice with tumor in the inguinal and 
axillary WAT, but with our small sample size and large variability, significance cannot be 
determined. Similar trends are observed when we quantify each cell type as a 
percentage of live cells (Figure 52 and Figure 53) or of CD45+ live cells (Figure 54 and 
Figure 55), so for our discussion, we focus on the CD45+ live results as the results are 
more physiologically relevant to our questions since CD45+ cells are white blood cells. 
The percentage of neutrophils and dendritic cells increases in adipose tissue 
pads of mice with tumor from both genotypes. Neutrophils can exhibit pro- or anti-
inflammatory characteristics in cancer in an environment-dependent manner (reviewed 
by [247]). Furthermore, a 2017 study using human breast cancer samples found that 
tumor-associated neutrophils are present in human breast cancer and are most 
commonly present in triple negative subtypes [248]. Dendritic cells are known to be 
present in the breast cancer microenvironment [249], although their function has been 
shown to be dependent on local factors and may be subtype-specific [250]. Taken 
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together, it is not surprising that there are more neutrophils and dendritic cells in 
adipose tissues in our breast cancer allograft model.  
There is, as inherently expected with the Rag1-/- mice, a decrease in the 
percentage of T and B cells in naïve Rag1-/- mice compared to wild-type naïve mice. 
Interestingly in both groups, the percentage of T and B cells in adipose tissue of mice 
with tumor decreased in both mouse strains. This is opposite of what we observe in 
neutrophil and dendritic cells. Most studies demonstrate an increase in T cell (especially 
T regulatory cells) and B cell populations in breast cancer [251-254]. It is possible that 
the decreased population levels that we see in the adipose tissue is the result of 
migration into the tumors themselves, but this is speculative. 
There were no noticeable changes in the percentage of macrophages in adipose 
tissue pads between naïve wild type and naïve Rag1-/- mice, which again is expected 
since Rag1-/- is related to only T and B cell maturation [244]. In several adipose tissue 
depots in both genotypes, there are more macrophages (pan-macrophages) in the mice 
with tumor compared to naïve controls. This trend is most notable in the right inguinal 
WAT, which is where 4T1 cells were injected. This suggests that the local tumor 
microenvironment elicits as more location-specific increase in macrophage infiltration, 
which adds to prior literature demonstrating other immune cell infiltration in cancer [255, 
256].   
Macrophages are often necessary for various aspects of tumor progression 
(recently reviewed by [257]) and are associated with poor prognosis in many cancers 
[258]. In general, macrophages often begin as inflammatory and later transition to a 
more anti-inflammatory role [259]. While the historical classification of macrophages as 
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M1 “inflammatory” and M2 “anti-inflammatory” has recently been challenged [260], prior 
studies demonstrate that macrophage phenotype can change in cancer. Considering 
that macrophages can be activated into various phenotypes [260], we looked at different 
sub-classes of macrophages based on MHCII and Ly6C expression in the adipose 
tissue pads. 
While there are inconsistent trends in the percentage of MHCII+/Ly6C+ 
macrophages, there is a decrease in the percentage of MHCII+Lys6C- macrophages, 
especially in right inguinal WAT. The percentage of both Ly6C-positive and -negative 
MHCII-negative macrophages was increased in the fat pads of mice with tumor. In a 
mouse model of hepatocellular carcinoma, Wang and colleagues demonstrate temporal 
changes in macrophage phenotype: macrophages expressing MHCII were found early 
in tumorigenesis, while macrophages lacking MHCII increased in number with tumor 
progression; furthermore, they demonstrated that the early, MHCII+ macrophages were 
associated with tumor progression [261]. In mice, Ly6C expression is representative of 
pro-inflammatory monocytes/macrophages (reviewed by [262]). Taken together with our 
results, we found a general decrease in MHCII-positive cells and increase in MHCII-
negative cells. The increase in MHCII-negative cells was most pronounced with the 
Ly6C-negative subtype, as this cell population increased by about 10% in adipose 
tissue in mice with tumor across both phenotypes (Figure 55). Our data therefore 
suggest, like prior literature, a shift towards anti-inflammatory macrophages (M2, or M2-
like) in breast cancer.  
Recently, alternatively activated macrophages have been implicated in WAT 
browning in burns [263]. In a murine model of high fat diet-induced obesity, an 
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increased M2-macrophage population resulting from of knock-down of receptor 
interacting protein 140 (RIP140) was found to induce WAT browning and protect mice 
from high fat diet-induced obesity and insulin resistance [264], and obesity-driven 
inflammation, which is mostly pro-inflammatory, has been shown to inhibit beige 
adipogenesis [265]. Although the mechanism remains controversial [266, 267], 
alterations in macrophage phenotype are clearly involved in the WAT browning process. 
Taken together with our results demonstrating an increase in anti-inflammatory 
macrophages in adipose tissues of mice with cancer, we believe that WAT browning in 
cancer is likely mediated by this cell population in vivo.   
There are several shortcomings to these experiments that future work can 
address. Experimental replication with a larger sample size powered to detect 
significant changes will be necessary. While our results point towards macrophages as 
a key driver of WAT browning in breast cancer, we cannot rule out other immune cell 
populations, especially those we did not measure in these preliminary studies. Other 
populations, such as eosinophils and T cells, have been shown to be involved in WAT 
browning (reviewed by [238]), so additional work must be done to explore the role of 
these cell types, both individually and in unison, in WAT browning. Additionally, these 
mice were raised in the barrier facilities at VCU, which is a ‘cleaner’ vivarium 
environment; it would be interesting to repeat these experiments in mice housed outside 
of this barrier vivarium to provide a more realistic environment that humans experience 
daily. Lastly, as the cell type(s) involved in this process are identified, individual 
molecular drivers and their mechanisms must be elucidated for future translation to 
alleviating WAT browning and CAC in patients.  
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5.4 Conclusion 
 
In these experiments, we investigated the role of several cancer cell lines, and 
IL6, in an in vitro model of WAT browning. Our results demonstrate that E0771, 4T1, 
and LLC cells secrete detectable IL6 in vitro, but not abundantly. We show that while 
IL6 treatment induce changes to white adipocyte gene expression patterns, WAT 
browning does not occur directly via IL6 signaling, pointing to other cell types and/or 
interactions with cells within the tumor microenvironment as the potential driver of these 
thermogenic changes. We show a potential change in Ucp1 expression after white 
adipocyte exposure to breast tumor lysate and tumor-isolated CD11b+ cells, and then 
moved in vivo to explore specific cell populations that may be driving WAT browning. 
Our results support prior literature regarding immune cell population changes in cancer 
and demonstrate an increase in anti-inflammatory macrophages in adipose tissue of 
mice with tumor. Further investigations are needed to understand the mechanisms 
behind these changes, the mechanisms by which these immune cell population induce 
WAT browning in cancer, and to test the effects on whole body energy expenditure and 
the development and progression of cancer-associated cachexia.   
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Chapter 6: Human Subjects Research – Maladaptive Adipose Tissue Activity in Cancer 
 
6.1 Rationale 
 In the last several chapters, we have demonstrated WAT browning and altered 
adipocyte gene expression in breast cancer and mechanistically determined that 
immune cell population changes may be the source of WAT browning in breast cancer 
using murine and human in vitro and in vivo techniques. While the exact mechanisms of 
WAT browning in breast cancer are not yet elucidated, we wanted to begin to explore 
the translational potential of this work. A recent 2018 study demonstrated that BAT 
activity is greater in patients with active cancer compared with BAT+ individuals without 
active cancer [268]. In another study, researchers analyzed 1740 patients with PET/CT 
scans and found that only 30 (1.72%) showed activated brown adipose tissue activity; 
however, of those 30 BAT+ scans, 21 of them (70%) were in patients with cancer, while 
the other 9 (30%) were in patients without malignancy. Using data collected regarding 
the neoplastic status of each cancer patient (N0, N1, N2, N3) with multiple linear 
regression analysis, the authors demonstrated a significant association between BAT 
metabolic activity and neoplastic status, irrespective of age, BMI, or gender [107]. In 
another study performed in France, researchers took 5 PET/CT images for each of 33 
female patients with either stage II or IIIA breast cancer at baseline and then after 1st, 
2nd, 3rd, and 6th courses of chemotherapy. Patients with more BAT uptake had lower 
BMI, which suggests a relationship between thermogenic adipose tissue and CAC 
[269]. 
 At the Virginia Commonwealth University Health System, we have access to a 
large amount of patient clinical data, as well as several different techniques with which 
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to measure energy expenditure in humans (Figure 2). We first ask if, via chart review, 
we could identify patients with cancer within the VCUHS who have activated BAT on 
PET/CT scans. Next, using whole room indirect calorimeters (which our lab has recently 
established incredible temporal accuracy for use in metabolic studies [15]), we ask two 
main questions: 1) if increased thermogenic adipose tissue activity in cancer is 
associated with increased resting energy expenditure, and 2) if increased temperature 
can ‘quench’ maladaptive thermogenic adipose tissue activity and decrease energy 
expenditure. Please refer to methods section 2.18 and Appendices for all protocols and 
pertinent information.  
 
 
6.2 Results 
 
6.2.1 Preliminary data: the VCUHS has an identifiable population of patients with cancer 
who have BAT activity detectable on PET/CT  
Within the queried 10 year timeframe in the Montage database and the search 
parameters described in methods section 2.18.1, there were 210 results for patients at 
least 40 years of age with BAT activity documented. However, there were several cases 
of non-cancer-related indications for PET/CT, and several cases of multiple scans for 
one patient. After these results were removed, we were left with 164 unique patients at 
least 40 years of age with a history of cancer and at least one PET/CT with BAT activity 
noted in the report.  
Of these 164 unique patients, 122 were female (74.4%), and 42 (25.6%) were 
male (Figure 56A). When stratified by age range (starting at age 40 based on inclusion 
criteria), we found 44 (26.8%) patients were between 40 and 49 years of age, 61 
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(37.2%) between 50-59, 40 (24.4%) between 60-69, 12 (7.3%) between 70-79, 6 (3.7%) 
between 80-89, and 1 (0.6%) between 90-99 (Figure 56B). 
 We also wanted to identify trends in primary cancer diagnosis and presence of 
BAT activity in this patient population. Of the 164 unique cases, we found that the 
majority (41, or 25%) of patients had a primary diagnosis of lymphoma (Figure 57). The 
second most common primary malignancy was breast cancer (34, or 20.7%), and the 
third most common was lung cancer (25, or 15.2%). The rest of the patients had a 
variety of different primary malignancies, and only 2 individuals had an unknown 
primary cancer diagnosis based on preliminary chart review. 
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Figure 56. Gender and age in patients with cancer and BAT activity on PET/CT scans  
A chart review was performed using the VCUHS medical record and medical imaging systems as 
described in methods. Percentage of patients with cancer and BAT activity on PET/CT scan by (A) 
gender and (B) age ranges.  
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Figure 57. Primary cancer type in patients with cancer and BAT activity on PET/CT scans 
A chart review was performed using the VCUHS medical record and medical imaging systems as 
described in methods. The y-axis includes all of the primary cancer types noted in patients with cancer 
and BAT activity on PET/CT scan, and x-axis is the number of patients with that particular cancer type. 
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6.2.2 Preliminary data: measurement of energy expenditure in human subjects with 
cancer 
 We began recruitment of participants for our study using whole-room indirect 
calorimetry as described in section 2.18.2. We just completed the first energy recording 
session for our first subject: a 54-year-old male with head & neck cancer who had BAT 
activity noted on the most recent PET/CT.  The raw data are shown in Figure 58 and 
described in more detail in the figure legend. After analysis of the raw data, this 
subject’s average respiratory exchange ratio was 0.73, and average metabolic rate was 
0.88kcal/min (approximately 1267kcal/day). 
  
 
 
211 
 
 
Figure 58. Whole-room indirect calorimetry, raw data 
Raw data from energy recording using whole room indirect calorimeters from 54 year old male with head 
and neck cancer. (A) General information viewed during recording session to ensure calorimeters 
maintain appropriate air flow. (B) black line = metabolic rate (MR) in kcal/min; red line = respiratory 
exchange ratio (RER or RQ). (C) black line = volume of oxygen (VO2) and red line = volume of carbon 
dioxide (VCO2). Large vertical lines indicate time in which subject entered and exited the calorimeters. 
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6.3 Discussion 
 In the first part of this human subjects research, we used a retrospective 
approach to search the VCUHS records for our target patient population. We searched 
the past 10 years to gain a solid understanding of the prevalence of BAT activity at our 
institution. Our preliminary results demonstrate that there is indeed a targetable patient 
population at the VCUHS for studying the effects of thermogenic adipose tissue activity 
in patients with cancer.  We found that the majority of these patients (74.4%) with 
cancer and BAT activity on PET/CT were female. This is not surprising, as several 
studies have demonstrated that women tend to have greater BAT mass and activity 
than men [38, 270, 271]. 
It is well established that thermogenic capacity decreases with age ([38], and 
recently reviewed by [272]); therefore, we chose 40 years as our minimum age as we 
believe it will optimize the number of patients with maladaptive thermogenic adipose 
tissue activity. We would expect very few patients over the age of 40 to have activated 
BAT activity on their PET/CT scans; however, we found 164 patients with what we 
hypothesize as maladaptive BAT activity. We were surprised that the number of patients 
in the 80-89 and 90-99 ages ranges with cancer and BAT activity were quite low, 
because although life expectancy at a given age decreases with age, the risk of dying of 
cancer has been shown to peak between ages 40-50 and decrease thereafter [273]. 
However, this could be due to a younger patient population seen at VCUHS versus 
other institutions in the surrounding area. We expected the 40-49 age range to contain 
the majority of BAT+ cases; however, we observed that most patients with cancer and 
BAT activity on PET were between 50 and 59 years of age. This adds stronger support 
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to our hypothesis that maladaptive activation of thermogenic adipose tissue occurs in 
cancer.  
 Our results demonstrate that lymphoma is the most common primary malignancy 
in this patient population. Of the 41 patients classified as having lymphoma as their 
primary malignancy, 13 had Hodgkin’s lymphoma, 12 had non-Hodgkin’s lymphoma, 
and 16 were not specified. Considering that interscapular BAT is in the same 
anatomical region as many lymph node changes, we are not certain that all of these 
patients have BAT activity versus cancerous FDG uptake. While CAC has been shown 
to affect patients across all cancer types [128], it has been previously reported that 
cancers such as gastric and esophageal have a higher prevalence of CAC compared to 
breast cancer (although we argue that the clinical implications of CAC in breast cancer 
are quite important, see Table 1). Interestingly, we found that the 2nd most common 
primary cancer in our patient population was breast cancer, with lung cancer being the 
3rd most common. This suggests that maladaptive activation of thermogenic adipose 
tissue can certainly occur in breast cancer, strengthening the rationale behind our use 
of breast cancer as model for our in vitro molecular studies.  
Several factors may have influenced our results. We must consider the potential 
for variability in training that may skew the prevalence of BAT activity towards 
lymphoma, breast, and lung cancers. As all three of these cancers are anatomically 
closer to interscapular region than other cancers such as colon cancer, it is possible the 
BAT activity may be under-represented in these results. Many factors may contribute to 
site-specific variations in patient population characteristics; regardless, it is clear that 
within the VCUHS, there are identifiable patients who have cancer with and without BAT 
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activity that we can recruit for energy characterization studies.  We will continue to 
collect additional data on these patients as described in the methods, such as ethnicity, 
BMI, weight, diabetes status, and thyroid function testing. In the 2009 study 
demonstrating that approximately 25% of patients with breast cancer have cachexia, the 
authors did not provide additional subanalyses on sex or ethnicity in each cancer type 
[128]. While breast cancer is far more common in women than in men, it would be 
interesting to know whether any of the breast cancer patients in this study were men, 
and if so, if any of them had cachexia. Additionally, information regarding ethnicity 
would be extremely helpful to provide information regarding potential racial differences 
in breast cancer-related CAC. We hope that our data collection and analyses within our 
patient population will provide useful information in these areas. We know that thyroid 
function contributes to energy expenditure (reviewed in [274]), and BAT activity has 
been found to be more prevalent in lean individuals regardless of age [270]. It will be 
interesting to determine if this trend persists in this particular patient population as well.  
The clinical implication of increased BAT activity relative to calorie utilization is 
not yet conclusive – estimates during cold exposure range from 15-25 kcal/day [108] to 
several hundred [275, 276]. While the prevalence of maladaptive thermogenic adipose 
tissue activity has been explored in several small studies as described in this chapter’s 
rationale, the clinical relevance and implications of this increased activity is not well 
understood. We therefore developed a pilot study protocol using whole room indirectly 
calorimetry to determine whether BAT activity increases REE in human subjects with 
cancer at our institution. Our preliminary results from our first participant demonstrate 
our capacity to measure resting energy expenditure in patients with cancer using the 
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whole-room indirect calorimeters (Figure 58). Our first subject’s average resting 
metabolic rate at 24ºC was approximately 1267kcal/day. While this appears low when 
taken at face-value, it is crucial that this information be considered along with individual 
body weight at the time of study. We will be sure to calculate metabolic rate (kcal/day) 
per unit body weight (kg) for each subject to ensure appropriate comparisons in energy 
expenditure between the BAT-positive and BAT-negative groups. 
We expect that patients with cancer with BAT activity on the PET/CT scans will 
have greater energy expenditure than those patients with cancer without BAT activity. 
Additionally, when we compare intra-individual energy expenditure differences, we 
expect that for patients with cancer who are BAT+, their resting energy expenditure will 
be decreased after exposure to the warmer temperature condition (27ºC, or 80.6ºF) 
compared to the ‘room temperature’ condition (24ºC or 75.2ºF). If the data support 
these hypotheses, our results would suggest that maladaptive browning does occur, 
and that warm temperature may have utility as a simple and safe therapeutic adjuvant.  
Although we have recruited one participant, we are far from our goal of 36 
patients. This highlights that clinical research and subject recruitment often takes longer 
than expected. Regardless, as we continue to recruit more subjects, we expect our 
results to provide a useful point-estimate difference in energy expenditure between 
BAT+ and BAT- patients with cancer, which is currently lacking in the literature. We 
have not analyzed the serum or urine samples obtained from this first patient, as we 
plan to analyze all samples together to minimize possible sources of result variability. 
However, we expect that our results, when combined with energy expenditure data, will 
provide useful clinical data for patients with cancer with or at risk for developing CAC. 
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 Even once our recruitment is completed, it is important to note several limitations 
to this pilot study as we interpret our results and as subsequent studies are considered. 
First, we cannot say with certainty whether patients who had BAT activity on their 
PET/CT scan used for inclusion criteria continue to have measurable BAT activity by the 
time they are recruited into the study. BAT FDG uptake is not always consistent within a 
series of scans of a given patient [269, 277]. Ideally, we would have patients undergo 
repeat PET/CT before beginning any energy expenditure recordings. In this pilot study, 
we were financially limited and needed to utilize PET/CT scans that were already 
performed; however, in any larger studies that develop, funding should be requested to 
obtain these repeat PET/CT scans to confirm whether participants do or do not have 
activated BAT.  Next, there is debate as to whether or not outdoor temperature and 
other related factors impact BAT activity on PET/CT scans, and if confers any change to 
energy expenditure; some studies demonstrate no significant relationship between BAT 
FDG uptake and outdoor temperature [269] while others demonstrate an association 
between photoperiod and seasonal variation with BAT activity [278]. We do our best to 
ensure patients complete their visits within the same season to decrease variability 
within a subject but individuals who enroll at different times of the year may have 
different results due to seasonal variability. It is also important to note that our study 
(and others) utilizing FDG uptake by BAT as a means to identify candidates inherently 
under-represents our ideal patient population: PET/CT is believed to underestimate the 
true prevalence of BAT activity (reviewed by [279]), and is not able to capture the more 
diffuse activity of beige adipose tissue activity in large WAT depots. Several methods 
are under development utilizing magnetic resonance or ultrasound (reviewed by [280]); 
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however, until these are validated and implemented in a widespread and cost-efficient 
manner, FDG PET/CT is still the ‘gold standard,’ even with its limitations. 
 
6.4 Conclusion 
 In this Chapter, we utilized human subjects research to begin to understand the 
clinical and translational implications of maladaptive thermogenic adipose tissue activity 
in patients with cancer. Our results demonstrate that within the VCUHS, there exists a 
patient population comprised of individuals with cancer, at least 40 years of age, with 
brown adipose tissue activation. We argue that this BAT activity represents maladaptive 
adipocyte plasticity. Furthermore, though still in the early stages of recruitment and data 
collection, we demonstrate that our institution’s whole-room indirect calorimeters are 
capable of measuring resting energy expenditure in patients with cancer. We expect to 
generate useful data quantifying the difference in energy expenditure between patients 
with cancer with and without BAT activity. Analysis of secondary endpoints will provide 
useful clinical data aimed towards improving quality of life in patients with cancer, 
especially those with or at risk for developing cancer-associated cachexia.  
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Chapter 7: Human Subjects Research – Unusual Case of Autoimmune Diabetes 
Mellitus in the Setting of Extra-Adrenal Paraganglioma with Loss of Succinate 
Dehydrogenase Expression  
 
Please note that the majority of the material within this Chapter comes from our recently 
published manuscript, DOI 10.4158/ACCR-2018-0072. The final, definitive version of 
this paper has been published in AACE Clinical Case Reports: November/December 
2018, Vol. 4, No. 6. [281] 
 
7.1 Rationale 
 Even if cancer is not directly adjacent to adipose tissue, cancer can influence 
thermogenic adipose tissue activity as well as normal adipose tissue functions such as 
glycemic control. Recently, a case of hypermetabolic BAT was found in a patient with 
paraganglioma [282]. Paragangliomas are referred to as ‘extra-adrenal 
pheochromocytomas,’ originating from chromaffin cells in the sympathetic and/or 
parasympathetic ganglia [283]. Functional pheochromocytomas and paragangliomas 
are often associated with impaired glycemic control and exacerbation of pre-existing 
diabetes mellitus [284]. Here we present a unique case of autoimmune diabetes with 
glycemic control that follows the course of diagnosis and management for a 
norepinephrine-secreting paraganglioma. 
 
7.2 Results (case report and bench laboratory findings) 
A 55-year-old African American man with history of nephrolithiasis presented to 
an outside institution with flank pain and hypertension. Computerized tomography (CT) 
imaging with contrast revealed a heterogeneous retroperitoneal mass measuring 4.5 x 
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5.4 x 4.9 cm, located anterior to, and abutting, the inferior vena cava and abdominal 
aorta (Figure 59A). Further evaluation was consistent with paraganglioma: his plasma 
normetanephrines were 260 pg/mL (normal 0-145 pg/mL) and blood pressure was 
160/90 mmHg (Figure 60). There is no known family history of paraganglioma, and only 
his mother has hypertension. He was started on Prazosin for control of hypertension in 
preparation for surgery. 
Concurrently at the time of paraganglioma presentation and diagnosis, his blood 
glucose levels were elevated and anti-glutamic acid decarboxylase-65 (anti-GAD65) 
antibodies were 97.9 U/mL (normal 0-1.5 U/mL). He was therefore diagnosed with latent 
autoimmune diabetes of adults (LADA) and started a basal-bolus insulin regimen of 
Lispro 5U with meals and Detemir 25U at bedtime with prompt improvement in his 
hyperglycemia. Three months after initial diagnosis, the patient underwent a successful 
surgery, but review of the resected tumor by surgical pathology demonstrated the 
presence of positive margins. Additionally, there was involvement of an adjacent lymph 
node and foci of vascular space invasion. Immunostaining demonstrated loss of 
succinate dehydrogenase subunit B (SDHB) expression in the paraganglioma cells 
(Figure 61). 
At post-surgery follow up, the patient reported normal blood pressure recordings 
and denied symptoms of catecholamine excess. He had self-decreased his insulin 
therapy because of reported improved glucose levels. Prandial insulin was 
discontinued. 
Six months after surgery, the patient continued to report stable blood pressure 
without medication and no symptoms or signs of catecholamine excess. Point of care 
 
 
220 
 
HbA1c was 5.5% (37 mmol/mol) (normal < 5.6% or < 38 mmol/mol), and home 
measurements indicated post-prandial glucose levels ranging 120-140 mg/dL. Basal 
insulin was discontinued at this visit. Blood tests revealed normal catecholamine levels, 
but markedly elevated anti-GAD65 (above the assay’s detection limit of 5000 U/mL) and 
anti-insulin antibodies of 137 µU/mL (normal 0 µU/mL) (Figure 60).  
Eleven months after surgery, the patient was still normotensive and euglycemic 
without medication, with a point of care HbA1c of 5.7% (39 mmol/mol). However, CT 
imaging with contrast of the abdomen and pelvis showed a “small focus of ill-defined 
soft tissues” near the bifurcation of the abdominal aorta, soft tissue thickening at site of 
resected mass, and an enlarged left periaortic lymph node. 
Eighteen months after surgery, the patient presented with unintentional weight 
loss, increased home glucose readings, and hypertension. Normetanephrines were 
significantly elevated at 841 pg/mL (normal 0-145 pg/mL), and HbA1c at 7.2% (55 
mmol/mol). CT and subsequent 18F-FDG positron emission tomography (PET)/CT 
imaging confirmed disease recurrence with metastasis to para-aortic lymph nodes 
(Figure 59B, C). Basal-bolus insulin regimen was resumed. 
Two years after surgery, he has not experienced hypertensive crises but 
complains of fatigue and hyperhidrosis. Glycemic control had significantly worsened 
since the last visit, and his basal and bolus insulin doses were increased to Glargine 
12U/day, and Lispro 5U before breakfast and 7U before lunch and dinner. He is also 
taking Benazepril 5mg and Hydrochlorothiazide 25mg daily for management of 
hypertension. He is undergoing cytoreductive therapy with Vincristine 1.4 mg/m2, 
Dacarbazine 600 mg/m2, and Cyclophosphamide 750 mg/m2 (Figure 60). 
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Archival (formalin fixed, paraffin embedded) paraganglioma tissue obtained 
during the initial surgery was recut and mounted onto slides for IHC. Staining for GAD65 
was negative in the paraganglioma (Figure 62). 
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Figure 59. CT and PET/CT images at paraganglioma diagnosis and recurrence 
Computed tomography images demonstrate the location of the paraganglioma at the time of first 
diagnosis (A) and at the time of recurrence (B). Recurrence was also imaged with positron emission 
tomography/computed tomography (C). White arrows point to the paraganglioma. 
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Figure 60. Timeline of events and corresponding lab results 
The symbol “-” designates no medication at that time. Blank cells designate no value obtained at that 
time. 
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Figure 61. Loss of succinate dehydrogenase in paraganglioma 
Immunohistochemistry imaging of the paraganglioma demonstrating loss of succinate dehydrogenase 
subunit B expression and positive fumarate hydratase staining for comparison. Scale bar in black is 
200μm. 
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Figure 62. Lack of GAD65 expression in paraganglioma 
Immunohistochemistry imaging of the paraganglioma (top) and control pancreas (bottom) with 
hematoxylin and eosin and glutamic acid decarboxylase-65 at low and high magnifications. Low 
magnification scale bar is 1 mm; high magnification scale bar is 200μm. 
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7.3 Discussion 
Functional pheochromocytomas and paragangliomas are classified into three 
major phenotypes: adrenergic, noradrenergic, and dopaminergic [285]. Most functional 
paragangliomas are noradrenergic, whereas many pheochromocytomas can be 
adrenergic because of the presence of phenylethanolamine N-methyltransferase in the 
adrenal medulla [286]. Because of excess catecholamine secretion, functional 
pheochromocytomas and paragangliomas are often accompanied with hyperglycemia. 
The mechanisms by which catecholamines induce this glucose intolerance include 
insulin resistance [287] with decreased glucose uptake into muscle and adipose tissue 
[288], decreased insulin release [289, 290], and stimulation of glucagon secretion [291]. 
We could not address the possibility of germline SDH mutations [292] since the patient 
declined genetic testing; however, it is well-documented that SDH mutations in 
paragangliomas confer an aggressive tumor phenotype and increased metastatic 
potential [293-295], so the clinical course of this patient’s tumor burden is not surprising.  
Cases have been presented demonstrating that in patients who already had type 2 
diabetes, paraganglioma resection dramatically improved their glycemic control [296]. 
However, to the best of our knowledge, this is the first description of a new diagnosis of 
autoimmune diabetes in the setting of a paraganglioma. The patient’s age at 
presentation, autoantibody positivity, and insulin dependence all meet the conventional 
requirements for the diagnosis of LADA [297]. It is interesting that the timing of 
autoimmune diabetes diagnosis matches that of the paraganglioma diagnosis, and that 
the waxing and waning of poor glycemic control seems to correlate with the timing of 
paraganglioma surgical debulking and subsequent recurrence. We postulate three 
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possible explanations: one, this patient has two concurrent, but unrelated, diagnoses of 
paraganglioma and LADA; two, the recurrence of poor glycemic control is caused 
primarily by the norepinephrine secreted by the paraganglioma; and three, this patient’s 
paraganglioma elicits an autoimmune response that targets the pancreatic beta cells 
leading to autoimmune diabetes. 
We cannot rule out the possibility that this patient’s glycemic trends are the result 
of the ‘honeymoon phase,’ or period of ‘remission,’ that can occur in patients with type 1 
diabetes, during which patients are often able to halt most or all of their insulin therapy 
and maintain euglycemia [298]. In the pediatric population, this period of remission can 
vary between three months to 13 years (reviewed by [298]). In adults, some cases 
report remission lasting beyond 14 months after cessation of insulin regimens [299], and 
this patient’s period of euglycemia without insulin fits within that timeframe.  
Closely related to the first possible explanation, we do not expect this patient’s 
glucose intolerance to be solely attributable to norepinephrine secretion by the 
paraganglioma. Norepinephrine excess can contribute to hyperglycemia, but less 
significantly than epinephrine because of differences in receptor affinities [296].  
Additionally, the patient’s anti-GAD65 antibodies were elevated at the time of 
paraganglioma diagnosis, and then were substantially increased at the time of 
confirmation of disease recurrence. The patient had no neuromuscular symptoms or 
signs that could be associated with Stiff-person syndrome [300]. The presence of anti-
GAD antibodies is clearly indicative of autoimmune-related diabetes, which to the best 
of our knowledge, is not attributable to norepinephrine excess.  
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Lastly, while we do not have anti-GAD65 levels preceding the diagnosis, or 
during the period of euglycemia post-surgery, their trend is suggestive of an 
autoimmune process which would result in loss of beta cell function, a condition which 
has not been described before in the setting of a paraganglioma. The patient’s 
improvement in glycemic control after surgical debulking could be the result of removal 
of antigen within the paraganglioma, whose burden increased as the tumor recurred 
and metastasized. Although our IHC results did not show GAD65 antigen present within 
the paraganglioma tissue, which supports one of the first two proposed hypotheses, we 
cannot exclude a tumor-induced autoimmune process toward other epitopes not 
recognized by the antibody utilized in our IHC. Interestingly, GAD65 expression in a 
small cell lung cancer has been reported in a case of LADA with high anti-GAD65 titers, 
indicative of a paraneoplastic syndrome [301]. The extraordinary rise in plasma antibody 
titer concomitant with the relapse of tumor is consistent with an increase in exposure to 
the antigen. This would support the hypothesis of a novel form of paraneoplastic 
autoimmune diabetes in the setting of paragangliomas, and should be further evaluated 
in future work. 
While not directly adjacent to adipose tissue, these results clearly demonstrate 
the role of tumor and tumor microenvironment on whole-body energy and glucose 
homeostasis, which inherently includes adipose tissue.  
 
7.4 Conclusion 
Catecholamine excess can cause hyperglycemia in patients with functional 
paragangliomas. This is a unique case of autoimmune diabetes diagnosed in the setting 
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of a functional paraganglioma, with glycemic control closely related to paraganglioma 
disease burden. Further research and testing should be done in patients with 
pheochromocytomas and paragangliomas to investigate a possible autoimmune role in 
certain cases. Additionally, this work highlights the importance of understanding the 
implications of cancer on whole-body energy and glucose homeostasis. 
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Summary 
 
 The role of adipose tissue in CAC is complex. Our results show that adipose 
tissue plasticity occurs in breast cancer. First, we demonstrate in murine models of 
breast cancer as well as in human samples of breast cancer that white adipose tissue, 
in the presence of tumor, undergoes WAT browning to a beige adipose tissue 
phenotype. We show that this effect is localized and seems to occur earlier in cancer 
progression (Figure 63A). 
 Next, we moved into in vitro models of adipogenesis and cancer to investigate 
the role of cancer secreted factors, as well as cancer:adipocyte cross-talk, on adipocyte 
plasticity. We show in both human and mice cell culture that cancer secreted factors 
and cross-talk decrease mRNA expression of classic WAT-related genes. In mice, we 
show that cross-talk specifically results in an increase in lipolysis-related mRNA 
expression, and in humans, cancer secreted factors reduce white adipocyte lipid droplet 
size. Regarding WAT browning, our results strongly suggest that in mice, neither cancer 
secreted factors nor cross talk with adipocytes is able to induce WAT browning; 
however, in human cell culture, our results are less conclusive (Figure 63B). 
 We demonstrate that IL6+IL6RA, regardless of its source, is able to induce IL6-
mediated signaling through STAT3 phosphorylation; however, that signaling alone is not 
sufficient to directly induce WAT browning. The last part of our bench laboratory 
experiments, we present preliminary data suggesting that immune cell population shifts 
within the white adipose tissue of mice with breast cancer tumors may be source of 
WAT browning (Figure 63B). 
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 Lastly, we show that the VCUHS has an identifiable population of patients with 
cancer over the age of 40 with brown adipose tissue activity on PET/CT scan. Our pilot 
clinical study is currently underway to test our hypothesis that this increased brown 
adipose tissue activity is maladaptive in this patient population, and to show the effects 
of these changes on whole body energy expenditure as well as other relevant 
secondary endpoints.  
 In conclusion, we have demonstrated that adipose tissue plasticity occurs in 
breast cancer and certain components are caused by different drivers with the tumor 
microenvironment. We predict that further exploration of the exact mechanisms and 
translational implications will provide useful information to lead to new therapeutic 
treatments for patients with cancer-associated cachexia.  
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Figure 63. Summary of work 
(A) Local WAT browning occurs in murine and human breast cancer, and in murine models we 
demonstrate that this occurs earlier in tumor progression. (B) Using in vitro cell culture models, we 
demonstrate that cancer secreted factors, cross talk between cancer cells and adipocytes, IL6+IL6RA, 
and immune cell population shifts are capable of inducing as host of effects related to adipocyte plasticity. 
  
 
 
233 
 
References 
 
 
1. Vaitkus, J.A. and F.S. Celi, The role of adipose tissue in cancer-associated 
cachexia. Exp Biol Med (Maywood), 2017. 242(5): p. 473-481. 
2. Cengel, Y.A., Boles, M.A., Thermodynamics: An Engineering Approach. 7 ed. 
2011: McGraw Hill. 
3. Manore, M.M., et al., Dynamic Energy Balance: An Integrated Framework for 
Discussing Diet and Physical Activity in Obesity Prevention-Is it More than Eating 
Less and Exercising More? Nutrients, 2017. 9(8). 
4. Organization, W.H. Obesity and Overweight Fact Sheet. 2017 October 2017 
[cited 2018 January 9]; Available from: 
http://www.who.int/mediacentre/factsheets/fs311/en/. 
5. Stefan, N., et al., Metabolically healthy obesity: epidemiology, mechanisms, and 
clinical implications. Lancet Diabetes Endocrinol, 2013. 1(2): p. 152-62. 
6. Fair, A.M. and K. Montgomery, Energy balance, physical activity, and cancer risk. 
Methods Mol Biol, 2009. 472: p. 57-88. 
7. Finkelstein, E.A., et al., Annual medical spending attributable to obesity: payer-
and service-specific estimates. Health Aff (Millwood), 2009. 28(5): p. w822-31. 
8. Williams, F.N. and D.N. Herndon, Metabolic and Endocrine Considerations After 
Burn Injury. Clin Plast Surg, 2017. 44(3): p. 541-553. 
9. Alverdy, J.C., Hypermetabolism and Nutritional Support in Sepsis. Surg Infect 
(Larchmt), 2018. 19(2): p. 163-167. 
10. Simsek, T., H.U. Simsek, and N.Z. Canturk, Response to trauma and metabolic 
changes: posttraumatic metabolism. Ulus Cerrahi Derg, 2014. 30(3): p. 153-9. 
11. Haugen, H.A., L.N. Chan, and F. Li, Indirect calorimetry: a practical guide for 
clinicians. Nutr Clin Pract, 2007. 22(4): p. 377-88. 
12. Psota, T. and K.Y. Chen, Measuring energy expenditure in clinical populations: 
rewards and challenges. Eur J Clin Nutr, 2013. 67(5): p. 436-42. 
13. Moon, J.K., Whole-body, human respiration calorimetry. 1991: University of 
Texas at Austin. 
 
 
234 
 
14. Brychta, R., et al., Energy expenditure: measurement of human metabolism. 
IEEE Eng Med Biol Mag, 2010. 29(1): p. 42-7. 
15. Chen, S., et al., Improving temporal accuracy of human metabolic chambers for 
dynamic metabolic studies. PLoS One, 2018. 13(4): p. e0193467. 
16. Cinti, S., Between brown and white: novel aspects of adipocyte differentiation. 
Annals of medicine, 2011. 43(2): p. 104-15. 
17. Cinti, S., The adipose organ: morphological perspectives of adipose tissues. Proc 
Nutr Soc, 2001. 60(3): p. 319-28. 
18. Cinti, S., The adipose organ at a glance. Dis Model Mech, 2012. 5(5): p. 588-94. 
19. Deng, T., et al., Obesity, Inflammation, and Cancer. Annu Rev Pathol, 2016. 11: 
p. 421-49. 
20. Dahlman, I., et al., Functional annotation of the human fat cell secretome. Arch 
Physiol Biochem, 2012. 118(3): p. 84-91. 
21. Hyvonen, M.T. and K.L. Spalding, Maintenance of white adipose tissue in man. 
Int J Biochem Cell Biol, 2014. 56: p. 123-32. 
22. Bartness, T.J., et al., Neural innervation of white adipose tissue and the control of 
lipolysis. Front Neuroendocrinol, 2014. 35(4): p. 473-93. 
23. Lolmede, K., et al., Immune cells in adipose tissue: key players in metabolic 
disorders. Diabetes Metab, 2011. 37(4): p. 283-90. 
24. Nie, T.D., W. Gao, X. Sun, W. Hui, X. Song, H. Qin, D. Xu, A. Li, P. Liu, P. Lai, L, 
Wu, D. , Reprogramming mature terminally differentiated adipocytes to induced 
pluripotent stem cells. Science Bulletin, 2015. 60(20): p. 1752-1758. 
25. Spalding, K.L., et al., Dynamics of fat cell turnover in humans. Nature, 2008. 
453(7196): p. 783-7. 
26. Macotela, Y., et al., Intrinsic differences in adipocyte precursor cells from 
different white fat depots. Diabetes, 2012. 61(7): p. 1691-9. 
27. Smith, S.R., et al., Contributions of total body fat, abdominal subcutaneous 
adipose tissue compartments, and visceral adipose tissue to the metabolic 
complications of obesity. Metabolism, 2001. 50(4): p. 425-35. 
 
 
235 
 
28. Romacho, T., et al., Adipose tissue and its role in organ crosstalk. Acta Physiol 
(Oxf), 2014. 210(4): p. 733-53. 
29. McGown, C., A. Birerdinc, and Z.M. Younossi, Adipose tissue as an endocrine 
organ. Clin Liver Dis, 2014. 18(1): p. 41-58. 
30. Giralt, M. and F. Villarroya, White, brown, beige/brite: different adipose cells for 
different functions? Endocrinology, 2013. 154(9): p. 2992-3000. 
31. Trayhurn, P. and J.R. Arch, New Physiological Aspects of Brown Adipose Tissue. 
Curr Obes Rep, 2014. 3(4): p. 414-21. 
32. Aherne, W. and D. Hull, Brown adipose tissue and heat production in the 
newborn infant. J Pathol Bacteriol, 1966. 91(1): p. 223-34. 
33. Lean, M.E., Brown adipose tissue in humans. Proc Nutr Soc, 1989. 48(2): p. 243-
56. 
34. Lean, M.E., et al., Brown adipose tissue uncoupling protein content in human 
infants, children and adults. Clin Sci (Lond), 1986. 71(3): p. 291-7. 
35. Hull, D., The function of brown adipose tissue in the newborn. Biochem Soc 
Trans, 1976. 4(2): p. 226-8. 
36. Bouillaud, F., et al., Detection of brown adipose tissue uncoupling protein mRNA 
in adult patients by a human genomic probe. Clin Sci (Lond), 1988. 75(1): p. 21-
7. 
37. Nedergaard, J., T. Bengtsson, and B. Cannon, Unexpected evidence for active 
brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab, 2007. 
293(2): p. E444-52. 
38. Cypess, A.M., et al., Identification and importance of brown adipose tissue in 
adult humans. N Engl J Med, 2009. 360(15): p. 1509-17. 
39. Virtanen, K.A., et al., Functional brown adipose tissue in healthy adults. N Engl J 
Med, 2009. 360(15): p. 1518-25. 
40. Hilton, C., F. Karpe, and K.E. Pinnick, Role of developmental transcription factors 
in white, brown and beige adipose tissues. Biochimica et biophysica acta, 2015. 
1851(5): p. 686-696. 
 
 
236 
 
41. Ussar, S., et al., ASC-1, PAT2, and P2RX5 are cell surface markers for white, 
beige, and brown adipocytes. Sci Transl Med, 2014. 6(247): p. 247ra103. 
42. Seale, P., et al., PRDM16 controls a brown fat/skeletal muscle switch. Nature, 
2008. 454(7207): p. 961-7. 
43. Timmons, J.A., et al., Myogenic gene expression signature establishes that 
brown and white adipocytes originate from distinct cell lineages. Proc Natl Acad 
Sci U S A, 2007. 104(11): p. 4401-6. 
44. Nicholls, D.G., The bioenergetics of brown adipose tissue mitochondria. FEBS 
Lett, 1976. 61(2): p. 103-110. 
45. Townsend, K.L. and Y.H. Tseng, Brown fat fuel utilization and thermogenesis. 
Trends in endocrinology and metabolism: TEM, 2014. 25(4): p. 168-77. 
46. Nicholls, D.G. and E. Rial, A history of the first uncoupling protein, UCP1. J 
Bioenerg Biomembr, 1999. 31(5): p. 399-406. 
47. Klingenberg, M. and S.G. Huang, Structure and function of the uncoupling 
protein from brown adipose tissue. Biochim Biophys Acta, 1999. 1415(2): p. 271-
96. 
48. Souza, B.M., et al., The role of uncoupling protein 2 (UCP2) on the development 
of type 2 diabetes mellitus and its chronic complications. Arq Bras Endocrinol 
Metabol, 2011. 55(4): p. 239-48. 
49. Boss, O., et al., Uncoupling protein-3: a new member of the mitochondrial carrier 
family with tissue-specific expression. FEBS Lett, 1997. 408(1): p. 39-42. 
50. Dalgaard, L.T. and O. Pedersen, Uncoupling proteins: functional characteristics 
and role in the pathogenesis of obesity and Type II diabetes. Diabetologia, 2001. 
44(8): p. 946-65. 
51. Schrauwen, P., J. Hoeks, and M.K. Hesselink, Putative function and 
physiological relevance of the mitochondrial uncoupling protein-3: involvement in 
fatty acid metabolism? Prog Lipid Res, 2006. 45(1): p. 17-41. 
52. Nedergaard, J., et al., UCP1: the only protein able to mediate adaptive non-
shivering thermogenesis and metabolic inefficiency. Biochimica et biophysica 
acta, 2001. 1504(1): p. 82-106. 
 
 
237 
 
53. Nedergaard, J., et al., Life without UCP1: mitochondrial, cellular and organismal 
characteristics of the UCP1-ablated mice. Biochemical Society transactions, 
2001. 29(Pt 6): p. 756-63. 
54. Villarroya, F., M. Peyrou, and M. Giralt, Transcriptional regulation of the 
uncoupling protein-1 gene. Biochimie, 2017. 134: p. 86-92. 
55. Bertholet, A.M. and Y. Kirichok, UCP1: A transporter for H(+) and fatty acid 
anions. Biochimie, 2017. 134: p. 28-34. 
56. Petrovic, N., et al., Chronic peroxisome proliferator-activated receptor gamma 
(PPARgamma) activation of epididymally derived white adipocyte cultures 
reveals a population of thermogenically competent, UCP1-containing adipocytes 
molecularly distinct from classic brown adipocytes. J Biol Chem, 2010. 285(10): 
p. 7153-64. 
57. Ishibashi, J. and P. Seale, Medicine. Beige can be slimming. Science, 2010. 
328(5982): p. 1113-4. 
58. Crossno, J.T., Jr., et al., Rosiglitazone promotes development of a novel 
adipocyte population from bone marrow-derived circulating progenitor cells. J 
Clin Invest, 2006. 116(12): p. 3220-8. 
59. Himms-Hagen, J., et al., Multilocular fat cells in WAT of CL-316243-treated rats 
derive directly from white adipocytes. Am J Physiol Cell Physiol, 2000. 279(3): p. 
C670-81. 
60. Celi, F.S., T.N. Le, and B. Ni, Physiology and relevance of human adaptive 
thermogenesis response. Trends in endocrinology and metabolism: TEM, 2015. 
61. Bostrom, P., et al., A PGC1-alpha-dependent myokine that drives brown-fat-like 
development of white fat and thermogenesis. Nature, 2012. 481(7382): p. 463-8. 
62. Wiseman, G. and F.N. Ghadially, A biochemical concept of tumour growth, 
infiltration, and cachexia. Br Med J, 1958. 2(5087): p. 18-21. 
63. Costa, G., Cachexia, the metabolic component of neoplastic diseases. Cancer 
Res, 1977. 37(7 Pt 2): p. 2327-35. 
64. Theologides, A., Cancer cachexia. Cancer, 1979. 43(5 Suppl): p. 2004-12. 
 
 
238 
 
65. Pareira, M.D., et al., Clinical response and changes in nitrogen balance, body 
weight, plasma proteins, and hemoglobin following tube feeding in cancer 
cachexia. Cancer, 1955. 8(4): p. 803-8. 
66. Fearon, K., et al., Definition and classification of cancer cachexia: an 
international consensus. Lancet Oncol, 2011. 12(5): p. 489-95. 
67. Laviano, A., et al., Therapy insight: Cancer anorexia-cachexia syndrome--when 
all you can eat is yourself. Nat Clin Pract Oncol, 2005. 2(3): p. 158-65. 
68. Vigano, A., et al., The cachexia clinic: from staging to managing nutritional and 
functional problems in advanced cancer patients. Crit Rev Oncog, 2012. 17(3): p. 
293-303. 
69. Blum, D., et al., Validation of the Consensus-Definition for Cancer Cachexia and 
evaluation of a classification model--a study based on data from an international 
multicentre project (EPCRC-CSA). Ann Oncol, 2014. 25(8): p. 1635-42. 
70. Sun, L., X.Q. Quan, and S. Yu, An Epidemiological Survey of Cachexia in 
Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status. 
Nutr Cancer, 2015: p. 1-7. 
71. Tisdale, M.J., Mechanisms of cancer cachexia. Physiol Rev, 2009. 89(2): p. 381-
410. 
72. Fearon, K.C., D.J. Glass, and D.C. Guttridge, Cancer cachexia: mediators, 
signaling, and metabolic pathways. Cell Metab, 2012. 16(2): p. 153-66. 
73. Dewys, W.D., et al., Prognostic effect of weight loss prior to chemotherapy in 
cancer patients. Eastern Cooperative Oncology Group. Am J Med, 1980. 69(4): 
p. 491-7. 
74. Argiles, J.M., et al., Cancer cachexia: understanding the molecular basis. Nat 
Rev Cancer, 2014. 14(11): p. 754-62. 
75. Baracos, V.E., Pitfalls in defining and quantifying cachexia. J Cachexia 
Sarcopenia Muscle, 2011. 2(2): p. 71-73. 
76. Fearon, K., J. Arends, and V. Baracos, Understanding the mechanisms and 
treatment options in cancer cachexia. Nat Rev Clin Oncol, 2013. 10(2): p. 90-9. 
77. Penet, M.F. and Z.M. Bhujwalla, Cancer cachexia, recent advances, and future 
directions. Cancer J, 2015. 21(2): p. 117-22. 
 
 
239 
 
78. Tian, M., et al., c9t11-Conjugated linoleic acid-rich oil fails to attenuate wasting in 
colon-26 tumor-induced late-stage cancer cachexia in male CD2F1 mice. Mol 
Nutr Food Res, 2011. 55(2): p. 268-77. 
79. Fearon, K.C., et al., Double-blind, placebo-controlled, randomized study of 
eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol, 
2006. 24(21): p. 3401-7. 
80. Jatoi, A., et al., Is bortezomib, a proteasome inhibitor, effective in treating cancer-
associated weight loss? Preliminary results from the North Central Cancer 
Treatment Group. Support Care Cancer, 2005. 13(6): p. 381-6. 
81. Dingemans, A.M., et al., Phase II drugs that are currently in development for the 
treatment of cachexia. Expert Opin Investig Drugs, 2014. 23(12): p. 1655-69. 
82. Takayama, K., et al., Anamorelin (ONO-7643) in Japanese patients with non-
small cell lung cancer and cachexia: results of a randomized phase 2 trial. 
Support Care Cancer, 2016. 24(8): p. 3495-505. 
83. Temel, J.S., et al., Anamorelin in patients with non-small-cell lung cancer and 
cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-
blind, phase 3 trials. Lancet Oncol, 2016. 17(4): p. 519-31. 
84. Dobs, A.S., et al., Effects of enobosarm on muscle wasting and physical function 
in patients with cancer: a double-blind, randomised controlled phase 2 trial. 
Lancet Oncol, 2013. 14(4): p. 335-45. 
85. Stewart Coats, A.J., et al., Espindolol for the treatment and prevention of 
cachexia in patients with stage III/IV non-small cell lung cancer or colorectal 
cancer: a randomized, double-blind, placebo-controlled, international multicentre 
phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle, 2016. 7(3): 
p. 355-65. 
86. Molfino, A., et al., Novel therapeutic options for cachexia and sarcopenia. Expert 
Opin Biol Ther, 2016: p. 1-6. 
87. Wu, J., P. Cohen, and B.M. Spiegelman, Adaptive thermogenesis in adipocytes: 
is beige the new brown? Genes & development, 2013. 27(3): p. 234-50. 
88. Thompson, M.P., et al., Modified Lipoprotein Lipase Activities, Rates of 
Lipogenesis, and Lipolysis as Factors Leading to Lipid Depletion in C57BL Mice 
Bearing the Preputial Gland Tumor, ESR-586. Cancer Research, 1981. 41(8): p. 
3228-3232. 
 
 
240 
 
89. Ebadi, M. and V.C. Mazurak, Potential Biomarkers of Fat Loss as a Feature of 
Cancer Cachexia. Mediators Inflamm, 2015. 2015: p. 820934. 
90. Ebadi, M. and V.C. Mazurak, Evidence and mechanisms of fat depletion in 
cancer. Nutrients, 2014. 6(11): p. 5280-97. 
91. Das, S.K., et al., Adipose triglyceride lipase contributes to cancer-associated 
cachexia. Science, 2011. 333(6039): p. 233-8. 
92. Bing, C., et al., Adipose atrophy in cancer cachexia: morphologic and molecular 
analysis of adipose tissue in tumour-bearing mice. Br J Cancer, 2006. 95(8): p. 
1028-37. 
93. Danai, L.V., et al., Altered exocrine function can drive adipose wasting in early 
pancreatic cancer. Nature, 2018. 558(7711): p. 600-604. 
94. Kliewer, K.L., et al., Adipose tissue lipolysis and energy metabolism in early 
cancer cachexia in mice. Cancer Biol Ther, 2015. 16(6): p. 886-97. 
95. Johns, N., C. Greig, and K.C. Fearon, Is tissue cross-talk important in cancer 
cachexia? Crit Rev Oncog, 2012. 17(3): p. 263-76. 
96. Petruzzelli, M. and E.F. Wagner, Mechanisms of metabolic dysfunction in cancer-
associated cachexia. Genes Dev, 2016. 30(5): p. 489-501. 
97. Bodine, S.C. and L.M. Baehr, Skeletal muscle atrophy and the E3 ubiquitin 
ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab, 2014. 
307(6): p. E469-84. 
98. Stephens, N.A., et al., Intramyocellular lipid droplets increase with progression of 
cachexia in cancer patients. J Cachexia Sarcopenia Muscle, 2011. 2(2): p. 111-
117. 
99. Julienne, C.M., et al., Cancer cachexia is associated with a decrease in skeletal 
muscle mitochondrial oxidative capacities without alteration of ATP production 
efficiency. J Cachexia Sarcopenia Muscle, 2012. 3(4): p. 265-75. 
100. Chance, W.T., A. Balasubramaniam, and J.E. Fischer, Neuropeptide Y and the 
development of cancer anorexia. Ann Surg, 1995. 221(5): p. 579-87; discussion 
587-9. 
 
 
241 
 
101. Kralova Lesna, I., et al., Characterisation and comparison of adipose tissue 
macrophages from human subcutaneous, visceral and perivascular adipose 
tissue. J Transl Med, 2016. 14(1): p. 208. 
102. Wiedenmann, B., et al., A multicenter, phase II study of infliximab plus 
gemcitabine in pancreatic cancer cachexia. J Support Oncol, 2008. 6(1): p. 18-
25. 
103. Tsoli, M., et al., Activation of thermogenesis in brown adipose tissue and 
dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer 
Res, 2012. 72(17): p. 4372-82. 
104. Hyltander, A., et al., Beta-adrenoceptor activity and resting energy metabolism in 
weight losing cancer patients. Eur J Cancer, 2000. 36(3): p. 330-4. 
105. Falconer, J.S., et al., Cytokines, the acute-phase response, and resting energy 
expenditure in cachectic patients with pancreatic cancer. Ann Surg, 1994. 219(4): 
p. 325-31. 
106. Shellock, F.G., M.S. Riedinger, and M.C. Fishbein, Brown adipose tissue in 
cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin 
Oncol, 1986. 111(1): p. 82-5. 
107. Huang, Y.C., et al., The relationship between brown adipose tissue activity and 
neoplastic status: an (18)F-FDG PET/CT study in the tropics. Lipids Health Dis, 
2011. 10: p. 238. 
108. Muzik, O., et al., 15O PET measurement of blood flow and oxygen consumption 
in cold-activated human brown fat. J Nucl Med, 2013. 54(4): p. 523-31. 
109. Brenta, G., et al., Acute thyroid hormone withdrawal in athyreotic patients results 
in a state of insulin resistance. Thyroid : official journal of the American Thyroid 
Association, 2009. 19(6): p. 665-9. 
110. Chen, K.Y., et al., Brown Adipose Reporting Criteria in Imaging STudies 
(BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments 
in Humans. Cell Metab, 2016. 24(2): p. 210-22. 
111. Frontini, A., et al., White-to-brown transdifferentiation of omental adipocytes in 
patients affected by pheochromocytoma. Biochim Biophys Acta, 2013. 1831(5): 
p. 950-9. 
 
 
242 
 
112. Petruzzelli, M., et al., A switch from white to brown fat increases energy 
expenditure in cancer-associated cachexia. Cell metabolism, 2014. 20(3): p. 433-
47. 
113. Kir, S., et al., Tumour-derived PTH-related protein triggers adipose tissue 
browning and cancer cachexia. Nature, 2014. 513(7516): p. 100-4. 
114. Park, J., D.M. Euhus, and P.E. Scherer, Paracrine and endocrine effects of 
adipose tissue on cancer development and progression. Endocr Rev, 2011. 
32(4): p. 550-70. 
115. Bochet, L., et al., Adipocyte-derived fibroblasts promote tumor progression and 
contribute to the desmoplastic reaction in breast cancer. Cancer Res, 2013. 
73(18): p. 5657-68. 
116. Dirat, B., et al., Cancer-associated adipocytes exhibit an activated phenotype 
and contribute to breast cancer invasion. Cancer Res, 2011. 71(7): p. 2455-65. 
117. Singh, R., et al., Increased Expression of Beige/Brown Adipose Markers from 
Host and Breast Cancer Cells Influence Xenograft Formation in Mice. Mol 
Cancer Res, 2016. 14(1): p. 78-92. 
118. Visweswaran, M., et al., Multi-lineage differentiation of mesenchymal stem cells - 
To Wnt, or not Wnt. Int J Biochem Cell Biol, 2015. 68: p. 139-47. 
119. Steward, A.J. and D.J. Kelly, Mechanical regulation of mesenchymal stem cell 
differentiation. J Anat, 2015. 227(6): p. 717-31. 
120. Pritchard, J.M., et al., The Relationship between Intramuscular Adipose Tissue, 
Functional Mobility, and Strength in Postmenopausal Women with and without 
Type 2 Diabetes. J Aging Res, 2015. 2015: p. 872726. 
121. Goodpaster, B.H., et al., Attenuation of skeletal muscle and strength in the 
elderly: The Health ABC Study. J Appl Physiol (1985), 2001. 90(6): p. 2157-65. 
122. Bang, E., et al., Relationship between thigh intermuscular adipose tissue 
accumulation and number of metabolic syndrome risk factors in middle-aged and 
older Japanese adults. Exp Gerontol, 2016. 79: p. 26-30. 
123. Tseng, Y.C., et al., Preclinical Investigation of the Novel Histone Deacetylase 
Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. J Natl Cancer Inst, 
2015. 107(12): p. djv274. 
 
 
243 
 
124. Schmidt, M., et al., Effects of a ketogenic diet on the quality of life in 16 patients 
with advanced cancer: A pilot trial. Nutr Metab (Lond), 2011. 8(1): p. 54. 
125. Organization, W.H. Breast cancer. 2015  [cited 2018 July 31]; Available from: 
http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. 
126. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 
2018. 68(1): p. 7-30. 
127. Group, U.S.C.S.W. U.S. Cancer Statistics Data Visualizations Tool, based on 
November 2017 submission data (1999-2015): U.S. Department of Health and 
Human Services, Centers for Disease Control and Prevention and National 
Cancer Institute. 2018  [cited 2018 July 31]; Available from: 
www.cdc.gov/cancer/dataviz. 
128. Fox, K.M., et al., Estimation of Cachexia among Cancer Patients Based on Four 
Definitions. J Oncol, 2009. 2009: p. 693458. 
129. Bland, K.I., et al., The breast : comprehensive management of benign and 
malignant diseases. Fifth edition. ed. 2018, Philadelphia, PA: Elsevier. xxii, 1114 
pages. 
130. McPherson, K., C.M. Steel, and J.M. Dixon, ABC of breast diseases. Breast 
cancer-epidemiology, risk factors, and genetics. BMJ, 2000. 321(7261): p. 624-8. 
131. Society, A.C. Breast Cancer Facts & Figures 2017-2018. 2017; Available from: 
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-
statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-
2018.pdf. 
132. Inoue, K. and E.A. Fry, Novel Molecular Markers for Breast Cancer. Biomark 
Cancer, 2016. 8: p. 25-42. 
133. BreastCancer.org. Metastatic Breast Cancer 2018; Available from: 
https://www.breastcancer.org/symptoms/types/recur_metast. 
134. Noman, M.Z., et al., Microenvironmental hypoxia orchestrating the cell stroma 
cross talk, tumor progression and antitumor response. Crit Rev Immunol, 2011. 
31(5): p. 357-77. 
135. Mahoney, B.P., et al., Tumor acidity, ion trapping and chemotherapeutics. I. Acid 
pH affects the distribution of chemotherapeutic agents in vitro. Biochem 
Pharmacol, 2003. 66(7): p. 1207-18. 
 
 
244 
 
136. Ansell, S.M. and R.H. Vonderheide, Cellular composition of the tumor 
microenvironment. Am Soc Clin Oncol Educ Book, 2013. 
137. Soysal, S.D., A. Tzankov, and S.E. Muenst, Role of the Tumor Microenvironment 
in Breast Cancer. Pathobiology, 2015. 82(3-4): p. 142-52. 
138. Sanchez-Alvarez, R., et al., Mitochondrial dysfunction in breast cancer cells 
prevents tumor growth: understanding chemoprevention with metformin. Cell 
Cycle, 2013. 12(1): p. 172-82. 
139. Meng, W., S. Xue, and Y. Chen, The role of CXCL12 in tumor microenvironment. 
Gene, 2018. 641: p. 105-110. 
140. Schaper, F. and S. Rose-John, Interleukin-6: Biology, signaling and strategies of 
blockade. Cytokine Growth Factor Rev, 2015. 26(5): p. 475-87. 
141. Rose-John, S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for 
the pro-inflammatory activities of IL-6. Int J Biol Sci, 2012. 8(9): p. 1237-47. 
142. Hagiwara, E., et al., Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, 
IL-10, IFN and TNF-alpha in human peripheral blood. Cytokine, 1995. 7(8): p. 
815-22. 
143. Harkins, J.M., et al., Expression of interleukin-6 is greater in preadipocytes than 
in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J Nutr, 2004. 
134(10): p. 2673-7. 
144. Tsoli, M., et al., Depletion of white adipose tissue in cancer cachexia syndrome is 
associated with inflammatory signaling and disrupted circadian regulation. PLoS 
One, 2014. 9(3): p. e92966. 
145. Zhang, L., et al., IL-6 signaling via the STAT3/SOCS3 pathway: functional 
analysis of the conserved STAT3 N-domain. Mol Cell Biochem, 2006. 288(1-2): 
p. 179-89. 
146. Mullberg, J., et al., The soluble interleukin-6 receptor is generated by shedding. 
Eur J Immunol, 1993. 23(2): p. 473-80. 
147. Mullberg, J., et al., Generation and function of the soluble interleukin-6 receptor. 
Biochem Soc Trans, 1999. 27(2): p. 211-9. 
148. Lust, J.A., et al., Isolation of an mRNA encoding a soluble form of the human 
interleukin-6 receptor. Cytokine, 1992. 4(2): p. 96-100. 
 
 
245 
 
149. Oberg, H.H., et al., Differential expression of CD126 and CD130 mediates 
different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T 
cells. Int Immunol, 2006. 18(4): p. 555-63. 
150. Ozbek, S., et al., The membrane proximal cytokine receptor domain of the 
human interleukin-6 receptor is sufficient for ligand binding but not for gp130 
association. J Biol Chem, 1998. 273(33): p. 21374-9. 
151. Taga, T., et al., Interleukin-6 triggers the association of its receptor with a 
possible signal transducer, gp130. Cell, 1989. 58(3): p. 573-81. 
152. Hibi, M., et al., Molecular cloning and expression of an IL-6 signal transducer, 
gp130. Cell, 1990. 63(6): p. 1149-57. 
153. Saito, M., et al., Molecular cloning of a murine IL-6 receptor-associated signal 
transducer, gp130, and its regulated expression in vivo. J Immunol, 1992. 
148(12): p. 4066-71. 
154. Gyamfi, J., et al., Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer 
Cell Interaction. Transl Oncol, 2018. 11(2): p. 275-285. 
155. Carson, J.A. and K.A. Baltgalvis, Interleukin 6 as a key regulator of muscle mass 
during cachexia. Exerc Sport Sci Rev, 2010. 38(4): p. 168-76. 
156. Zimmers, T.A., M.L. Fishel, and A. Bonetto, STAT3 in the systemic inflammation 
of cancer cachexia. Semin Cell Dev Biol, 2016. 54: p. 28-41. 
157. Lee, J., et al., Transition into inflammatory cancer-associated adipocytes in 
breast cancer microenvironment requires microRNA regulatory mechanism. 
PLoS One, 2017. 12(3): p. e0174126. 
158. Han, J., et al., Interleukin-6 induces fat loss in cancer cachexia by promoting 
white adipose tissue lipolysis and browning. Lipids Health Dis, 2018. 17(1): p. 14. 
159. Aune, U.L., L. Ruiz, and S. Kajimura, Isolation and differentiation of stromal 
vascular cells to beige/brite cells. J Vis Exp, 2013(73). 
160. Klein, J., et al., Novel adipocyte lines from brown fat: a model system for the 
study of differentiation, energy metabolism, and insulin action. BioEssays : news 
and reviews in molecular, cellular and developmental biology, 2002. 24(4): p. 
382-8. 
 
 
246 
 
161. Lownik, J.C., et al., ADAM10-Mediated ICOS Ligand Shedding on B Cells Is 
Necessary for Proper T Cell ICOS Regulation and T Follicular Helper 
Responses. J Immunol, 2017. 199(7): p. 2305-2315. 
162. Unkeless, J.C., Characterization of a monoclonal antibody directed against 
mouse macrophage and lymphocyte Fc receptors. J Exp Med, 1979. 150(3): p. 
580-96. 
163. Smith, S.C., et al., A distinctive, low-grade oncocytic fumarate hydratase-
deficient renal cell carcinoma, morphologically reminiscent of succinate 
dehydrogenase-deficient renal cell carcinoma. Histopathology, 2017. 71(1): p. 
42-52. 
164. Giatromanolaki, A., et al., Thermogenic protein UCP1 and UCP3 expression in 
non-small cell lung cancer: relation with glycolysis and anaerobic metabolism. 
Cancer Biol Med, 2017. 14(4): p. 396-404. 
165. Martelotto, L.G., et al., Breast cancer intra-tumor heterogeneity. Breast Cancer 
Res, 2014. 16(3): p. 210. 
166. Turashvili, G. and E. Brogi, Tumor Heterogeneity in Breast Cancer. Front Med 
(Lausanne), 2017. 4: p. 227. 
167. Ewens, A., E. Mihich, and M.J. Ehrke, Distant metastasis from subcutaneously 
grown E0771 medullary breast adenocarcinoma. Anticancer Res, 2005. 25(6B): 
p. 3905-15. 
168. Perry, S.W., et al., Stromal matrix metalloprotease-13 knockout alters Collagen I 
structure at the tumor-host interface and increases lung metastasis of C57BL/6 
syngeneic E0771 mammary tumor cells. BMC Cancer, 2013. 13: p. 411. 
169. Battle, M., et al., Obesity induced a leptin-Notch signaling axis in breast cancer. 
Int J Cancer, 2014. 134(7): p. 1605-16. 
170. Carrasco, E., et al., Meroxest improves the prognosis of immunocompetent 
C57BL/6 mice with allografts of E0771 mouse breast tumor cells. Arch Med Sci, 
2016. 12(5): p. 919-927. 
171. Lai, N., et al., Adipocyte induction of preadipocyte differentiation in a gradient 
chamber. Tissue Eng Part C Methods, 2012. 18(12): p. 958-67. 
 
 
247 
 
172. Xue, J.C., et al., Distinct stages in adipogenesis revealed by retinoid inhibition of 
differentiation after induction of PPARgamma. Mol Cell Biol, 1996. 16(4): p. 
1567-75. 
173. Schwarz, E.J., et al., Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-
mediated transcription. Mol Cell Biol, 1997. 17(3): p. 1552-61. 
174. Cantwell, M.T., et al., STAT3 suppresses Wnt/beta-catenin signaling during the 
induction phase of primary Myf5+ brown adipogenesis. Cytokine, 2018. 111: p. 
434-444. 
175. Nadra, K., et al., Cell autonomous lipin 1 function is essential for development 
and maintenance of white and brown adipose tissue. Mol Cell Biol, 2012. 32(23): 
p. 4794-810. 
176. Kim, H.J., et al., MicroRNAs are required for the feature maintenance and 
differentiation of brown adipocytes. Diabetes, 2014. 63(12): p. 4045-56. 
177. Zhang, G., et al., Toll-like receptor 4 mediates Lewis lung carcinoma-induced 
muscle wasting via coordinate activation of protein degradation pathways. Sci 
Rep, 2017. 7(1): p. 2273. 
178. Kir, S., et al., PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney 
Failure and Cancer. Cell Metab, 2016. 23(2): p. 315-23. 
179. Green, H. and M. Meuth, An established pre-adipose cell line and its 
differentiation in culture. Cell, 1974. 3(2): p. 127-33. 
180. Cochran C, T.P., Lin K, Zhang Y, Abel E. Sex Differences in the Response of 
C57BL/6 Mice to Ketogenic Diets. in American Diabetes Association 2018. 
Orlando, Florida. 
181. Link, J.C. and K. Reue, Genetic Basis for Sex Differences in Obesity and Lipid 
Metabolism. Annu Rev Nutr, 2017. 37: p. 225-245. 
182. Karastergiou, K., et al., Sex differences in human adipose tissues - the biology of 
pear shape. Biol Sex Differ, 2012. 3(1): p. 13. 
183. Ni, B., et al., A novel role for PTK2B in cultured beige adipocyte differentiation. 
Biochem Biophys Res Commun, 2018. 501(4): p. 851-857. 
184. Kaur, G. and J.M. Dufour, Cell lines: Valuable tools or useless artifacts. 
Spermatogenesis, 2012. 2(1): p. 1-5. 
 
 
248 
 
185. Alge, C.S., et al., Differential protein profiling of primary versus immortalized 
human RPE cells identifies expression patterns associated with cytoskeletal 
remodeling and cell survival. J Proteome Res, 2006. 5(4): p. 862-78. 
186. Wu, J., et al., Beige adipocytes are a distinct type of thermogenic fat cell in 
mouse and human. Cell, 2012. 150(2): p. 366-76. 
187. Kalinovich, A.V., et al., UCP1 in adipose tissues: two steps to full browning. 
Biochimie, 2017. 134: p. 127-137. 
188. Tanaka-Yachi, R., et al., Promoting Effect of alpha-Tocopherol on Beige 
Adipocyte Differentiation in 3T3-L1 Cells and Rat White Adipose Tissue. J Oleo 
Sci, 2017. 66(2): p. 171-179. 
189. Yonezawa, A., et al., Boosting Cancer Immunotherapy with Anti-CD137 Antibody 
Therapy. Clin Cancer Res, 2015. 21(14): p. 3113-20. 
190. Kohrt, H.E., et al., Stimulation of natural killer cells with a CD137-specific 
antibody enhances trastuzumab efficacy in xenotransplant models of breast 
cancer. J Clin Invest, 2012. 122(3): p. 1066-75. 
191. Jarde, T., et al., Leptin and leptin receptor involvement in cancer development: a 
study on human primary breast carcinoma. Oncol Rep, 2008. 19(4): p. 905-11. 
192. Vona-Davis, L. and D.P. Rose, Angiogenesis, adipokines and breast cancer. 
Cytokine Growth Factor Rev, 2009. 20(3): p. 193-201. 
193. Cheng, C.S., Z. Wang, and J. Chen, Targeting FASN in Breast Cancer and the 
Discovery of Promising Inhibitors from Natural Products Derived from Traditional 
Chinese Medicine. Evid Based Complement Alternat Med, 2014. 2014: p. 
232946. 
194. Fukuda, H., et al., Transcriptional regulation of fatty acid synthase gene by 
insulin/glucose, polyunsaturated fatty acid and leptin in hepatocytes and 
adipocytes in normal and genetically obese rats. Eur J Biochem, 1999. 260(2): p. 
505-11. 
195. Nomura, D.K., et al., Monoacylglycerol lipase regulates a fatty acid network that 
promotes cancer pathogenesis. Cell, 2010. 140(1): p. 49-61. 
196. Johnstone, C.N., et al., Functional and molecular characterisation of EO771.LMB 
tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic 
mammary cancer. Dis Model Mech, 2015. 8(3): p. 237-51. 
 
 
249 
 
197. Pulaski, B.A. and S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr 
Protoc Immunol, 2001. Chapter 20: p. Unit 20 2. 
198. Yang, S., J.J. Zhang, and X.Y. Huang, Mouse models for tumor metastasis. 
Methods Mol Biol, 2012. 928: p. 221-8. 
199. Yang, F., et al., Inhibition of dipeptidyl peptidase-4 accelerates epithelial-
mesenchymal transition and breast cancer metastasis via the 
CXCL12/CXCR4/mTOR axis. Cancer Res, 2018. 
200. Barnes, D. and G. Sato, Serum-free cell culture: a unifying approach. Cell, 1980. 
22(3): p. 649-55. 
201. Arrigoni O, D.T., M, The role of ascorbic acid in cell metabolism: between gene-
directed functions and unpredictable chemical reactions. Journal of Plant 
Physiology, 2000. 157(5): p. 481-488. 
202. Coughlin, S.R., et al., Acidic and basic fibroblast growth factors stimulate tyrosine 
kinase activity in vivo. J Biol Chem, 1988. 263(2): p. 988-93. 
203. Keshet, R., et al., c-Abl tyrosine kinase promotes adipocyte differentiation by 
targeting PPAR-gamma 2. Proc Natl Acad Sci U S A, 2014. 111(46): p. 16365-
70. 
204. Martin, G., et al., The human fatty acid transport protein-1 (SLC27A1; FATP-1) 
cDNA and gene: organization, chromosomal localization, and expression. 
Genomics, 2000. 66(3): p. 296-304. 
205. Challa, T.D., et al., Regulation of De Novo Adipocyte Differentiation Through 
Cross Talk Between Adipocytes and Preadipocytes. Diabetes, 2015. 64(12): p. 
4075-87. 
206. Yen, M.C., et al., Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell 
Growth, Migration, and Invasion in Breast Cancer Cells. Int J Mol Sci, 2018. 
19(11). 
207. Lasar, D., et al., Peroxisome Proliferator Activated Receptor Gamma Controls 
Mature Brown Adipocyte Inducibility through Glycerol Kinase. Cell Rep, 2018. 
22(3): p. 760-773. 
208. Kotta-Loizou, I., C. Giaginis, and S. Theocharis, The role of peroxisome 
proliferator-activated receptor-gamma in breast cancer. Anticancer Agents Med 
Chem, 2012. 12(9): p. 1025-44. 
 
 
250 
 
209. Papadaki, I.M., E; Giannopoulou, I; Markaki, S; Keramopoulos, A; Nakopoulou, 
L., PPARγ expression in breast cancer: clinical value and correlation with ERβ. 
Histopathology, 2005. 46(1): p. 37-42. 
210. Wu, Q., et al., Breast cancer-released exosomes trigger cancer-associated 
cachexia to promote tumour progression. Adipocyte, 2018. 
211. Puigserver, P., et al., A cold-inducible coactivator of nuclear receptors linked to 
adaptive thermogenesis. Cell, 1998. 92(6): p. 829-39. 
212. Fisher, F.M., et al., FGF21 regulates PGC-1alpha and browning of white adipose 
tissues in adaptive thermogenesis. Genes Dev, 2012. 26(3): p. 271-81. 
213. Carriere, A., et al., Browning of white adipose cells by intermediate metabolites: 
an adaptive mechanism to alleviate redox pressure. Diabetes, 2014. 63(10): p. 
3253-65. 
214. Hankir, M.K., et al., Differential effects of Roux-en-Y gastric bypass surgery on 
brown and beige adipose tissue thermogenesis. Metabolism, 2015. 64(10): p. 
1240-9. 
215. Abramczyk, H., et al., The role of lipid droplets and adipocytes in cancer. Raman 
imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to 
adipocytes in cancerous human breast tissue. Analyst, 2015. 140(7): p. 2224-35. 
216. Lapeire, L., et al., Secretome analysis of breast cancer-associated adipose tissue 
to identify paracrine regulators of breast cancer growth. Oncotarget, 2017. 8(29): 
p. 47239-47249. 
217. Skurk, T. and H. Hauner, Primary Culture of Human Adipocyte Precursor Cells: 
Expansion and Differentiation #, in T Human Cell Culture Protocols. 2011. p. 
215-226. 
218. Dore-Savard, L., et al., The Angiogenic Secretome in VEGF overexpressing 
Breast Cancer Xenografts. Sci Rep, 2016. 6: p. 39460. 
219. Sastre-Serra, J., et al., Estrogen down-regulates uncoupling proteins and 
increases oxidative stress in breast cancer. Free Radic Biol Med, 2010. 48(4): p. 
506-12. 
220. Bartucci, M., et al., Differential insulin-like growth factor I receptor signaling and 
function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-
231 breast cancer cells. Cancer Res, 2001. 61(18): p. 6747-54. 
 
 
251 
 
221. Suchanek, K.M., et al., Peroxisome proliferator-activated receptor alpha in the 
human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog, 2002. 
34(4): p. 165-71. 
222. Seki, T., et al., Endothelial PDGF-CC regulates angiogenesis-dependent 
thermogenesis in beige fat. Nat Commun, 2016. 7: p. 12152. 
223. Wang, F., et al., The Warburg effect in human pancreatic cancer cells triggers 
cachexia in athymic mice carrying the cancer cells. BMC Cancer, 2018. 18(1): p. 
360. 
224. Shyh-Chang, N., Metabolic Changes During Cancer Cachexia Pathogenesis. 
Adv Exp Med Biol, 2017. 1026: p. 233-249. 
225. Edmondson, R., et al., Three-dimensional cell culture systems and their 
applications in drug discovery and cell-based biosensors. Assay Drug Dev 
Technol, 2014. 12(4): p. 207-18. 
226. Chang, Q., et al., The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and 
metastasis. Neoplasia, 2013. 15(7): p. 848-62. 
227. Basolo, F., et al., Growth-stimulating activity of interleukin 6 on human mammary 
epithelial cells transfected with the int-2 gene. Cancer Res, 1993. 53(13): p. 
2957-60. 
228. Mohamed-Ali, V., et al., Subcutaneous adipose tissue releases interleukin-6, but 
not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab, 1997. 82(12): p. 
4196-200. 
229. Sanguinetti, A., et al., Interleukin-6 and pro inflammatory status in the breast 
tumor microenvironment. World J Surg Oncol, 2015. 13: p. 129. 
230. Heinrich, P.C., et al., Interleukin-6-type cytokine signalling through the 
gp130/Jak/STAT pathway. Biochem J, 1998. 334 ( Pt 2): p. 297-314. 
231. Schumacher, N., et al., Shedding of Endogenous Interleukin-6 Receptor (IL-6R) 
Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a 
Full-length IL-6R Isoform Localizes to Circulating Microvesicles. J Biol Chem, 
2015. 290(43): p. 26059-71. 
232. Kuang, Y., Z. Zhang, and X. Zhang, [Interleukin-6 and its soluble receptors in 
human breast cancer]. Zhonghua Zhong Liu Za Zhi, 1998. 20(4): p. 305-7. 
 
 
252 
 
233. Sakaguchi, M., et al., Role and regulation of STAT3 phosphorylation at Ser727 in 
melanocytes and melanoma cells. J Invest Dermatol, 2012. 132(7): p. 1877-85. 
234. Decker, T. and P. Kovarik, Serine phosphorylation of STATs. Oncogene, 2000. 
19(21): p. 2628-37. 
235. White, J., IL-6, cancer and cachexia: metabolic dysfunction creates the perfect 
storm. Translational cancer research, 2017. 6(Supplement 2). 
236. Stephens, J.M. and C.M. Elks, Oncostatin M: Potential Implications for 
Malignancy and Metabolism. Curr Pharm Des, 2017. 23(25): p. 3645-3657. 
237. Gross, B.P., et al., A therapeutic microparticle-based tumor lysate vaccine 
reduces spontaneous metastases in murine breast cancer. AAPS J, 2014. 16(6): 
p. 1194-203. 
238. Villarroya, F., et al., Toward an Understanding of How Immune Cells Control 
Brown and Beige Adipobiology. Cell Metab, 2018. 27(5): p. 954-961. 
239. Harris, E.S., et al., The leukocyte integrins. J Biol Chem, 2000. 275(31): p. 
23409-12. 
240. Eruslanov, E., et al., Altered expression of 15-hydroxyprostaglandin 
dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for 
immune evasion in cancer. J Immunol, 2009. 182(12): p. 7548-57. 
241. Cattin, S., et al., Bevacizumab specifically decreases elevated levels of 
circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. 
Oncotarget, 2016. 7(10): p. 11137-50. 
242. Zhang, Q.Q., et al., CD11b deficiency suppresses intestinal tumor growth by 
reducing myeloid cell recruitment. Sci Rep, 2015. 5: p. 15948. 
243. De, P. and K.K. Rodgers, Putting the pieces together: identification and 
characterization of structural domains in the V(D)J recombination protein RAG1. 
Immunol Rev, 2004. 200: p. 70-82. 
244. Mombaerts P, I.J., Johnson RS, Herrup K, Tonegawa S, Papaioannou VE., RAG-
1-deficient mice have no mature B and T lymphocytes. Cell, 1992. 68(5): p. 869-
877. 
 
 
253 
 
245. Yu, Y., et al., Role of PYK2 in the development of obesity and insulin resistance. 
Biochemical and biophysical research communications, 2005. 334(4): p. 1085-
91. 
246. Shen, T. and Q. Guo, Role of Pyk2 in Human Cancers. Med Sci Monit, 2018. 24: 
p. 8172-8182. 
247. Sionov, R.V., Z.G. Fridlender, and Z. Granot, The Multifaceted Roles Neutrophils 
Play in the Tumor Microenvironment. Cancer Microenviron, 2015. 8(3): p. 125-
58. 
248. Soto-Perez-de-Celis, E., et al., Tumor-Associated Neutrophils in Breast Cancer 
Subtypes. Asian Pac J Cancer Prev, 2017. 18(10): p. 2689-2693. 
249. Palucka, K., L.M. Coussens, and J. O'Shaughnessy, Dendritic cells, 
inflammation, and breast cancer. Cancer J, 2013. 19(6): p. 511-6. 
250. Michea, P., et al., Adjustment of dendritic cells to the breast-cancer 
microenvironment is subset specific. Nat Immunol, 2018. 19(8): p. 885-897. 
251. Wang, Z.K., et al., Regulatory T cells increase in breast cancer and in stage IV 
breast cancer. Cancer Immunol Immunother, 2012. 61(6): p. 911-6. 
252. Watanabe, M.A., et al., Regulatory T cells and breast cancer: implications for 
immunopathogenesis. Cancer Metastasis Rev, 2010. 29(4): p. 569-79. 
253. Tsuda, B., et al., B-cell populations are expanded in breast cancer patients 
compared with healthy controls. Breast Cancer, 2018. 25(3): p. 284-291. 
254. Shen, M., J. Wang, and X. Ren, New Insights into Tumor-Infiltrating B 
Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. 
Front Immunol, 2018. 9: p. 470. 
255. Stoll, G., L. Zitvogel, and G. Kroemer, Immune infiltrate in cancer. Aging (Albany 
NY), 2015. 7(6): p. 358-9. 
256. van der Woude, L.L., et al., Migrating into the Tumor: a Roadmap for T Cells. 
Trends Cancer, 2017. 3(11): p. 797-808. 
257. Condeelis, J. and J.W. Pollard, Macrophages: obligate partners for tumor cell 
migration, invasion, and metastasis. Cell, 2006. 124(2): p. 263-6. 
 
 
254 
 
258. Bingle, L., N.J. Brown, and C.E. Lewis, The role of tumour-associated 
macrophages in tumour progression: implications for new anticancer therapies. J 
Pathol, 2002. 196(3): p. 254-65. 
259. Swann, J.B., et al., Demonstration of inflammation-induced cancer and cancer 
immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A, 2008. 
105(2): p. 652-6. 
260. Martinez, F.O. and S. Gordon, The M1 and M2 paradigm of macrophage 
activation: time for reassessment. F1000Prime Rep, 2014. 6: p. 13. 
261. Wang, B., et al., Transition of tumor-associated macrophages from MHC class 
II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol, 
2011. 12: p. 43. 
262. Yang, J., et al., Monocyte and macrophage differentiation: circulation 
inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res, 
2014. 2(1): p. 1. 
263. Abdullahi, A., et al., Alternatively Activated Macrophages Drive Browning of 
White Adipose Tissue in Burns. Ann Surg, 2017. 
264. Liu, P.S., et al., M1-M2 balancing act in white adipose tissue browning - a new 
role for RIP140. Adipocyte, 2015. 4(2): p. 146-8. 
265. Chung, K.J., et al., A self-sustained loop of inflammation-driven inhibition of beige 
adipogenesis in obesity. Nat Immunol, 2017. 18(6): p. 654-664. 
266. Fischer, K., et al., Alternatively activated macrophages do not synthesize 
catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat 
Med, 2017. 23(5): p. 623-630. 
267. Nguyen, K.D., et al., Alternatively activated macrophages produce 
catecholamines to sustain adaptive thermogenesis. Nature, 2011. 480(7375): p. 
104-8. 
268. Bos, S.A., et al., Preliminary investigation of brown adipose tissue assessed by 
PET/CT and cancer activity. Skeletal Radiol, 2018. 
269. Rousseau, C., et al., Brown fat in breast cancer patients: analysis of serial (18)F-
FDG PET/CT scans. Eur J Nucl Med Mol Imaging, 2006. 33(7): p. 785-91. 
 
 
255 
 
270. Lee, P., et al., A critical appraisal of the prevalence and metabolic significance of 
brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab, 2010. 
299(4): p. E601-6. 
271. Pfannenberg, C., et al., Impact of age on the relationships of brown adipose 
tissue with sex and adiposity in humans. Diabetes, 2010. 59(7): p. 1789-93. 
272. Graja, A., S. Gohlke, and T.J. Schulz, Aging of Brown and Beige/Brite Adipose 
Tissue. Handb Exp Pharmacol, 2018. 
273. White, M.C., et al., Age and cancer risk: a potentially modifiable relationship. Am 
J Prev Med, 2014. 46(3 Suppl 1): p. S7-15. 
274. Vaitkus, J.A., J.S. Farrar, and F.S. Celi, Thyroid Hormone Mediated Modulation 
of Energy Expenditure. Int J Mol Sci, 2015. 16(7): p. 16158-75. 
275. Ouellet, V., et al., Brown adipose tissue oxidative metabolism contributes to 
energy expenditure during acute cold exposure in humans. J Clin Invest, 2012. 
122(2): p. 545-52. 
276. Cannon, B. and J. Nedergaard, Yes, even human brown fat is on fire! J Clin 
Invest, 2012. 122(2): p. 486-9. 
277. Cohade, C., K.A. Mourtzikos, and R.L. Wahl, "USA-Fat": prevalence is related to 
ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med, 
2003. 44(8): p. 1267-70. 
278. Au-Yong, I.T., et al., Brown adipose tissue and seasonal variation in humans. 
Diabetes, 2009. 58(11): p. 2583-7. 
279. Lecoultre, V. and E. Ravussin, Brown adipose tissue and aging. Curr Opin Clin 
Nutr Metab Care, 2011. 14(1): p. 1-6. 
280. Sampath, S.C., et al., Imaging of Brown Adipose Tissue: State of the Art. 
Radiology, 2016. 280(1): p. 4-19. 
281. Vaitkus, J.A.S., S. C.; Boikos, S. A.; Celi, F. S., Unusual Case of Autoimmune 
Diabetes Mellitus in the Setting of Extra-Adrenal Paraganglioma with Loss of 
Succinate Dehydrogenase Expression AACE Clinical Case Reports, 2018. 4(6): 
p. 457-462. 
282. Ogawa, Y., et al., FDG-PET and CT findings of activated brown adipose tissue in 
a patient with paraganglioma. Eur J Radiol Open, 2018. 5: p. 126-130. 
 
 
256 
 
283. Lam, A.K., Update on Adrenal Tumours in 2017 World Health Organization 
(WHO) of Endocrine Tumours. Endocr Pathol, 2017. 28(3): p. 213-227. 
284. La Batide-Alanore, A., G. Chatellier, and P.F. Plouin, Diabetes as a marker of 
pheochromocytoma in hypertensive patients. J Hypertens, 2003. 21(9): p. 1703-
7. 
285. Gupta, G., K. Pacak, and A.A.S. Committee, Precision Medicine: An Update on 
Genotype/Biochemical Phenotype Relationships in 
Pheochromocytoma/Paraganglioma Patients. Endocr Pract, 2017. 23(6): p. 690-
704. 
286. Ziegler, M.G., et al., Location, development, control, and function of extraadrenal 
phenylethanolamine N-methyltransferase. Ann N Y Acad Sci, 2002. 971: p. 76-
82. 
287. Deibert, D.C. and R.A. DeFronzo, Epinephrine-induced insulin resistance in man. 
J Clin Invest, 1980. 65(3): p. 717-21. 
288. Mullins, G.R., et al., Catecholamine-induced lipolysis causes mTOR complex 
dissociation and inhibits glucose uptake in adipocytes. Proc Natl Acad Sci U S A, 
2014. 111(49): p. 17450-5. 
289. Porte, D., Jr. and R.H. Williams, Inhibition of insulin release by norepinephrine in 
man. Science, 1966. 152(3726): p. 1248-50. 
290. Walters, J.M., et al., The effect of norepinephrine on insulin secretion and 
glucose effectiveness in non-insulin-dependent diabetes. Metabolism, 1997. 
46(12): p. 1448-53. 
291. Sorenson, R.L., R.P. Elde, and V. Seybold, Effect of norepinephrine on insulin, 
glucagon, and somatostatin secretion in isolated perifused rat islets. Diabetes, 
1979. 28(10): p. 899-904. 
292. Astuti, D., et al., Gene mutations in the succinate dehydrogenase subunit SDHB 
cause susceptibility to familial pheochromocytoma and to familial paraganglioma. 
Am J Hum Genet, 2001. 69(1): p. 49-54. 
293. Tischler, A.S., K. Pacak, and G. Eisenhofer, The adrenal medulla and extra-
adrenal paraganglia: then and now. Endocr Pathol, 2014. 25(1): p. 49-58. 
 
 
257 
 
294. Guo, Z. and R.V. Lloyd, Pheochromocytomas and Paragangliomas: An Update 
on Recent Molecular Genetic Advances and Criteria for Malignancy. Adv Anat 
Pathol, 2015. 22(5): p. 283-93. 
295. Ezzat Abdel-Aziz, T., et al., Phaeochromocytomas and paragangliomas: A 
difference in disease behaviour and clinical outcomes. J Surg Oncol, 2015. 
112(5): p. 486-91. 
296. Mesmar, B., S. Poola-Kella, and R. Malek, The Physiology Behind Diabetes 
Mellitus in Patients with Pheochromocytoma: A Review of the Literature. Endocr 
Pract, 2017. 23(8): p. 999-1005. 
297. Laugesen, E., et al., Latent autoimmune diabetes of the adult: current knowledge 
and uncertainty. Diabet Med, 2015. 32(7): p. 843-52. 
298. Sokołowska, M.C., A.; Jarosz-Chobot, P., The honeymoon phase – what we 
know today about the factors that can modulate the remission period in type 1 
diabetes. Pediatr Endocrino Diabetes Metab, 2016. 22(2): p. 66-70. 
299. Moole, H., et al., Spontaneous complete remission of type 1 diabetes mellitus in 
an adult - review and case report. J Community Hosp Intern Med Perspect, 2015. 
5(5): p. 28709. 
300. Shaw, P.J., Stiff-man syndrome and its variants. Lancet, 1999. 353(9147): p. 86-
7. 
301. Asakura, T., et al., Small Cell Lung Cancer Expressing Glutamate Decarboxylase 
with Latent Autoimmune Diabetes in Adults. Intern Med, 2015. 54(23): p. 3035-7. 
 
  
 
 
258 
 
 
 
Vita 
 
 
Janina Vaitkus Pearce was born August 31st, 1991 as Janina Aldona Vaitkus in 
Montgomery County, Maryland, and is an American Citizen. She graduated from South 
River High School in Edgewater, Maryland, in 2009. She received her Bachelor of 
Science in Bioengineering, Cum Laude, from the University of Maryland College Park in 
Spring 2013. In Summer/Fall 2013, she entered the M.D.-Ph.D. graduate program at 
Virginia Commonwealth University School of Medicine. 
 
  
 
 
259 
 
Presentations from or related to this work 
 
Please note my maiden name (Janina Aldona Vaitkus, or Vaitkus, J. A.) or my married 
name (Janina Vaitkus Pearce, or Pearce, J. V.) for these conferences and 
presentations. 
 
 
 
 
Submitted: S Chen, J Luo, L Zhao, JV Pearce, FS Celi. Fast Detection of Brown 
Adipose Tissue in Cancer Patients by Localizing Supraclavicular Fossae. SNMMI 
Annual Meeting; June 22-25 2019; Anaheim, California, USA.  
 
J.A. Vaitkus, J.S. Farrar, B. Ni, F.S. Celi. WHITE ADIPOSE TISSUE BROWNING IN 
BREAST CANCER IS NOT DIRECTLY MEDIATED BY TUMOR CELL SERCRETOME 
OR INTERLEUKIN-6. Virginia Commonwealth University Massey Cancer Center 2018 
Cancer Research Retreat, June 8, 2018; Richmond, Virginia, USA. 
 
J. Vaitkus, S. C. Smith, and F. S. Celi. UNUSAL CASE OF AUTOIMMUNE DIABETES 
IN THE SETTING OF EXTRA-ADRENAL PARAGANGLIOMA WITH SUCCINATE 
DEHYDROGENASE DEFICIENCY. 27th Annual AACE Scientific & Clinical Congress; 
May 17, 2018; Boston, Massachusetts, USA. 
P. Rao, B. Ni, J. Vaitkus, P. Puri, F. Celi. THYROID HORMONE HOMEOSTASIS 
ACROSS THE SPECTRUM OF FATTY LIVER DISEASE. 27th Annual AACE Scientific 
& Clinical Congress; May 19, 2018; Boston, Massachusetts, USA. 
J. Vaitkus, B. Ni, and F. S. Celi. Local white adipose tissue browning in breast cancer is 
not mediated by direct tumor-adipocyte interactions. American Physician Scientist 
Asossication Annual Meeting, April 20, 2018, Chicago Illinois USA. 
JS Farrar, J.A. Vaitkus, B. Ni, FS Celi. Quantitative real-time PCR for the assessment 
of white, classical brown, and beige adipose tissue. Keystone Symposia Obesity and 
Adipose Tissue Biology; January 23, 2017, 2017; Keystone, Colorado USA. 
J.A. Vaitkus, J.S. Farrar, B. Ni, F.S. Celi. WHITE ADIPOSE TISSUE BROWNING IN 
BREAST CANCER. Virginia Commonwealth University Massey Cancer Center 2016 
Cancer Research Retreat, June 17, 2016; Richmond, Virginia, USA. 
 
 
 
  
 
 
260 
 
Publications from or related to this work 
 
Please note my maiden name (Janina Aldona Vaitkus, or Vaitkus, J. A.) or my married 
name (Janina Vaitkus Pearce, or Pearce, J. V.) for these publications. 
 
 
 
 
Submitted: Pearce JV, Farrar JS, Lownik JC, Ni B, Chen S, Kan TW, Celi FS. E0771 
breast cancer cells and interleukin 6 alter gene expression patterns but do not induce 
browning in cultured white adipocytes. Biochemistry and Biophysics Reports.  
 
Vaitkus JA, Smith SC, Boikos SA, Celi FS. Unusual Case of Autoimmune Diabetes 
Mellitus in the Setting of Extra-Adrenal Paraganglioma with Loss of Succinate 
Dehydrogenase Expression. AACE Clinical Case Reports: November/December 2018, 
Vol. 4, No. 6, pp. e457-e462 
 
Vaitkus JA, Celi FS. The role of adipose tissue in cancer-associated cachexia. Exp Biol 
Med (Maywood). 2017;242(5):473-481.  
 
Ni B., Farrar JS, Vaitkus JA, and Celi FS. Metabolic Effects of FGF-21: 
Thermoregulation and Beyond. Front Endocrinol (Lausanne), 2015. 6: 148. 
 
Vaitkus JA, Farrar JS, and Celi FS. Thyroid Hormone Mediated Modulation of Energy 
Expenditure. Int J Mol Sci, 2015. 16(7): p. 16158-75.  
 
 
261 
 
Appendices: Human Subjects Research 
All documents current as of 2/4/2019 
 
Appendix A 
Human Subjects Research IRB Study Smartform
 
 
262 
 
 
 
263 
 
 
 
264 
 
 
 
265 
 
 
 
266 
 
 
 
267 
 
 
 
268 
 
 
 
269 
 
 
 
270 
 
 
 
271 
 
 
 
272 
 
 
 
273 
 
 
 
274 
 
 
 
275 
 
 
 
276 
 
 
 
277 
 
 
 
278 
 
 
 
279 
 
 
 
280 
 
 
 
 
281 
 
 
 
282 
 
 
 
283 
 
 
 
284 
 
 
 
285 
 
 
 
286 
 
 
 
287 
 
 
 
288 
 
 
 
289 
 
 
 
290 
 
 
 
291 
 
 
 
292 
 
 
 
293 
 
 
 
294 
 
 
 
295 
 
 
 
296 
 
 
 
297 
 
 
 
298 
 
 
  
 
 
299 
 
Appendix B 
Human Subjects Research Protocol 
 
 
 
300 
 
 
 
 
301 
 
 
 
 
302 
 
 
 
 
303 
 
 
 
 
304 
 
 
 
 
305 
 
 
 
 
 
 
 
306 
 
 
 
 
307 
 
 
 
 
308 
 
 
 
 
309 
 
 
 
 
310 
 
 
 
 
311 
 
 
 
 
312 
 
 
 
 
313 
 
 
 
 
314 
 
 
 
 
315 
 
 
 
 
316 
 
 
 
 
317 
 
 
 
 
318 
 
 
 
 
319 
 
 
 
 
320 
 
 
 
 
321 
 
 
 
 
322 
 
 
 
 
323 
 
 
 
 
324 
 
 
 
 
325 
 
 
 
 
326 
 
 
 
 
327 
 
 
 
 
328 
 
 
 
 
329 
 
 
 
 
330 
 
 
 
 
331 
 
 
 
 
332 
 
 
 
 
333 
 
 
 
 
334 
 
 
 
 
335 
 
 
 
 
336 
 
 
 
337 
 
 
 
 
 
 
 
338 
 
Appendix C 
Human Subjects Research Quality of Life Questionnaire
 
 
339 
 
 
 
340 
 
 
 
 
 
341 
 
Appendix D 
Human Subjects Research Thermal Comfort Questionnaire 
 
 
 
342 
 
Appendix E 
Human Subjects Research Informed Consent Document 
 
 
 
343 
 
 
 
 
344 
 
 
 
 
345 
 
 
 
 
346 
 
 
 
 
347 
 
 
 
 
348 
 
 
 
 
349 
 
 
 
 
350 
 
 
 
 
351 
 
 
 
 
352 
 
 
 
 
353 
 
 
 
 
 
 
 
354 
 
Appendix F 
Human Subjects Research Recruitment Documents
 
 
355 
 
 
 
356 
 
 
 
357 
 
 
 
 
358 
 
Appendix G 
Human Subjects Research Results Letter 
 
 
 
359 
 
Appendix H 
Human Subjects Research Screening/Case Report Worksheets  
 
 
 
360 
 
 
 
 
361 
 
 
 
 
 
 
 
362 
 
 
 
 
 
 
 
363 
 
 
 
 
 
 
 
364 
 
 
 
 
 
 
 
365 
 
 
 
 
 
 
 
366 
 
 
  
 
 
367 
 
Appendix I 
Blood/Plasma and Urine Banking Standard Operating Procedure 
 
 
 
368 
 
 
 
 
369 
 
 
